


Annual Report 2023

Discover. Translate. Integrate.







The Heart to Heal, The Strength to Grow.

Our spirit is strong, it thrives as we embrace those whom we must always care for.


Our journey has been long and we will continue to flourish as we open our hearts to those who walk with us. **Always.**

This artwork concept and narrative was developed by David Williams. David is a proud Wakka Wakka artist at Gilimbaa.


Mater acknowledges that our services are provided on Aboriginal and Torres Strait Islander lands and pays respect to their Elders – past, present and emerging.

Contents

Foreword.....	6
Executive Director Report.....	7
Our Year at a Glance	8
About Us	11
Leadership.....	11
Our Vision, Mission and Values.....	12
Our Strategy	12
Our History.....	14
Research Advisory Board.....	16
Research, Education and Executive Group Committee.....	18
Mater Student Research Committee.....	19
Student Successes.....	20
Early and Mid-Career Researcher Committee	22
Equity, Diversity and Inclusion Committee	23
Mater Research Consumer and Community Involvement.....	24



Future Leaders Symposium	26
Mater Research Showcase	28
Mater Research Governance and Ethics	30
Clinical Trials	32
Organisational Chart	34
iSEARCH	36
MEDCAN3	38
Aurora	39
The Light Knee Study	40
Mater Research Biobanks	42
Program Reports	44
Cancer Program	46
Chronic and Integrated Care Program	48
Healthcare Delivery and Innovation Program	50
Mother and Baby Program	52
Neuroscience Program	54
Grant Successes 2023 – Lead Investigator	56
External Grants	56
Internal Grants	58
Awards 2023	60
External Awards	60
Internal Awards	61
Publication Information	64
Publication List	68



Foreword

I write this foreword at the year's end, a time for looking back with quiet reflection. Having worked with Mater Research for the past sixteen years, firstly as Deputy Chair of the Mater Research Board and now as Chair of the Research Advisory Board, provides me with a unique perspective of Mater Research.

Perhaps what stands out most, given my longstanding association with Mater Research, is how far we've come. This was no more evident than at the 2023 Mater Research Showcase in November. It filled me with pride to see the breadth and quality of research on display, and to see so many inspiring presentations from young, up-and-coming researchers like Dr Siobhan Loughnan, Dr Taylan Gurgenci and Mr Cheng Xiang Foo, who will ensure this long continues. This was all seen in the context of our keynote speaker Laureate Professor Emeritus Peter Doherty, who grew up in Oxley and who talked about how Queensland and Queenslanders are coming of age.

My colleagues on the Research Advisory Board and I would like to acknowledge the continued performance of Mater Researchers, as evidenced by manuscripts, grants and awards. Our special congratulations go particularly to those who have given a lifetime of service to medical research – to Professor David Hume for being awarded an AO, to Emeritus

Professors David McIntyre and Tim Florin for Emeritus Professorships, and to Professor Janet Hardy for her Mater Research Lifetime Achievement Award.

We continue to lead the way with gender equity, with women making up two-thirds of our group leaders. The Strategic Grant for Outstanding Women, funded by the Mater Foundation, to assist women to overcome career breaks has supported many women since inception, many of whom have gone on to succeed in their research careers (Professor Katharina Ronacher, Dr Sandy Richardson and Associate Professor Sumaira Hasnain to name but a few) with this year's grant awarded to Dr Sahar Keshvari for her work on the burgeoning health problem of fatty liver disease.

Mater Research has now matured such that its research is being successfully translated into clinical practice. An example is Associate Professor Kym Rae and colleagues, who were awarded a \$4.69 million National Health and Medical Research Council (NHMRC) clinical trial and cohort study to improve the health of First Peoples families during pregnancy and early infant life. Industry collaborations include the Glycomimetics drug from Associate Professor Ingrid Winkler's research that is now in Phase 3

and the novel therapeutic being commercialised in association with another industry partner, based on research by Professor Josephine Forbes and her team. This product may slow the onset of Type 1 diabetes. It has already been shown to be safe in adults and is going into further clinical trials in younger patients.

The keynote address at the Future Leaders Symposium given by Professor Lewis Perrin, Gynaecological Oncology Group Lead at Mater Research, and health consumer Dr Chamari Jayawardena also showcased a successful translation. Dr Jayawardena was treated by Prof Perrin for advanced ovarian cancer at Mater Private Hospital Brisbane using a novel chemotherapy treatment called HIPEC.

On a personal note, a big thank you to Professors Maher Gandhi and Allison Pettit who lead Mater's research and Ms Emily Bailey, Director of Operations, for a successful 2023 and best wishes for continued success in 2024.

Finally, on behalf of all at Mater Research, a special thank you to Mater Foundation and all of our donors and friends – we can only continue to discover, translate and integrate our research with your support.



Dr Carrie Hillyard AM
FTSE FAICD

Executive Director Report



Professor Maher Gandhi
Executive Director

Our commitment is to improve unmet health needs of the community through excellence in medical research. We take this commitment seriously and believe that the 2023 Mater Research Annual Report is a testament to our success in this endeavour. Across our research programs, we continue to tackle global health and medical research challenges and there are so many 'notables' across the year that are worthy of mention. Not all can be laid out in this introduction, so here is my personal selection.

2023 has been a year when issues pertaining to 'closing the gap' have gained particular national prominence. Along this theme, the importance of maternal health has been identified as a critical national research priority by Indigenous communities. Mater Research is not new to successful


implementation research in the area of Indigenous health, having previously established, through its ground-breaking 'Birthing in Our Community' initiative, a culturally safe maternal and infant health service. This year, the Indigenous Health Research Group, led by Associate Professor Kym Rae (a recent Strategic Grant for Outstanding Women winner), further built upon those foundations. The group were awarded \$4.69 million by the National Health and Medical Research Council. Their clinical trials and cohort studies grant, with the lay title "The Strong Families Study" will examine the strengths and risks to health for mothers and their infants, across culturally designed

programs to improve mental health and neurodevelopmental outcomes. I wish Kym and her team every success in this important endeavour.

There are many inspiring stories shared in these pages, and many more being uncovered every day. In line with the broader Mater mission, we strive for excellence in all that we do. Hopefully you agree that in 2023 we hit this target. It's a privilege to work with so many inspired researchers and dedicated professional staff and I thank them all.

It's my pleasure to introduce the 2023 Mater Research Annual Report. Thank you for your ongoing support.

Our Year at a Glance



Associate Professor Ingrid Winkler was awarded \$148,000 from **Leukaemia Foundation Australia** for her project "Manipulating vascular environments to alleviate cancer therapy side-effects."



Professor Katharina Ronacher published in the **European Respiratory Journal** – "GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection"



Professor Lewis Perrin received the **2022 Jeannie Ferris Cancer Australia Award** for his outstanding contribution to improving care for women with gynaecological cancers.



Professor Geoff Faulkner published in the journal **Neuron** – "Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect"



Professor Maher Gandhi published in the journal **Blood** – "Genetic susceptibility to EBV-related disease"

Quarter 1

Dr Beth Mah joined **Mater Research** as Director of Catherine's House for Mothers, Babies and Families.



Professor David Hume AO was appointed an **Officer of the Order of Australia** in recognition of his distinguished service to biological science and tertiary education.




Associate Professor Kym Rae was awarded a **\$4.69m NHMRC grant** – the largest grant funding awarded to a Mater Research lead scientist – for the project titled "First Peoples Co-Designed Cohort to support improved perinatal and early childhood outcomes."



Dr Chloe Yap and **Associate Professor Jake Gratten** published in the journal **Nature Medicine** – "Interactions between the lipidome and genetic and environmental factors in autism"





Associate Professor Sumaira Hasnain was awarded the inaugural Laurie Powell AC Grant Award from the Gastroenterology Society of Australia.



Emeritus Professor David McIntyre was awarded a Lifetime Achievement Award from the Australian Diabetes Society. The award recognises the outstanding lasting impact his work has had on diabetes.



Professor David Hume AO and Associate Professor Katharine Irvine were awarded \$875,000 ARC Discovery Project Round for the project "A macrophage-centric holistic view of postnatal development."



Dr Irina Buckle was awarded USD\$200,000 by the Juvenile Diabetes Research Foundation for the project "Understanding RAGE Expression and Function in Human T and Dendritic Cells to Refine the Use of RAGE Targeting Therapeutics for Type 1 Diabetes Prevention".


Quarter 3

Quarter 4

Dr John Kemp joins Mater Research as a Group Leader for the Musculoskeletal Genomics Group.



Dr John Kemp was awarded an NHMRC Investigator Emerging Leadership 2 grant, valued at \$1,586,190 over five years for the project "Using human genetics, single-cell transcriptomics and animal models to accelerate drug development for patients with osteoporosis".



Dr Sahar Keshvari was awarded an NHMRC Investigator Emerging Leadership 1 grant valued at \$637,040 for five years for the project "Macrophage Therapeutic Potential in Paediatric Non-Alcoholic Fatty Liver Disease".

Professor John Hooper was awarded \$300,000 by Pankind – the Pancreatic Cancer Foundation – for the project "Receptor-directed precision medicines for pancreatic cancer".



Associate Professor Jakob Begun was awarded a \$1.67m NHMRC Ideas Grant for the project 'Harnessing microbial immunomodulatory function to treat inflammatory bowel diseases'.





About Us



Based on a bench-to-bedside philosophy, Mater Research is a recognised leader in medical research and is the research arm of Mater. Collaboration sees us working across Mater's hospitals and health services, Princess Alexandra (PA) Hospital and our partners The University of Queensland, the world-class Translational Research Institute (TRI) and Health Translation Queensland (HTQ).

We have a strong commitment to working closely with Mater Health and Mater Education and our growing network of partners and collaborators to turn scientific discovery into the best possible treatment,

care, and outcomes for patients and the broader community.

Our strong track record of successful grant applications and fellowship recipients is underpinned by the significant financial support of Mater Foundation which contributes millions of dollars to fund pilot clinical trials, research projects, vital infrastructure and resources, student scholarships and backfilling clinical time to enable more clinician-led research and fellowships for our senior researchers. This allows us the flexibility to sustain research beyond short-term grants.

With expertise across all facets of medical research—study design, ethics and governance, data collection, biobank management, analysis, and implementation science—we are responsible for the robust management of all research and clinical trials at Mater.

We maintain a broad external focus, horizon scanning national and international high-quality research to reduce duplication of effort and wasted resources, working alongside Mater Education and Mater Health to support the prompt and efficient translation of research into clinical care.

Leadership



Professor Maher Gandhi

Executive Director and
Director Clinical Research

Holding the roles of Executive Director and Director of Clinical Research, Prof Gandhi's role is to set strategy and create clinical research programs that influences future national and international health policy and practice through the full integration of Mater Research with clinical care.



Professor Allison Pettit

Director Biomedical Research

In her role as Director of Biomedical Research, Prof Pettit provides oversight, leadership and guidance in the management and execution of biomedical research activities at Mater. She is involved in strategic planning, developing and executing organisational frameworks and supports improving clinical connectivity of biomedical research activity.



Ms Emily Bailey

Director of Operations

As Director of Operations, Emily oversees a portfolio which is responsible for the operational management of Mater Research (including finance, facilities and compliance), continuing to strengthen existing and new partnerships, and research commercialisation activities.



About Us

Our Vision, Mission and Values

Vision

To translate our research discoveries and integrate them into improved healthcare.

Mission

To discover new knowledge central to the Mater mission, translate this knowledge into practice and integrate these research outcomes into improved healthcare and educational practices across Mater.

Mercy Values

Mater Research wholeheartedly commits to the Mater Values:

- We honour and promote the dignity of human life and of all creation
- We act with compassion and integrity
- We strive for excellence.

Mater Research

In addition to the Mercy Values, working across our five research programs, Mater Research is committed to upholding the values relating to our scientific, medical and management mission:

-  **Integrity** – we conduct ourselves and our work honestly and ethically to build a culture of excellence.
-  **Innovation** – developing and extending knowledge to improve health.
-  **Inspiration** – educating and imparting knowledge to inspire each other and future generations.
-  **Engagement** – fostering and encouraging group work, collaboration and commitment to the community.

Our Strategy

To achieve health impact through integrated research excellence:

-  Develop the quality and output of researchers in Mater-relevant areas of focus.
-  Enhance Mater's expertise in areas of excellence through high-quality research.
-  Ensure the balance of research across discovery, translation and integration is aligned with Mater's strategy.
-  Establish and maintain a strong culture of collaboration.
-  Develop links with academic institutions and commercial agencies.
-  Prioritise internal and external partnerships in areas of strategic focus.



 **mate**
research

TRI 



About Us

Our History



Mater Medical Research (MMRI) was founded by the Sisters of Mercy and commenced operations with 10 staff. First Director was Professor Derek Hart.

1998

1999



Initial discussions with Federal Government for the Translational Research Institute

2004



Professor John Prins was appointed CEO of MMRI

2009



MMRI was opened by Governor General Sir William Dean AC

2006

MMRI incorporated – owned 50 per cent by Sisters of Mercy and 50 per cent by Mater Misericordiae Limited (MML)

MMRI became an NHMRC accredited Institute and a member of the Association of Australian Medical Research Institutes

Professor Ian Zimmer was the inaugural Chair

The Kiel-Williamson report recommended MMRI develop a closer relationship with Mater Foundation and Mater Hospital





Canonical responsibility for MML was transferred to Mercy Partners. MMRI became a wholly owned subsidiary of MML

Jim Walker AM became Chair of MMRI

Establishment agreement for MRI-UQ (an unincorporated joint venture) was signed

Translational Research Institute opened



A new Mater and The University of Queensland alliance agreement was signed



The research programs were enhanced with new leadership and alignment to reflect the changing needs of the community



Final year of funding for MMRI from Mater Health

2013

2017

2020

2021

2023

2016

2019



Research Advisory Board (RAB) established



CEO of MMRI joins Mater Hospital Group Executive



MMRI was rebranded as Mater Research Ltd

Professor Maher Gandhi commenced as Executive Director of Mater Research and Director of MRI-UQ



Research Advisory Board

The Research Advisory Board was established to provide independent strategic advice on clinical research or scientific-related matters to the Mater Research Executive Leadership Group and Mater Chief Executive Officer.

Advisory Board Chair



Dr Carrie Hillyard AM chairs Fitgenes Australia Limited board and was a Director of the Academy of Technology and Engineering (ATSE) until 2022. Previously, she was Chair of UniQuest, and a co-founder of venture fund CM Capital Investments, a Director of several of its investee companies and led its Life Sciences group. Dr Hillyard served as Deputy Chair of the Mater Research Board from 2007–2020.

Board Members

Professor Denise Doolan is Deputy Director of Research at the Institute for Molecular Bioscience at The University of Queensland. She was previously the Deputy Director of the Australian Institute of Tropical Health and Medicine and Director of the JCU Centre for Molecular Therapeutics at James Cook University. She is a member of the national expert advisory panel, The Australian Medical Research Advisory Board that advises the Minister for Health and Aged Care on prioritising spending from the Medical Research Future Fund (MRFF).



Professor Frank Gannon was the Director and CEO of QIMR Berghofer Medical Research Institute from 2011 to 2020 and has been the Director General and board member of Science Foundation Ireland (The Irish Research Funding Agency) and Executive Director of the European Molecular Biology Organisation. He is an active science communicator and has advised many research institutes, companies and government agencies and is a current advisor to Health Translation Queensland.



Professor Karen Moritz has been the Associate Dean of Research at The University of Queensland Faculty of Medicine since 2021. She was previously the Director of the Child Health Research Centre from 2016–2021 and is internationally renowned for her work in understanding how early life health issues contribute to risk of developing disease in adulthood.




Professor Cameron Turtle is the Clearbridge Chair in Cancer Immunotherapy at The University of Sydney and joined the Mater Research Advisory Board in 2023. He completed his PhD in dendritic cell immunotherapy through Mater Research in 2005, under the supervision of Mater Research's inaugural Director, Professor Derek Hart, for which he was awarded the Sister Regis Mary Dunne Medal. He trained as a haematologist and has worked at the Fred Hutchinson Cancer Center, Seattle USA, leading clinical and laboratory research teams in the field of cellular immunotherapy.



Professor Sir John Savill has been Executive Director of the Melbourne Academic Centre for Health (MACH) since July 2019, with a background in clinical and academic renal and acute medicine. Past roles include Director of the University of Edinburgh/Medical Research Council Centre for Inflammation Research, Vice-Principal and Head of the College of Medicine and Veterinary Medicine and Regius Chair of Medical Science in 2017.





**We ask the
questions and
find the answers
that save lives.**



Research, Education and Executive Group Committee

The Research, Education and Executive Group (REEG) is a standing committee that has inclusive representation of Mater Research's diverse research workforce across both campuses. It includes early/mid-career representation. REEG is a mechanism to achieve rapid consultation and decision making on a broad range of matters relating to research and education policy, procedures, strategy, engagement, supports and culture.

In 2023 REEG was responsible for:

- Review and ranking of the Mater Research Publication of the Year scheme and ranking of expressions of interest from internal candidates for applicant capped funding schemes. Reviewed policies, procedures and eligibility criteria for internal award schemes to make these more transparent and inclusive.
- Supporting the Mater Research Engagement team in the design and delivery of schemes to assist researchers produce competitive external grant submissions.
- Consideration of a range of conference/award sponsorship requests. Sponsorship of the Welcome to Country and the First Nations Change Maker Award at the Women in Technology Gala successfully raised the profile of Mater Research's commitment to improving health outcomes for Aboriginal and Torres Strait Islanders.
- Proactively identifying and promoting Mater Research applications to local, national, and international Award opportunities and ensuring an equity and diversity lens is applied to this process.
- Research Australia Awards nominations for Dr Chloe Yap and Professor Brian Gabrielli, achieving Highly Commended and Finalist recognition, respectively.

Research, Education and Executive Group members:



Professor Allison Pettit (Chair)



Associate Professor Katharine Irvine



Dr Kavita Bisht



Professor Maher Gandhi



Ms Sara Coram



Dr Sandra (Sandy) Richardson



Associate Professor Paul Dawson



Dr Christine Andrews



Associate Professor Jake Gratten



Associate Professor Kym Rae

Mater Student Research Committee

2023 saw the Mater Student Research Committee (MSRC) lead numerous activities to attract new students and support a high-quality research program for the more than 120 students based at Mater Research. Some highlights of MSRC-led activities include:

- The inaugural Mater Research Student Retreat was held at North Stradbroke Island over three days, with 20 students from across Mater Research in attendance. Activities included scientific presentations, a group dinner, group-building activities and a trip to Point Lookout.
- Organisation of the Mater Research Future Leaders Symposium, which celebrated the success of Mater Research Students and Early Career Researchers.
- A series of Professional development training courses for Higher Degree by Research (HDR) students, such as the BRIDGE Training Program and Pre R1 Workshops.
- Review and administration of new student applications and the Mater Research HDR travel awards, including the prestigious Dr David Serisier Student Training Award.
- The monthly Mater Research Mixer, held on the last Friday of each month.
- Student social events, including BBQs and pizza lunches.
- The Mater Research Three Minute Thesis (3MT®) Competition with two Mater Research PhD students progressing to The University of Queensland Faculty of Medicine 3MT® Final. Jade Kubler progressed to The University of Queensland 3MT® Final which was held in September, and Aleysha Martin won the People's Choice Award.
- A student group participated in the Mater Foundation International Women's Day Fun Run.
- Honours student research presentation events.
- TRI Student Information Event with tours and lunch to welcome prospective students to Mater Research.
- Weekly communication via the "Happy Wednesday" email.

Mater Student Research Committee members:



Ms Sarah Doyle



Associate Professor Liisa Laakso



Ms Jade Kubler



Associate Professor Paul Dawson



Dr Christine Andrews



Mr Shivam Vora



Professor Brian Gabrielli



Dr Jay Gunawardana



Ms Chenping (Lucy) Du



Ms Sara Coram



Dr Kavita Bisht



Mr Elias Roro



Student Successes



Dr Selwin Samuel

Awarded runner-up for the 2023 The University of Queensland, Faculty of Medicine PhD Graduate of the Year.

A 2023 PhD graduate, won the People's Choice Presentation at the OneTRI conference.



Ms Aleysha Martin

Won the People's Choice Award in The University of Queensland, Faculty of Medicine 3MT® Competition.

Won the National Quality Improvement Award from the Stroke Foundation.

Won the Dr David Serisier Student Training Award.



Ms Jade Kubler

Won The University of Queensland, Faculty of Medicine Three Minute Thesis (3MT®) competition for her outstanding presentation.

Won the Mater Research 3MT® competition.

Won a Mater Research International Travel Award.



Dr Taylan Gurgenci

Won the Dr Laurence Catley Clinical HDR Prize at the Mater Research Showcase.



Dr Jennifer Stables

A 2023 PhD graduate, was a finalist in both the Judges' Award and the Breaking Barriers Award in the 2023 Queensland Women in STEM Prize Awards.



Mr Cheng Xiang Foo

Won a Mater Research International Travel Award.

Biomedical HDR Prize Winner at the Mater Research Showcase.



Mr Muhammed B. Sabdia

Won the best presentation at the OneTRI Conference.




Mr Shivam Vora

Awarded a Runner-Up Prize in the ATA Scientific Instruments Young Scientist Encouragement Award.



Ms Madeline Gough

Won a Mater Research International Travel Award.



Dr Chloe Yap

Won graduate of the year for exceptional academic achievement and contributions to the community at The University of Queensland's 2023 Alumni Awards.



Early and Mid-Career Researcher Committee

In 2023, the Early and Mid-Career Research (EMCR) Committee ran multiple activities. Some of the highlights include:

- Coordination of the Monday Mater Research Seminar Series. With over 20 theme-based seminars held and attended by more than 40 attendees each event.
- Organisation and chairing of the TRI EMCR Professional Development Workshop, OneTRI Conference and Future Leader Symposium.
- Contributing as judges for the Mater Research finals for the UQ 3MT competition, Mater Junior Doctor Symposium and Mater Allied Health Symposium.
- A Mater Research EMCR Group participated in the Mater Foundation International Women's Day Fun Run.

- Expanding mentoring opportunities and initiating collaborations between biomedical EMCRs and clinician-researchers.

Over 50 EMCRs are supported by the Mater EMCR committee, which offers peer support and professional development opportunities. The priority for co-chairs Dr Kavita Bisht and Dr Christine Andrews over the last 12-months has been to expand and embed leadership opportunities within the committee. Overall, Mater EMCRs would not receive the level of support they do without all committee members' combined contributions and leadership.

Chairs of the EMCR Committee:



Dr Kavita Bisht



Dr Christine Andrews

Equity, Diversity and Inclusion Committee

In 2023, the Mater Research Equity, Diversity, and Inclusion Committee (EDIC) collaborated with The University of Queensland Faculty of Medicine to organise TRI events. Some of these events are highlighted below:

- At the International Women's Day Event on 10 March, a panel discussion on "Cracking the Code to Equity" was held with guest speaker, Professor Louise Purton. There was a highlight on practical, financial, and social challenges associated with having a disability.
- In the first week of July, NAIDOC week was celebrated with a focus on the 2023 theme, "For Our Elders." The event highlighted how traditional knowledge can inform contemporary science, featuring the ground-breaking work of a UQ spin-out company, Trioda Wilingi, that utilises native spinifex grass.

The EDIC acknowledges the outcome of the referendum, which has caused great hurt and sadness for many Aboriginal and

Torres Strait Islander researchers in our community. We reaffirm our commitment to highlighting Indigenous issues and providing a supportive and inclusive environment to promote a more just and equitable academic environment for all Australians.

Members of the Equity, Diversity and Inclusion Committee:



Associate Professor Sumaira Hasnain



Ms Sara Coram



Dr M Arifur Rahman



Dr Sandy Richardson



Associate Professor Ingrid Winkler



Ms Jane Campbell



Associate Professor Kym Rae



Dr Soi Law



Associate Professor Jake Gratten



Dr Natasha Jansz



Dr Mitchell Sullivan



Mater Research Consumer and Community Involvement

Consumers are people with lived experience as a patient and/or providing support as a carer, family, or community member and are the ultimate funders, users, and beneficiaries of health and medical research and innovation. Consumers bring a broad range of valuable perspectives and experiences, including diversity in culture, linguistics, gender, and ability. This improves the quality, relevance and impact of research at Mater Research to the community at large.

Mater Research recognises the importance of meaningful engagement and effective involvement of consumers throughout all stages of research and healthcare. Structural and cultural change, time, and resources are required to strengthen consumer and community involvement (CCI) with research teams across various stages of the research cycle. Farhana Matin leads our consumer engagement portfolio, actively working towards facilitating consumer engagement with researchers.

To align with the CCI objectives of National funding bodies we partner with The University of Queensland Faculty of Medicine (UQ FoM), Health Translation Queensland (HTQ), Translational Research Institute (TRI) and

the Association of Australian Medical Research Institutes (AAMRI) to leverage opportunities, reflect emerging policy and achieve best practice in CCI in health and medical research across our five programs.

In 2023, through these partnerships Mater Research has taken a shared approach to CCI activities including the development of co-designed resources, organisation of workshops/training opportunities for researchers and clinicians, and co-contribution in microgrant schemes. One example is the UQ CCI Kickstart Funding Scheme that builds sustainable relationships between CCI stakeholders across Queensland.

Mater Research is in the process of establishing an advisory group for the Neuroscience program to provide an avenue for active CCI and input into all current and future research undertaken within the Neuroscience Program. In response to the recently implemented National Clinical Trials Governance Framework (NCTGF), Mater Research has established a Strategy Working Group that includes within its remit, integration of consumers within clinical trials across the organisation.

Our researchers give patients hope that their disease may one day be preventable or curable.





Future Leaders Symposium

The 2023 Future Leaders Symposium was held at the Translational Research Institute (TRI) on Wednesday 6 September. Researchers, Mater People, Year 12 students from All Hallows' School and Mater Foundation donors and supporters came together to celebrate the achievements of Mater Research Higher Degree Research (HDR) students and Early-Mid Career Researchers (EMCRs).

The Dr John Prins Oration was delivered jointly by Professor Lewis Perrin, Director of Gynaecological Oncology at Mater Hospital Brisbane and Gynaecological Oncology Group Lead at Mater Research, and health consumer Dr Chamari Jayawardena. Prof Perrin met Dr Jayawardena when he was treating her for advanced ovarian cancer at Mater Private Hospital Brisbane using a novel chemotherapy treatment – HIPEC treatment. She is now in complete remission.

The Symposium included presentations from Mater Research's most promising clinical and biomedical PhD students and EMCRs. Mater Research congratulates all award winners and finalists who were recognised at the Symposium:

Mater Research International Travel Award Winners:

Jade Kubler, Cheng Xiang Foo and Madeline Gough


Mater Research International Travel Awards will enable PhD students Jade, Cheng and Madeline to present their research findings at national and international conferences:

- Jade's project is looking at the effects of physical activity and sedentary behaviour during pregnancy on placental morphology and function,
- Cheng's PhD focuses on investigating the role of oxidized cholesterol in the host defence against respiratory pathogens, and
- Madeline's PhD is investigating ways to improve the selection of patients for targeted therapies using novel and established biomarkers.

Dr David Serisier Student Training Award Winner:

Aleysha Martin

The prestigious Dr David Serisier Student Training Award was presented to final year PhD student and occupational therapist at Mater Hospital Brisbane, Aleysha Martin. Her PhD project is focused on reducing duplication and repetition between allied health stroke assessments, and her research has transformed these assessments at Mater Hospital Brisbane. Aleysha used the award to travel to Antwerp, Belgium, to present at the 23rd International Conference on Integrated Care (ICIC23) to discuss her work on a transdisciplinary approach to allied health initial assessment of stroke patients.





Early Career Researcher Seeding Grant (Clinical) Winner:

Dr Uyen Pham

Dr Pham is a consultant endocrinologist and clinical member within the Glycation and Diabetes Complications Research Group. She proposes to use the \$20,000 grant to evaluate if markers of mitochondrial function associate with the risk of developing diabetic kidney disease in young people. Dr Pham will do this using blood and urine samples that were collected from a unique cohort of young people with diabetes and a high incidence of kidney disease who are at significant risk of early death.

Early Career Researcher Seeding Grant (Biomedical) Winner:

Dr Yuanhao Yang

Dr Yang has a growing national profile in neuropsychiatric genomics and proposes to use the \$20,000 biomedical grant to improve knowledge of the underlying molecular mechanisms that present in the onset and progression of Parkinson's disease. He is focused on facilitating the discovery and repurposing of drugs to improve the quality of life for Parkinson Disease patients.

Pictured top right: Cheng Xiang Foo, Madeline Gough, Dr Uyen Pham, Mater Foundation supporter Maureen Stevenson, Dr Yuanhao Yang and Aleysha Martin.



Mater Research Showcase

Mater Researchers were celebrated at the 2023 Mater Research Showcase, an annual event where Mater Research comes together to reflect on the collective achievements from the year alongside the broader Mater community.

Held at the Brisbane Convention and Exhibition Centre on 10 November 2023 with 190 attendees, the Showcase celebrated the outstanding research that Mater Research's experienced and emerging researchers have contributed to the advancement of healthcare.

As the event began, Song Man Derek Oram Sandy, founder of the Yerongpan Dancers and a proud Yuggera man, delivered a poignant Welcome to Country speech,

sharing with us naming origins of many Brisbane landmarks and links with First Nations People.


Laureate Professor Emeritus Peter Doherty gave the keynote address and regaled the audience with insightful stories from his life, starting with his childhood in Brisbane and throughout his long and illustrious career in medical research – which has included a Nobel Prize (in 1996) and a research institute named in his honour. Professor Janet Hardy, an internationally acclaimed clinical researcher in palliative care who has led the Mater Research Cancer program since 2015, received a Mater Research Special Award for her outstanding achievements and contributions.

In his remarks, Mater Research Executive Director Professor Maher Gandhi highlighted the fantastic work of Mater Researchers over the past 12 months, including early career researchers and senior researchers.

Alanna Jacoby, Mater's Chief of Mission, spoke about the history of the Sisters of Mercy and introduced the medals named in their honour to recognise individuals who have made an outstanding contribution throughout the year in the areas of research output, student supervision, translating research into clinical care and supporting Mater Research operations.

We congratulate everyone who was recognised on the day.





Awards, Prizes and Grants

Mater Research Early Career Researcher Prize:

Dr Siobhan Loughnan

Senior Research Officer,
Stillbirth Centre of
Research Excellence

Dr Laurence Catley Clinical Research Student Prize:

Dr Taylan Gurgenci

Mater Palliative Care
Research Fellow

Mater Research Higher Degree Research Student Prize (Biomedical):

Cheng Xiang Foo,

Infection Immunity and
Metabolism Research

Sister Medal Winners

Sister Regis Mary Dunne Medal:

Dr Kylie Alexander

Stem Cell Biology Research

Sister Michaeleen Mary Ahern Medal:

Professor Brian Gabrielli

Smiling for Smiddy Cell
Cycle Research

Sister Eileen Pollard Medal:

Associate Professor Jake Begun

Inflammatory Bowel Disease
(IBD) Research and Director
of Gastroenterology at
Mater Hospital Brisbane.

Sister Madonna Josey Medal:

Ruth Lee (*Winner*)

Research Project Officer Mater
Research Ethics and Governance

Alice Yin (*Highly-commended*)

Finance Manager

Betty McGrath Healthcare Delivery and Innovation and Education Seeding Grants

The Betty McGrath Healthcare Delivery and Innovation and Education Seeding Grants, made possible through the generous support of Mater Foundation, were also presented at the Mater Research Showcase. These grants are designed to enhance research capability of Mater People and help clinicians, educators and researchers create new models of health service delivery, and new methods for the education of future clinicians.

2023 Betty McGrath Education Seeding Grant winners:

Dr Sarah Janssens

Director of Obstetrics
and Gynaecology, Mater
Mothers' Hospital

Dr Jasmine Antoine

Staff Specialist Neonatology,
Mater Mothers' Hospital

2023 Betty McGrath Healthcare Delivery and Innovation Seeding Grant winners:

Dr Beth Mah

Medical Director, Catherine's House

Dr Honnie Gorry

Clinical Psychologist and
Clinical Neurophysiologist, Mater

Dr Neisha D'Silva

Senior Staff Specialist,
Endocrinology at the
Queensland Diabetes and
Endocrine Centre (QDEC)

Associate Professor Liisa Laakso

Principal Research Fellow,
Allied Health



Mater Research Governance and Ethics

All research conducted with or about human participants at Mater requires approval from a Human Research Ethics Committee (HREC). Members of Mater Research's NHMRC accredited HREC are volunteers who generously provide their time and expertise. They include Professor Ross Pinkerton (Chairperson), Ms Odette Petersen (Deputy Chairperson), Mr John Larkin, Ms Genevieve Waldie, Ms Lucy Lai, Ms Maree Patane, Professor Sailesh Kumar, Associate Professor Simon Bowler, Ms Alanna Jacoby, Ms Courtney Coyne, Ms Katrina Chambers, Associate Professor Adam Ewing, Ms Sonia Hancock, Dr Bridget Pratt, Associate Professor Simon Denny and Professor Michael Kimlin.

The Mater Research Compliance team, led by Ms Imelda Ryan, ensures researchers adhere to best practice standards and procedures. This ensures that research is conducted according to the appropriate regulatory, ethical and scientific standards, which involves a two-step process, research ethics and research governance reviews.

During September 2023, the Research Compliance Team held workshops focused on research governance, research agreements, and ethics approval processes. The workshops were held in response to growing concern within Mater's research community about the impact of research administration on research commencement timing and a desire for a streamlined and consistent approach. As part of the consultation process, researchers were encouraged to share any frustrations regarding the ongoing management of their research projects and the pain points they experienced while seeking approval for their research.

In response to feedback from these workshops, the Research Compliance team has developed a program of priority improvement projects to address the critical concerns identified by researchers.

As part of the efforts to reduce researcher burden, a simplified

SSA (Site Specific Assessment) form was released, which reduces the documentation that must be submitted for studies where Mater is not the Therapeutic Goods Administration sponsor. A Research Resources Library has also been created by the Research Compliance team with Guidelines, Fact Sheets, Templates and other resources to assist researchers in obtaining approvals.

Members of the Mater Research Compliance Team:

- Ms Imelda Ryan
- Ms Jodie Savini
- Ms Amanda Sands
- Ms Laisa Teleni
- Ms Dominique Williams
- Ms Ruth Lee
- Ms Julia Britain
- Mr Raunak Prasad
- Ms Erin Robson
- Ms Danielle Wade
- Ms Eloise French





Clinical Trials

Clinical trials are an essential component of modern healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, medical devices and other health interventions, and offer alternative options for patients with unmet needs under the current standard of care.

Part of Mater's commitment to providing patients with access to the best quality healthcare includes giving patients the opportunity to participate in clinical trials. These trials translate scientific discoveries into the best possible treatment, care and outcomes for patients and our broader community. Patients taking part in clinical trials learn more about their health, play a more active role in decision-making, and have better health outcomes.

Mater Clinical Trials (MCT) – a division of Mater Research – is highly experienced in clinical trials. Led by Ms Alicia Rooney, MCT provides support for clinicians to run clinical trials in Mater hospitals across a broad range of therapeutic focus areas including:

- Maternal and Neonatal Health
- Medical Oncology
- Gynaecological Oncology
- Neuroscience
- Respiratory Disease
- Infection
- Haematology
- Liver Disease
- Metabolic Medicine
- Intensive Care
- Surgery.



MCT facilitates the coordination of clinical trials to ensure compliance with national and international regulatory requirements (NHMRC, TGA, ICH GCP). The types of clinical trials supported by MCT include:

Industry sponsored

These trials are sponsored by an industry organisation that has approached Mater to gain access to suitable patient cohorts. Generally, the primary purpose is to assess the safety and/or efficacy in humans of a novel drug, device, diagnostic, treatment, preventative measure, or other intervention when delivered in a 'real world' clinical setting.

Collaborative group trials

Collaborative groups of practising clinician researchers conduct these trials across multi-sites. These researchers (often several hundred per network) come together to identify important clinical questions and design large multi-centre clinical trials to answer them.

Investigator-initiated trials

Defined as unsolicited, independent studies with scientific and medical merit developed and sponsored by an independent investigator or academic organisation. An investigator-initiated trial may be funded via various means, including Mater Foundation or other philanthropic sources and competitive grant schemes.

Cohort studies

A type of research design, they are also called longitudinal studies.

MCT currently supports 68 principal Investigators across 242 active clinical trials based at Mater hospitals. The unit has undergone a restructure to streamline its services and has gone from strength to strength.

The knowledge gained through clinical trials is necessary to deliver evidence-based practice.

Administering and actioning clinical trials requires specialist research staff, including Clinical Research Managers, Clinical Trial Coordinators, Research Nurses, Research Assistants, Administrative Assistants, Technicians and other specialists employed through MCT. Without the expertise and dedication of the clinical trials research staff, clinical trials for patients at Mater wouldn't be possible. Mater Foundation funding has been integral in establishing the MCT and subsidising support of innovative Mater-based investigator-led clinical trials and cohort studies.

From June 2023, hospital accreditation (through the Australian Health Service Safety and Quality Accreditation scheme) includes an assessment against a new National Clinical Trials Governance Framework that aims to embed clinical trial delivery into clinical care and report back to consumers, workforce and governance structure. MCT is working with Mater Health to implement the Framework.



Clinical Trials


Organisational Chart




Director of Clinical Research
Prof Maher Gandhi




Senior Manager, Clinical Trials
Ms Alicia Rooney





Principal Investigator main oversight of teams





Clinical Trials

iSEARCH: Can intrapartum Sildenafil safely Avert the Risks of Contraction-induced Hypoxia in labour? A Pragmatic Phase 3 Randomised Controlled Trial.

In Australia, almost one in four caesarean sections are performed for suspected fetal distress, which occurs when the placenta cannot supply sufficient oxygen and nutrients in labour. The only therapeutic options are emergency caesarean section or instrumental vaginal birth, which can have serious consequences.

Mater Research's Genesis Maternal Fetal Medicine Research Group, which is led by Professor Sailesh Kumar, Senior Staff Specialist at Mater Mothers' Hospital, is currently running a clinical trial named iSEARCH. The trial is an Australia-wide multicentre randomised controlled trial that is rigorously evaluating the potential of using Sildenafil Citrate (otherwise known by the trade name VIAGRA™) to a placebo. Funded by the Australian Medical Research Future Fund (MRFF), iSEARCH aims to improve outcomes for women and babies by reducing fetal distress during labour.

Sildenafil Citrate, which works by dilating blood vessels during labour, increases placental blood flow to the baby.

If Sildenafil Citrate is proven to improve birth outcomes, it is likely to change clinical practice. Sildenafil Citrate is already used in the Neonatal Critical Care Unit (NCCU) to treat babies with pulmonary hypertension, so its safety is well established.

The Group's earlier phase two clinical trial, RIDSTRESS, showed very promising results, with Sildenafil Citrate reducing the risk of fetal distress and the need for emergency delivery by caesarean section, vacuum or forceps by 50 per cent in comparison to the control group. Women who were in the Sildenafil Citrate group were also found to have shorter labours and fewer babies passing meconium in the womb (which can cause severe lung complications).

The Genesis Maternal Fetal Medicine Research Group is also running another smaller trial, RidStress2, that is supported by the National Health and Medical Research Council (NHMRC) and MRFF. RidStress2 is investigating the potential of Sildenafil Citrate to improve birth outcomes for small for gestational age babies.

Pictured right: Mater Research Genesis Maternal Fetal Medicine Research Group. L-R: Carmel Mallon, Dr Jesrine Hong, Dr Kylie Crawford, Jasmine Wood, Gabby Rowsell, Bianca Ryan, Helen Kay, Kate Jarrett, Dr Tegan Triggs, Erika Cavanagh, Prof Sailesh Kumar and Jenny Hong (not pictured: Dr Shannyn Rosser).



**The iSEARCH
Group comprises
six midwives and
three obstetricians.**

Obstetricians:

- Prof Sailesh Kumar
- Dr Shannyn Rosser (PhD candidate)
- Dr Tegan Triggs (PhD candidate)

Midwives:

- Ms Helen Kay
- Ms Bianca Ryan
- Ms Jasmine Wood
- Ms Gabby Rowsell
- Ms Elyse Fitzpatrick
- Ms Kate Jarrett



Clinical Trials



MEDCAN3: Improving Symptom Management in Advanced Cancer.

Each year, approximately 100,000 patients in Australia receive end-of-life support in palliative care. Despite improvements to medical care, patients with advanced cancer still experience substantial symptom distress, therefore it is of critical importance that better treatments to reduce end-of-life pain and distress for both patients and carers are found.

Whilst medication provides a core component of improving symptoms, there remains a need for more effective options to improve symptom control, especially in areas such as fatigue, anorexia, anxiety and weight loss, and medicinal cannabis presents an alternate “natural” option for managing the symptoms of those with advanced cancer.

Mater Research’s Palliative and Supportive Care Group is currently running MEDCAN3, an investigator-Initiated study, led by Professor Phillip Good and Professor Janet Hardy. MEDCAN3 builds upon the Group’s internationally leading medicinal cannabis research program, aiming to determine if medicinal cannabis improves the symptoms of advanced cancer, such as pain, nausea, shortness of breath, anxiety and depression.

Whilst there has been increasing interest in the use of medicinal cannabis to relieve symptoms in palliative care patients in recent years, to date, there is little high-quality evidence supporting the benefit. MEDCAN3 hopes to change this.


MEDCAN3 is being run across various sites throughout Australia and is the first medicinal cannabis clinical trial in Australia that is being run across more than one state. The trial also includes regional facilities, including Townsville and the Sunshine Coast, facilitating equitable access to medicinal cannabis trials for rural and remote-based patients through tele-trials.

MEDCAN3 offers a safe and carefully monitored environment to build a high-quality evidence base for the benefits of the community using cannabidiol (CBD) dominant medicinal cannabis, with minimal amounts of Tetrahydrocannabinol (THC—the primary psychoactive component of cannabis).

Medicinal cannabis was approved for use by the Australian Government, despite the lack of clinical evidence to effectively

guide its use by physicians. The use of medicinal cannabis includes many unknown factors, including which of the many cannabinoids found in the cannabis plant is best suited to which symptom, what is the best dose and dosing schedule and what are the dose-limiting side effects.

Previous trials in the medicinal cannabis area run by the group included an open-label pilot study that showed promising preliminary data of improvement in emotional well-being, two completed randomised controlled trials (RCTs), one of which was published in the prestigious Journal of Clinical Oncology, showing no benefit of pure cannabidiol (CBD) over good palliative care alone in reducing symptom burden; and a qualitative study exploring patients’ views of MC. MEDCAN3 expands into new areas highlighted during their research so far. Such as new dose combinations, impact on sleep, carer experience and the role of genomics.



AURORA: an Australian multicentre, prospective observational cohort study to evaluate the real-life experience of Ustekinumab in patients with moderate to severe Crohn's disease – study protocol.

Crohn's disease is a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhoea, and a predisposition to bowel cancer. Crohn's disease can develop at any age but usually first appears in people aged 15 to 30. Crohn's disease is more common in people living in the western world, but it's also becoming more common in developing countries. Australia has one of the highest rates of IBD in the world, with Crohn's disease affecting more than 60,000 Australians.

There is currently no cure for Crohn's disease, and patients with Crohn's disease have limited therapeutic options. First-line drug treatment options are only effective in a proportion of patients and the development of treatment resistance is common. Therefore, alternative therapies are required for disease management.

The MCT IBD Group investigator-initiated study, led by Dr Yoon-Kyo An and supported by pharmaceutical company Janssen,

aims to determine the clinical outcomes after Ustekinumab treatment in patients with Crohn's disease in a real-world setting. Ustekinumab is a monoclonal antibody medication that suppresses the immune system and is one of the few biologics available to patients resistant or intolerant to the usual first-line treatments for Crohn's disease.

The IBD Group led a national multi-centre prospective observational cohort study of Ustekinumab for moderate to severe Crohn's disease sufferers. Patients were recruited from nineteen centres over three years. This large real-world study confirmed that Ustekinumab is most effective in Crohn's disease patients who had not previously received biological therapies with significantly higher response and remission rates than those patients who had. This could represent a novel predictor of long-term clinical outcomes.

"Ustekinumab is a monoclonal antibody medication that suppresses the immune system and is one of the few biologics available to patients resistant or intolerant to the usual first-line treatments for Crohn's disease."



Clinical Trials

The Light Knee Study: The effects of light therapy on post-operative pain and functional mobility in people undergoing knee replacement surgery.

Osteoarthritis is the most common form of arthritis, causing inflammation and damage to the joints and progressive structural damage. While the condition, which makes walking, climbing stairs, and other physical activities challenging, can affect any joint in the body, it most commonly affects the knees. Over 67,000 knee replacements were performed in Australia in 2022, however, approximately one in five of these people are dissatisfied with the result due to ongoing pain.

In a bid to help patients get back on their feet faster and pain-free, Mater Researcher Associate Professor Liisa Laakso is working with a medical device company to run an investigational study. This study is looking at the effects of photobiomodulation (PBM) therapy on post-operative pain and functional recovery involving 60 patients who have had knee replacement surgery at Mater Hospital Brisbane.

Participants are randomly assigned to either an active or “sham” treatment group and provided four “light patches” to place on their leg for 30 minutes daily for several weeks before and after knee surgery to test the effectiveness of a light-emitting adhesive patch that shines red and blue light on the knee joint and thigh muscle.

The device being investigated uses a novel, 3-D printed self-adhesive patch with hundreds of micro-diodes (light emitting diodes are found in many home appliances) that emit specific light frequencies that have been found in other research to reduce inflammation and pain.

The sham group participants are given a device that looks and feels like an active device, but no photonic energy will be emitted between the light pulses. Participants are shown how to self-apply the patches at home to standardised positions over

the large muscle at the front of the thigh, behind the knee, and above and below the knee at each treatment and remove the patches following each 30-minute daily treatment.

The trial includes multiple home visits both before and after the scheduled surgery (for up to one year) by a qualified physiotherapist to assess pain and mobility using standardised tests. Bone and fluid samples taken from the knee during surgery will also be collected to investigate biological mechanisms if therapy is demonstrated as being effective.

The study aims to determine whether there are improvements in inflammation, pain, and movement recovery in the active intervention group compared to the sham group and whether this intervention provides a drug-free treatment alternative to improve knee replacement surgery outcomes.

“The study uses a novel, 3-D printed self-adhesive patch with hundreds of micro-diodes that emit light frequencies to reduce inflammation and pain.”



 mater
research

Care  Wear
Large Carrying Kit



Mater Research Biobanks

Biobanking is storing remaining human tissue that has been removed during a medical procedure such as an operation, a biopsy, or a blood test. This extra tissue is not needed for diagnosis or treatment. Written consent is obtained from a donor and the tissue is sent to a biobank, where it is carefully preserved and protected.

Mater Research has four major biobanks – the David Serisier Research Biobank, the Gynaecological and Breast Cancer Biobank, the Mater Inflammatory Bowel Disease Biobank and the Queensland Family Cohort Study Biobank. These biobanks underpin many programs of research from discovery and translational research through to clinical trials.

Gynaecological and Breast Cancer Biobank


Gynaecological malignancies represent one of the most common causes of female cancer death worldwide. Breast cancer alone is the most commonly diagnosed cancer and the second leading cause of cancer death in Australian females.


Mater Research's Gynaecological and Breast Cancer Biobank provides long-term storage of processed samples and can supply live tissue immediately for research use in functional studies, including research studies developing rapid therapeutic effectiveness assays to provide clinicians with precision information to inform the best treatment pathway.

Mater Inflammatory Bowel Disease Biobank

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gut believed to have a multi-factorial aetiology. The Mater IBD Biobank was conceived to collect biospecimens from patients and healthy controls undergoing endoscopy to help elucidate the complex causes of IBD, the progression of disease over time, the various phenotypic manifestations and explore the complex interaction between the immune system and the gut ecosystem (including microbiota).

The biobank houses matched tissue biopsy specimens for histologic analysis, RNA expression analysis and DNA for mucosal microbiome composition analysis as well as serum samples, germline DNA from whole blood and stool samples for microbial analysis. This is paired with a clinical database for IBD patients which captures disease behaviour, disease activity (at each site), medications, and other clinical data.





The David Serisier Research Biobank

The David Serisier Respiratory Biobank (DSRB) is the only biobank in Australia dedicated to aiding and facilitating research into respiratory disease. Named in honour of the late Dr David Serisier, who was Mater's Director of Respiratory Medicine, the DSRB collects specimens for research into chronic respiratory disease, respiratory infections and lung cancer. By providing valuable samples for use in ethically approved research projects, the DSRB hopes to improve the health of respiratory patients in Australia and the world.

The DSRB biobank recently expanded to include a broader range of biological samples beyond respiratory samples.

Queensland Family Cohort Biobank

The Mater Research-led Queensland Family Cohort Study (QFC) aims to understand factors influencing healthy growth, well-being, and aging to support children and families throughout their lives. Parallel to this, Mater Research is contributing to closing the Aboriginal and Torres Strait Islander Health gap by adapting the QFC protocol to create a more targeted Indigenous QFC (IQFC). Ultimately, the QFC looks to recruit 12,500 pregnant families across Queensland and intends to follow up with families and children for three decades. Pregnant women and their partners are enrolled at 24 weeks gestation and followed up at defined intervals before and after birth, where questionnaires, biological samples, and physical measurements are completed/provided.



Above: The late Dr David Serisier



Program Reports






Mater Research is a recognised leader in medical research. Our bench to bedside philosophy means we are committed to working closely with Mater Health, Mater Education and our collaborating partners to turn scientific discovery into the best possible treatment, care, and outcomes for patients and our broader community.

Four of our programs are co-led by a clinical and biomedical lead, while our Healthcare Delivery and Innovation program has a medical and nursing co-lead.

Our programs are Cancer, Chronic and Integrated Care, Healthcare Delivery and Innovation, Mother and Baby and Neuroscience. We encourage our programs to be interlinked, and many of our research groups perform ground-breaking research that spans across individual programs.





Cancer Program

We're investigating the biological basis of many solid and blood borne malignancies, advancing diagnosis, developing and trialling new therapies, and improving all aspects of the management of cancer including palliative care.

Program Lead:



Professor Janet Hardy
Palliative and Supportive
Care Research



**Associate Professor
Adam Ewing**
Translational
Bioinformatics Research
from 1 November 2023



Professor Kristen Radford
Cancer Immunotherapies
Research
until 1 November 2023

Group Leaders:



Professor Maher Gandhi
Blood Cancer Research



Professor Allison Pettit
Bones and Immunology
Research



Professor John Hooper
Cancer Biology Research



Professor Brian Gabrielli
Smiling for Smiddy Cell Cycle
Melanoma Research



**Associate Professor
Ingrid Winkler**
Stem Cells and Cancer
Research

Meet Our People

Associate Professor Adam Ewing



Associate Professor Adam Ewing is a Research Fellow and leads the Translational Bioinformatics Research Group at Mater Research. He became the Biomedical Program Leader for the Cancer Program at Mater Research in 2023. A/Prof Ewing has had successful Australian Research Council funding and holds a Medical Research Future Fund Fellowship. His Research Group focusses on applying computational modelling backed

by molecular and cellular biology expertise to better understand the genetic complexity of mutations in disease-related processes such as cancer.

A key factor in understanding this is to better understand how human genes have duplicated and what these duplicates do to control gene activity and make essential proteins. One focus of A/Prof Ewing and his group is to investigate how newly duplicated genes are linked to genetic diseases and cancer. His team has developed and implemented ideas using state-of-the-art technologies such as nanopore sequencing and CRISPR interference. The knowledge will help understand the functions of human genes to improve precision medicine.

Another focus is to use new technologies to measure DNA methylation in order to study imprinted genes, which are genes where the copy from the mother and the copy from the father behave differently. Given that growth and development early

in life are known to be driven and regulated by imprinted genes, it stands to reason that they may also suppress or promote tumour growth. Imprinting is controlled through methylation, which is a chemical modification of DNA that may be retained as cells divide to make more cells. The group's aim is to identify changes in imprinting by comparing tumour tissue to precancerous tissues and to non-tumour tissue in order to identify regions of the genome where imprinting is altered as cancer develops.

A/Prof Ewing and his Group aim to expand their research into imprinted genes and genetic variation into triple-negative breast cancer and high-grade serous ovarian carcinomas. These are aligned with Mater Health's collaborators' interests and expertise in women's cancer care. These conditions are significant contributors to mortality and morbidity among women, not only in Australia but also worldwide, with the associated economic and human burdens being substantial.



Chronic and Integrated Care Program

We're building greater understanding of the biological basis of a broad range of chronic diseases, and developing preventative strategies and innovative treatments to improve patient outcomes.

Program Lead:



Professor Josephine Forbes
Glycation and Diabetes Complications Research



Associate Professor Lucy Burr
Respiratory and Infectious Diseases Research

Group Leaders:



Professor Jean-Pierre Levesque
Stem Cell Biology Research



Associate Professor Sumaira Hasnain
Immunopathology Research



Professor Katharina Ronacher
Infection, Immunity and Metabolism Research



Associate Professor Jake Begun
Inflammatory Bowel Diseases Research



Professor David Hume AO
Macrophage Biology Research




Professor Kim Summers
Genetics, Genomics and Transcriptomics Research



Associate Professor Katharine Irvine
Innate Immunity and Inflammation



Dr John Kemp
Musculoskeletal Genomics Group



Meet Our People

Professor Josephine Forbes



Professor Josephine Forbes is a NHMRC Investigator grant holder and Program Leader of Mater Research's Chronic and Integrated Care Research Program. Prof Forbes leads a Group of 10 researchers at Mater Research focused on glycation and diabetes complications. Her group investigates new treatments for diabetes and its debilitating chronic complications, including kidney disease, blindness, amputations and heart disease. One of the areas that Prof Forbes is working on is investigating why more children are getting Type 1 diabetes. As the newly appointed President

of the Australian Diabetes Society, she advocates for patients and researchers through Diabetes Australia and JDRF.

Type 1 diabetes develops due to an autoimmune response where the body's immune system destroys its own insulin-producing beta cells in the pancreas. It is still unclear what triggers this autoimmunity. However, several factors may be important, including viral infections during pregnancy and early childhood, environmental pollutants and genetics. By identifying the factors that initiate islet autoimmunity in early life, Prof Forbes and her group can potentially prevent Type 1 diabetes before the autoimmune process begins.

In collaboration with partners, Prof Forbes is working on a potential new therapeutic that may slow the development of islet autoimmunity. This therapeutic is safe in adults and there are to conduct an early-stage clinical trial in younger people.

Prof Forbes is also involved in the Environmental Determinants of Islet Autoimmunity Study (ENDIA). Since 2013, the study has followed 1,500 families, including

children from birth, with an immediate relative with Type 1 diabetes. In the 10 years since the ENDIA study began, a wealth of biological samples and surveys have been collected, including from Mater Mothers' Hospital.

Type 1 diabetics are also at risk of kidney disease, which leads to cardiovascular complications. The diabetes community has many resources, including the ENDIA biobank, which holds biological samples, data, and surveys. To solve the mystery of what causes this increase in Type 1 diabetes in children, Prof Forbes' group plans to access this biobank and analyse the data.

Prof Forbes' Research Group will continue working on their studies in young people with Type 1 diabetes. They have also actively been extending these studies to include other vulnerable and under-served groups, both young people with Type 2 diabetes and young people of Indigenous descent at Queensland Children's Hospital before and at the diagnosis of diabetes. They will continue to focus on completing these studies in First Peoples and youth with Type 2 diabetes.





Healthcare Delivery and Innovation Program

Our multi-disciplinary teams are addressing health-related research questions that impact across all health disciplines. We're working across areas including education, health economics and implementation science, and seek robust consumer input to address research topics that have relevance for the community.

Program Lead:



**Associate Professor
Simon Denny**
Mater Young Adult
Research



Dr Beth Mah
Director of Catherine's House
for Mothers, Babies and
Families

Group Leaders:



**Associate Professor
Liisa Laakso**
Allied Health Research




Professor Sandie McCarthy
Living Well with Cancer Program

Collaborative Research Group Lead:



Professor Claire Jackson
Centre for Health System
Reform and Integration



Meet Our People

Dr Beth Mah



Dr Beth Mah joined Mater in 2022 as the inaugural Director of Catherine's House for Mothers, Babies, and Families, Queensland's first integrated perinatal mental health service where parents experiencing serious depression, anxiety and other mental health issues after the birth of their baby can stay with their infants while receiving treatment.

Catherine's House provides a comprehensive, integrated perinatal mental health service, 10 in-patient beds for public and private patients, a Parent Support Centre for parents and babies up to six months after birth, home visiting services to help improve infant-parent relationships, individual and group therapy treatments, and day programs. A multidisciplinary group of psychiatrists, lactation consultants, allied health practitioners, paediatricians, nurses, and other professionals care for families.

As an experienced perinatal and infant psychiatrist, Dr Mah is also the Program Leader for Mater Research's Healthcare Delivery and Innovation Program, where she supports the translation of innovative healthcare approaches. Her research into perinatal mental health includes treating trauma that presents in the perinatal period. She also has a special focus on vulnerable

populations and improving outcomes for Aboriginal and Torres Strait Islander mothers and babies, including those affected by childhood trauma and neurofeedback treatment of complex post-traumatic stress disorder (PTSD) symptoms in Indigenous foster children.

Since Catherine's House opened in March 2023, Dr Mah has been instrumental in initiating its service offerings, and in the nine months since it opened, Catherine's House has admitted over 30 patients. Most patients admitted to Catherine's House have PTSD as their primary diagnosis, with almost 20 per cent of patients presenting with this issue as their primary complaint. As well as PTSD, many patients have co-morbid diagnoses such as depression and/or anxiety. Prior to joining Mater, she was the clinical lead psychiatrist at Saint John of God Healthcare.





Mother and Baby Program

We're studying the pathophysiology and improving clinical management of pregnancy complications, and optimising the care of women during healthy pregnancy. We're also focused on improving women's postnatal and broader gynaecological health. We're continuing to advance the care and outcomes for sick neonates, and studying the relationship between fetal development, early life experience and lifelong health.

Program Lead:



Professor Vicki Flenady
Centre of Research
Excellence in Stillbirth



Professor Helen Liley
Critical Care of At-Risk
Newborns Research

Group Leaders:



Professor Vicki Clifton
Pregnancy Development
Research



Professor Sailesh Kumar
Genesis Maternal Fetal
Medicine Research



**Associate Professor
Kym Rae**
Indigenous Health Research



Dr Sandy Richardson
Developmental Molecular
Genetics Research

Pictured opposite: A/Prof Kym Rae and Research Assistant Loretta Weatherall

Meet Our People

Associate Professor Kym Rae



Associate Professor Kym Rae is the Principal Research Fellow in Indigenous Health at Mater Research, as well as Leader of the Queensland Family Cohort Study and Group Leader of Indigenous Health Research.

Her work in Indigenous Health has been recognised through various awards, including the 2022 Women in Technology Award for Inspiring Diversity, the 2022 The University of Queensland Faculty of Medicine Spirit of Reconciliation Award and a recent \$4.69 million grant from the National Health and Medical Research Council (NHRMC) that aims to close the healthcare gap for Aboriginal and Torres Strait Islander families.

Despite communities consistently agreeing that the perinatal period is of critical importance for future health, to date, there have been no studies using a co-designed approach to investigate the critical importance of the first 1,000 days in the development of Aboriginal and Torres Strait Islander children to healthy adults.

For this reason, A/Prof Rae and her research group are co-designing a longitudinal study—the Strong Families Study—with First Nations communities of Queensland, that will follow Aboriginal and Torres Strait Islander parents and their children for the first 1,000 days of life.

The study, which aims to improve health outcomes for First Peoples' communities, has seen A/Prof Rae and her research group spend 2023 growing deep connections with Queensland's First Peoples communities, undertaking 52 focus groups with 10 communities across the state. This extensive work has been done to ensure that the voices of First Peoples communities are heard and to determine the direction of research being undertaken by her group.

By partnering with communities, the research team is forging strong alliances and focusing on improving the understanding of the serious health issues identified by community members to support the growth of strong families in communities.

First Peoples communities identified that the Strong Families Study should be co-led with Indigenous researchers and co-designed with an Indigenous Steering Group. Over half of the Investigatory Group identify as Indigenous and the project is partnered with several Aboriginal community-controlled health services. The Indigenous Steering Group members had their first meeting in December 2023 to begin co-designing the research details of the cohort. Aboriginal Health Workers will be at the frontline of the study at each site

to work with local community-controlled services and health and hospital services to ensure families can access healthcare and support services as and when needed, without going on lengthy waiting lists – which means better outcomes for families in need.

Yarns held with communities to date have identified important impacting health outcomes including social and emotional wellbeing, exposure to trauma, grief and loss and impacts of racism and access to basic healthcare interventions, such as hearing, eyes and dental care.

The Strong Family Study plans to improve the understanding of the drivers of long-term health for First Peoples and understand what can influence disease development. Notably, the study is also a mechanism to undertake early diagnoses and referrals to culturally safe healthcare interventions for parents and their children. First Peoples' communities have a higher risk of chronic health conditions, such as diabetes, heart disease and kidney disease, but often struggle to get the care they need. Babies also face a higher risk of being born prematurely and with low weight which puts them at greater risk for poor neurodevelopmental outcomes.

Having a strong culture improves health and resilience for Aboriginal and Torres Strait Islander people. The Research Group is determined to walk hand in hand with Aboriginal and Torres Strait Islander communities to create a better today, a better tomorrow and a stronger future for their families.



Neuroscience Program

We're seeking greater understanding of the genetics and pathophysiology of diseases of the brain and nervous system, and improving the diagnosis and surgical, medical and psychological management of neurological disease, intellectual disability and cognitive health.

Program Lead:



Professor Geoffrey Faulker
Genome Plasticity and Disease Research



Dr Cathy Franklin
Queensland Centre for Intellectual and Developmental Disability

Group Leaders:



Associate Professor Jake Gratten
Cognitive Health Genomics



Dr Dhanisha Jhaveri
Neural Stem Cell Biology Research



Professor Peter Nestor
Cognitive Neurology



Dr Andrew Swayne
Neuroimmunology Research



Associate Professor Paul Dawson
Neurodevelopmental Research



Professor Aileen McGonigal
Epilepsy, Rhythms and Behaviour Research



Dr Carlie Cullen
Glial Neurobiology, Cognition and Behavioural Research

Meet Our People

Professor Aileen McGonigal



Professor Aileen McGonigal joined Mater in early 2022 as head of the Epilepsy, Rhythms and Behaviour Research Group. She also holds a clinical appointment as director of the Epilepsy Unit at Mater Hospital Brisbane.

Prof McGonigal and her group are working on improving the prediction of the origin of seizures to optimise treatment and understanding the changes in the brain's network associated with stress. Around a third of patients with epilepsy don't respond to drug treatment; this is known as focal drug-resistant epilepsy and for these patients, surgical intervention is the only option.

The main aim of Prof McGonigal's clinical research is to improve patient care through a better

understanding of epilepsy, especially for patients with drug-resistant epilepsy who may benefit from surgical intervention. Prof McGonigal specialises in stereoelectroencephalography (SEEG), which is a diagnostic method used to investigate patients with focal drug-resistant epilepsy who usually need surgery to control or prevent seizures. SEEG records seizures and investigates how behaviour is related to brain rhythms. She has initiated an Australia-wide SEEG consortium to facilitate collaboration, and a retrospective analysis of all SEEG studies (around 250 cases over the last 10 years, in 6 centres including Mater) is underway. This consortium is also facilitating increased international collaboration for SEEG studies.

A key finding of Prof McGonigal's group was the description of successful surgical outcomes in "MRI-negative" epilepsies using SEEG brain localisation. This led to changes in clinical practices worldwide. The SEEG has replaced subdural EEG as the preferred intracranial EEG presurgical evaluation method. Prof McGonigal's research has also contributed to the understanding of epileptogenic brain networks and their relationship to seizure symptoms, shifting the paradigm of epilepsy as a network disorder

and influencing surgical strategies. Furthermore, national guidelines for SEEG use have contributed to her widespread recognition and citation internationally.

Prof McGonigal is also collaborating with the David Serisier Biobank and with neuroscience researchers at The University of Queensland to study changes in the brain tissue of people who have previously undergone epilepsy surgery. Researchers will study changes in metabolism and synaptic function and shed new light on mechanisms of epilepsy that can help shape the development of future treatment options.

As a result, more targeted and personalised treatments can be used for people with epilepsy. Patients will be more effectively selected for surgery and can undergo more precise and effective surgery. This will reduce society's health and economic burden and improve quality of life for patients and caregivers. In addition, more centres may evaluate patients, relieving the burden on the few specialist centres and bringing benefits to patients from regional Australia and resource-poor countries.



Grant Successes 2023 – Lead Investigator

External Grants



\$13.7m
24 grants

National Health & Medical Research Council

A/Prof Kym Rae, Clinical Trials and Cohort Studies, First Peoples co-designed cohort to support improved perinatal and early childhood outcomes.

\$4,687,886

A/Prof Jake Begun, Ideas Grant, Harnessing microbial immunomodulatory function to treat inflammatory bowel diseases.

\$1,655,520

Dr Sahar Keshvari, Investigator Grant (Emerging Leadership 1 Level), Macrophage Therapeutic Potential in Paediatric Non-Alcoholic Fatty Liver Disease

\$637,040

Dr John Kemp, Investigator Grant (Emerging Leadership 2 Level), Using human genetics, single-cell transcriptomics and animal models to accelerate drug development for patients with osteoporosis.

\$1,586,190

Australian Government – Department of Health

Dr Siobhan Loughnan, Improving quality of care and outcomes for parents and families following perinatal loss across maternity services in Australia – Expansion of the IMPROVE education program.

\$980,042

Australian Centre for Accelerating Diabetes Innovations

Dr Amelia Fotheringham, Early Career Research Grant, Targeting the receptor for advanced glycation end products (RAGE) to prevent diabetic kidney disease; Using a spatially resolved approach to understanding RAGE's immunomodulatory role

\$40,000

Dr Irina Buckle, Early Career Research Grant, Receptor for Advanced Glycation Endproducts (RAGE) Targeting for Treatment and Prevention of Type 1 diabetes

\$40,000

Industry, Government and other Research Funding

Dr Richard Fernandes, Crohn's and Colitis Australia, PhD Scholarship, Improving our understanding of post-operative Crohn's disease recurrence.

\$84,000

A/Prof Sumaira Hasnain, Gastroenterology Society of Australia (GESA), Project Grant, Pancreatology: Developing Pancreas-Targeted Interleukin-22 as a Therapeutic for Chronic Pancreatitis.

\$50,000

Dr Richard Fernandes, GENIUS Research Fellowship, Assessing for post-operative Crohn's disease recurrence with early intestinal ultrasound: POCIUS Study.

\$50,000

A/Prof Begun, GENIUS Research Grant, Assessing the utility of handheld ultrasound devices for gastrointestinal ultrasound by inflammatory bowel disease expert users.

\$50,000

Dr Caroline Nicholson, HCF Research Foundation, Research Grant, to identify and provide management support for people at risk of frailty in general practice to reduce potentially preventable hospitalisations

\$331,337.60

A/Prof Ingrid Winkler, Leukaemia Research Foundation, Strategic Ecosystem Research Partnerships (LF SERP), Manipulating vascular environments to alleviate cancer therapy side-effects

\$148,016

Dr Minh Dao Ngo, Lung Foundation Australia, CREATE Hope Fellowship in Pulmonary Fibrosis Research, Targeting the Oxysterol/Gpr183 Axis to Treat Idiopathic Pulmonary Fibrosis

\$75,000

A/Prof Jake Begun, Micromune Therapeutics Pty Ltd, CUREator Grant, Micromune Research Project - Microbiome derived IBD small molecule

\$225,492.30

Dr Grace Branjerdporn, Queensland Government, Safe & Diverse Communities Fund, The HELP Project: Health professional Educational Learning Package supporting the identification of and response to domestic and family violence in the peripartum for culturally and linguistically diverse families

\$25,000

Prof Kristen Radford, Ovarian Cancer Research Foundation, Research Grant

Under embargo

Prof John Hooper, Pankind, Accelerator Grants – New Treatments, Receptor-directed precision medicines for pancreatic cancer

\$300,000

Prof Claire Jackson, Queensland Government, Queensland Health, Health System Reform and Health Integration

\$450,000

Prof Vicki Clifton, Queensland Government, Health and Wellbeing Impact Grants Round, QFC – capturing the data on GEN Q

\$200,000

Overseas Agencies

Dr Joshua Tobin, American Society of Clinical Oncology, Young Investigator Award, Metabolic Reprogramming of Malignant B-cells Impairs Immune-Fitness of Intratumoral T-Cells in Follicular Lymphoma

USD\$50,000 / AUD\$75,522

Dr Irina Buckle, International Juvenile Diabetes Research Foundation, Pilot and Feasibility Study, Understanding RAGE Expression and Function in Human T and Dendritic Cells to Refine the Use of RAGE Targeting Therapeutics for Type 1 Diabetes Prevention


\$USD200,000 / \$AUD\$303,861

Prof Kristen Radford, Commercial Research

Confidential

Grant funding by Research Income category:

- Category 1: **Australian Competitive Grants Register**
- Category 2: **Other Public Sector Research Income**
- Category 3: **Industry and Other Research Income**
- Category 6: **Contract/Commercial Research**





Internal Grants

Betty McGrath Healthcare Delivery and Innovation Seeding Grants

The Betty McGrath Healthcare Delivery and Innovation Seeding Grants fund novel and well supported research projects carried out by Mater People with the potential to enhance healthcare delivery at Mater into the future.

The 2023 recipients of the Betty McGrath Healthcare Delivery and Innovation Seeding Grants are:



Dr Beth Mah

Psychedelic Assisted Psychotherapy in a Perinatal Mental Health Inpatient Unit setting: A Mixed Methods and Feasibility study



Dr Neisha D'Silva

Evaluation of a Novel Eating Disorder Prevention Program for Young Women with Type 1 Diabetes: A Randomised Control Trial



Dr Honnie Gorry

Feasibility Study and Pilot RCT of EEG Neurofeedback in a Hospital Setting



A/Prof Liisa Laakso

Physical Activity during Chemotherapy to Enhance Recovery (PACER)

Betty McGrath Education Seeding Grants

Seeding Grants fund novel and well supported research projects by Mater People with the potential to improve evidence-based practice in the areas of education, training, learning and development, simulation, and practice development at Mater, and improving teaching and learning outcomes.

The 2023 recipients of the Betty McGrath Education Seeding Grants are:



A/Prof Sarah Janssens

Evaluating the Impact of a focused Education Program for the Implementation of the Maternity Team Approach in Clinical Practice.



Dr Jasmine Antoine

Enhancing Trainee's Technical and Non-Technical Skills in Neonatal Intubation (ETT NOTES)

Early Career Researcher Seeding Grants

The Early Career Researcher Seeding Grants are open to eligible Mater Early Career Researchers and each round funds one biomedical and one clinical/health research project. This competitive scheme aims to assist successful applicants to be competitive in national and/or international grant schemes.

The recipients of the 2023 Early Career Research Seeding Grants are:



Dr Yuanhao Yang
Biomedical Seeding Grant

Dissecting the role of alpha-synuclein in Parkinson's disease using high-throughput proteomics



Dr Uyen Pham
Clinical Seeding Grant

Mitochondrial dysfunction and immune system activation in early diabetic kidney disease

Strategic Grant for Outstanding Women

Through the generous support from the Mater Foundation, the Mater Research Strategic Grant for Outstanding Women was implemented as a step toward closing the 'research academic gender gap'. The grant amplifies women who have excelled in their field by providing funding for two years to support the research and career progression of high-profile and high-potential female researchers at Mater. This better positions these high performing women for success in research, accelerating their progress toward academic promotion.

The recipient of the 2023 Mater Research Strategic Grant for Outstanding Women is Dr Sahar Keshvari.





Awards 2023

External Awards



Prof David Hume AO

Appointed an Officer of the Order of Australia in recognition of his distinguished service to biological science and tertiary education



A/Prof Sumaira Hasnain

Received the inaugural Laurie Powell AC Award from the Gastroenterology Society of Australia



Dr Katie Brooker

Received the Margo Prior ECR Award from the Australasian Society for Autism Research



Prof Lewis Perrin

Received the 2022 Jeannie Ferris Cancer Australia Award for his outstanding contribution to improving care for women with gynaecological cancers



Emeritus Prof Tim Florin

Awarded the 2023 Distinguished Researcher Prize from the Gastroenterology Society of Australia in recognition of his work in improving the treatment of inflammatory bowel disease



Dr Josephine Laurie

Awarded the 2023 Australasian Diabetes in Pregnancy Graz Clock Award for overall best presentation



Emeritus Prof David McIntyre

Awarded a Lifetime Achievement Award from the Australian Diabetes Society. The award recognises the outstanding lasting impact his work has had on diabetes



Dr Chloe Yap

Awarded highly commended for the Research Australia Griffith University Discovery Award

Internal Awards



Prof Josephine Forbes

Awarded Mater Research Excellence at the Mater People Awards



Dr Siobhan Loughnan

Awarded the Early Career Researcher Prize



Ms Alicia Rooney

Awarded Mater Early Career Excellence at the Mater People Awards



Mr Cheng Xiang Foo

Awarded the Higher Degree Biomedical Student Prize



Dr Taylan Gurgenci

Awarded the Dr Laurence Catley Clinical Student Prize

Special Award

Awarded to Professor Janet Hardy, who has an international reputation as one of the foremost clinical researchers in palliative medicine, and a proven ability to lead high quality trials in palliative care.

Her key research interests revolve around symptom clusters, the palliation of pain, dyspnoea and nausea/vomiting and in the use and abuse of medications such as dexamethasone and opioids.





Awards 2023

Sisters of Mercy Medals

Sister Michaeleen Ahern Medal



Awarded to a person who has made an exceptional contribution to supervising and mentoring Mater Research students.



Prof Brian Gabrielli (*winner*)

Sister Madonna Josey Medal



Awarded to a person who has made a significant contribution to the operations of Mater Research in 2023.



Ms Ruth Lee (*winner*)



Ms Alice Yin (*highly commended*)

Sister Eileen Pollard Medal



Awarded to a person who has consistently translated research into clinical practice.



A/Prof Jakob Begun (*winner*)

Sister Regis Mary Dunne Medal



Awarded to a person who has made an outstanding contribution to the research output and impact of Mater Research.



Dr Kylie Alexander (*winner*)

Publication of the Year Award



Dr Yuanhao Yang et al.

"The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders." Cell Genomics 3.2 (2023).



Dr Neisha D'Silva et al.

"Emotional well-being and HbA1c following the implementation of the Diabetes Psychosocial Assessment Tool (DPAT) in young adults with type 1 diabetes (T1DM): An observational study." Diabetes Research and Clinical Practice 200 (2023): 110696.



Prof Lewis Perrin et al.

"Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context." Australian and New Zealand Journal of Obstetrics and Gynaecology (2023).



Dr Chloe Yap et al.


"Interactions between the lipidome and genetic and environmental factors in autism." Nature Medicine 29.4 (2023): 936-949.




Publication Information




424
total number
publications



Publication journal quality across research programs 2023



Historical Comparison of Mater-affiliated Publications



Source: Mater Research EndNote Library – Last import conducted on 03 January 2023. Please note: epub dates for publications during 1 January – 31 December 2023 have been used. Program allocation is based on first author/ corresponding author Program affiliation. Where the author name is unfamiliar, the title/abstract of the publication has been used for Program allocation.

Notes: N/A denotes that the journal is not currently ranked by SCImago (Scopus Data) or could not be found in the SCImago database. Field-weighted Quartiles are derived from the SCImago Journal Rank (SJR) (scientific influence) of a publication. These 'best quartiles' are assigned based on the published research alignment with the subject area of a journal.



Outstanding Mater Research Achievements in 2023

Grant funding awarded

Total funding
\$13.7m 

23
Total number of grants



138 new clinical studies

68
Clinical trials 

37
Cohort studies 


33 
Clinical studies other than clinical trials and cohort studies

Publications

424 
Total number of publications

259 
Top tier journals

Education

111 
Current HDR students

11 
Degrees conferred






OLYMPUS
CKX41



Publication List



Citations added to the Endnote database from 1 January – 31 December 2023. Publications from all five programs have been combined together in one list. Publications have been arranged in alphabetical order by first author's last name.

1. Adam, S., McIntyre, H. D., Tsoi, K. Y., Kapur, A., Ma, R. C., Dias, S., . . . McAuliffe, F. M. (2023). *Pregnancy as an opportunity to prevent type 2 diabetes mellitus: FIGO Best Practice Advice*. *Int J Gynaecol Obstet*, 160 Suppl 1(Suppl 1), 56–67. doi:10.1002/ijgo.14537
2. Akosile, W., Bor, W., Tilse, A., Hunt, G., Rushton, A., McDermott, B., . . . McBride, M. (2023). *Predictors of completion of an adolescent residential alcohol and other drug withdrawal program*. *Journal of Substance Use*. doi:10.1080/14659891.2023.2166608
3. al-Tamimi, K., van Herwerden, L., Abdul, M., & Utter, J. (2023). *Hospital-Based Food Environment Interventions to Improve Workforce Dietary Behaviour: A Systematic Literature Review*. *American Journal of Lifestyle Medicine*. doi:10.1177/15598276231184813
4. Alabbas, S. Y., Giri, R., Oancea, I., Davies, J., Schreiber, V., Florin, T. H., & Begun, J. (2023). *Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver*. *J Gastroenterol Hepatol*, 38(4), 609–618. doi:10.1111/jgh.16102
5. Ali, S., Coory, M., Donovan, P., Na, R., Pandeya, N., Pearson, S. A., . . . Neale, R. E. (2023). *Association between unstable diabetes mellitus and risk of pancreatic cancer*. *Pancreatology*. doi:10.1016/j.pan.2023.11.009
6. Allen, J., Gao, Y., Germain, J., O'Connor, M., Hurst, C., & Kildea, S. (2023). *Impact of the Thompson method on breastfeeding exclusivity and duration: Multi-method design*. *Int J Nurs Stud*, 141, 104474. doi:10.1016/j.ijnurstu.2023.104474
7. Alwash, S., McIntyre, D., & Mamun, A. (2023). *The pre-pregnancy fasting blood glucose, glycated hemoglobin and lipid profiles as blood biomarkers for gestational diabetes mellitus: evidence from a multigenerational cohort study*. *J Matern Fetal Neonatal Med*, 36(1), 2195524. doi:10.1080/14767058.2023.2195524
8. Alwash, S. M., Huda, M. M., McIntyre, H. D., & Mamun, A. A. (2023). *Time trends and projections in the prevalence of gestational diabetes mellitus in Queensland, Australia, 2009–2030: Evidence from the Queensland Perinatal Data Collection*. *Aust N Z J Obstet Gynaecol*. doi:10.1111/ajog.13734
9. Amarasena, L., Samir, N., Sealy, L., Hu, N., Rostami, M. R., Isaacs, D., . . . Zwi, K. (2023). *Offshore detention: cross-sectional analysis of the health of children and young people seeking asylum in Australia*. *Archives of Disease in Childhood*, 108(3), 185–191. doi:10.1136/archdischild-2022-324442
10. Andersen, L. M., Goh, I. Y., & Siriwardhane, M. (2023). *High-grade dysplasia of the cystic duct margin: how should this be managed?* *BMJ Case Rep*, 16(12). doi:10.1136/bcr-2023-255492
11. Andrews, C., Pade, A., Flenady, V., Moore, J., Tindal, K., Farrant, B., . . . Pollock, D. (2023). *Improving the capacity of researchers and bereaved parents to co-design and translate stillbirth research together*. *Women Birth*. doi:10.1016/j.wombi.2023.12.005
12. Aouira, N., Khan, S., Heussler, H., Haywood, A., Karaksha, A., & Bor, W. (2023). *Understanding the Perspective of Youths on Undergoing Metabolic Monitoring While on Second-Generation Antipsychotics: Challenges, Insight, and Implications*. *J Child Adolesc Psychopharmacol*, 33(7), 279–286. doi:10.1089/cap.2023.0016
13. Acheson, R. J., Burne, T. H. J., & Dawson, P. A. (2023). *Serum sulfate level and Slc13a1 mRNA expression remain unaltered in a mouse model of moderate vitamin D deficiency*. *Molecular and Cellular Biochemistry*, 478(8), 1771–1777. doi:10.1007/s11010-022-04634-7
14. Austin, R. J., Straube, J., Halder, R., Janardhanan, Y., Bruedigam, C., Witkowski, M., . . . Bywater, M. J. (2023). *Oncogenic drivers dictate immune control of acute myeloid leukemia*. *Nat Commun*, 14(1), 2155. doi:10.1038/s41467-023-37592-9
15. Baba, A., Webbe, J., Butcher, N. J., Rodrigues, C., Stallwood, E., Goren, K., . . . Offringa, M. (2023). *Heterogeneity and Gaps in Reporting Primary Outcomes From Neonatal Trials*. *Pediatrics*, 152(3). doi:10.1542/peds.2022-060751
16. Babl, F. E., Eapen, N., Herd, D., Borland, M. L., Kochar, A., Zhang, M., . . . Hearps, S. (2023). *Agreement of Clinician-Administered and Modified Parent-Administered House-Brackmann Scales in Children with Bell's Palsy*. *OTO Open*, 7(1), e44. doi:10.1002/oto.2.44
17. Bai, A., Dai, S., Hung, J., Kirpalani, A., Russell, H., Elder, J., . . . Tan, Z. (2023). *Multicenter Validation of Deep Learning Algorithm ROP.AI for the Automated Diagnosis of Plus Disease in ROP*. *Transl Vis Sci Technol*, 12(8), 13. doi:10.1167/tvst.12.8.13
18. Bailey, C., Medeiros, P. B., Ellwood, D. A., Middleton, P., Andrews, C. J., & Flenady, V. J. (2023). *A systematic review of interventions to increase the use of smoking cessation services for women who smoke during pregnancy*. *Aust N Z J Obstet Gynaecol*. doi:10.1111/ajog.13745
19. Balaji, A., Bell, C. A., Houston, Z. H., Bridle, K. R., Genz, B., Fletcher, N. L., . . . Thurecht, K. J. (2023). *Exploring the impact of severity in hepatic fibrosis disease on the intrahepatic distribution of novel biodegradable nanoparticles targeted towards different disease biomarkers*. *Biomaterials*, 302, 122318. doi:10.1016/j.biomaterials.2023.122318
20. Balmer, A., Brömdal, A., Mullens, A., Kynoch, K., & Osborne, S. (2023). *Effectiveness of interventions to reduce sexually transmitted infections and blood-borne viruses in incarcerated adult populations: a systematic review protocol*. *JBI Evid Synth*, 21(11), 2247–2254. doi:10.11124/jbies-22-00444
21. Barbier, H., Carberry, C. L., Karjalainen, P. K., Mahoney, C. K., Galán, V. M., Rosamilia, A., . . . Thariani, K. (2023). *International Urogynecology consultation chapter 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction*. *Int Urogynecol J*. doi:10.1007/s00192-023-05629-8

22. Barsha, L., McCray, S., & Maunder, K. (2023). *Is meal order timing and flexibility key to improving patient satisfaction with hospital foodservice?* *J Hum Nutr Diet*, 36(5), 1964–1969. doi:10.1111/jhn.13186
23. Baxter, T. E., & Grimmett, W. G. (2023). *Investigation of the HotDog, polymer resistive patient warming device.* *Anaesth Intensive Care*, 310057x231181405. doi:10.1177/0310057x231181405
24. Bebia, Z., Reyes, O., Jeanfreau, R., Kantele, A., De Leon, R. G., Sánchez, M. G., . . . Henry, O. (2023). *Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPref3) in Mothers and Their Infants: A Phase 2 Randomized Trial.* *J Infect Dis*, 228(3), 299–310. doi:10.1093/infdis/jjad024
25. Bednarska, K., Chowdhury, R., Tobin, J. W. D., Swain, F., Keane, C., Boyle, S., . . . Gandhi, M. K. (2023). *Epstein-Barr virus-associated lymphomas decoded.* *Br J Haematol*. doi:10.1111/bjh.19255
26. Beker, F., Hughes, I. P., Jacobs, S., Liley, H. G., Bora, S., Simcock, G., & Davis, P. G. (2023). *Smell and taste of milk during tube feeding of preterm infants: neurodevelopmental follow-up of the randomized TASTE trial, study protocol.* *Trials*, 24(1), 290. doi:10.1186/s13063-023-07224-0
27. Bell, M. F., Segal, L., Dennison, S., Kinner, S. A., Dawe, S., Spittal, M. J., & Preen, D. B. (2023). *Numeracy and literacy attainment of children exposed to maternal incarceration and other adversities: A linked data study.* *J Sch Psychol*, 100, 101241. doi:10.1016/j.jsp.2023.101241
28. Bendall, A., Schreiber, V., Crawford, K., & Kumar, S. (2023). *Predictive utility of the fetal cerebroplacental ratio for hypoxic ischaemic encephalopathy, severe neonatal morbidity and perinatal mortality in late-preterm and term infants.* *Aust N Z J Obstet Gynaecol*, 63(4), 491–498. doi:10.1111/ajo.13668
29. Bennett, C., Rivers, E. J., Woo, W., Bloch, M., Cheung, K., Griffin, P., . . . Mallory, R. M. (2023). *Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.* *J Infect Dis*. doi:10.1093/infdis/jiad508
30. Bertram, G., Becuzzi, N., & Wilson, E. (2023). *Trends in perinatal mental health within a tertiary institution from 2013 to 2022.* *Aust N Z J Obstet Gynaecol*. doi:10.1111/ajo.13720
31. Best, K. P., Gould, J. F., Makrides, M., Sullivan, T., Cheong, J., Zhou, S. J., . . . Green, T. (2023). *Prenatal iodine supplementation and early childhood neurodevelopment: the PoppiE trial – study protocol for a multicentre randomised controlled trial.* *BMJ Open*, 13(5), e071359. doi:10.1136/bmjopen-2022-071359
32. Bhaumik, S., Lockett, J., Cuffe, J., & Clifton, V. L. (2023). *Glucocorticoids and Their Receptor Isoforms: Roles in Female Reproduction, Pregnancy, and Foetal Development.* *Biology (Basel)*, 12(8). doi:10.3390/biology12081104
33. Bock, N., Forouz, F., Hipwood, L., Clegg, J., Jeffery, P., Gough, M., . . . Meinert, C. (2023). *GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids.* *Pharmaceutics*, 15(1). doi:10.3390/pharmaceutics15010261
34. Bonazzi, V. F., Aoude, L. G., Brosda, S., Bradford, J. J., Lonie, J. M., Loffler, K. A., . . . Barbour, A. P. (2023). *C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.* *Asia Pac J Clin Oncol*. doi:10.1111/ajco.13993
35. Bora, S. (2023). *Beyond Survival: Challenges and Opportunities to Improve Neurodevelopmental Outcomes of Preterm Birth in Low- and Middle-Income Countries.* *Clin Perinatol*, 50(1), 215–223. doi:10.1016/j.clp.2022.11.003
36. Boyd, R. N., Novak, I., Morgan, C., Bora, S., Sakzewski, L., Ware, R. S., . . . Oftedal, S. (2023). *School readiness of children at high risk of cerebral palsy randomised to early neuroprotection and neurorehabilitation: protocol for a follow-up study of participants from four randomised clinical trials.* *BMJ Open*, 13(2), e068675. doi:10.1136/bmjopen-2022-068675
37. Bradford, B. F., Hayes, D. J. L., Damhuis, S., Shub, A., Akselsson, A., Radestad, I., . . . Gordijn, S. J. (2023). *Decreased fetal movements: Report from the International Stillbirth Alliance conference workshop.* *Int J Gynaecol Obstet*. doi:10.1002/ijgo.15242
38. Bradford, N., Moore, E., Taylor, K., Cook, O., Gent, L., Beane, T., . . . the C. B. o. D. (2023). *The cancer nursing workforce in Australia: a national survey exploring determinants of job satisfaction.* *BMC Nursing*, 22(1), 461. doi:10.1186/s12912-023-01629-7
39. Branjerdporn, G., Gillespie, K., Martin, E., Kissane, V., De Young, A., Eweis, T., . . . Beckmann, M. (2023). *Effectiveness and cost-effectiveness of an electronic mindfulness-based intervention to improve maternal mental health in the peripartum: study protocol for a randomised controlled trial.* *Trials*, 24(1), 747. doi:10.1186/s13063-023-07746-7
40. Bremner, A., Chan, L. Y., Jones, C., & Shah, S. P. (2023). *Comparison of Weight-Gain-Based Prediction Models for Retinopathy of Prematurity in an Australian Population.* *J Ophthalmol*, 2023, 8406287. doi:10.1155/2023/8406287
41. Bricknell, L., Keogh, C., Sandstrom, A., & Siriwardhane, M. (2023). *Laparoscopic cholecystectomy prevents readmissions. A 9-year review of acute pancreatitis in pregnancy in an Australian tertiary center.* *HPB (Oxford)*, 25(11), 1364–1372. doi:10.1016/j.hpb.2023.06.017
42. Brown, H., De'Ambrosio, B., Yong-Gee, S., Griffin, A., & Muir, J. (2023). *Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance.* *Australas J Dermatol*, 64(2), 234–241. doi:10.1111/ajd.14008
43. Brown, H., De'Ambrosio, B., Yong-Gee, S., & Muir, J. (2023a). *Reply to: Adler et al.'s Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance.* *Australas J Dermatol*, 64(4), e399–e400. doi:10.1111/ajd.14124
44. Brummel, B., van Heumen, C., Smits, A., van den Berg, M., Ezendam, N. P. M., Pijnenborg, J. M. A., . . . van der Meij, B. S. (2023). *Barriers to and facilitators of a healthy lifestyle for patients with gynecological cancer: a systematic review of qualitative and quantitative research with healthcare providers and patients.* *Maturitas*, 177, 107801. doi:10.1016/j.maturitas.2023.107801
45. Brunelli, V. N., Ramis, M. A., & Kynoch, K. (2023). *Roles and practices of specialist lung cancer nurses: A scoping review protocol.* *JBI Evid Synth*, 21(4), 769–776. doi:10.11124/JBIES-22-00047
46. Buchan, E. J., Haywood, A., Syrmis, W., & Good, P. (2023). *Medically assisted hydration for adults receiving palliative care.* *Cochrane Database Syst Rev*, 12(12), Cd006273. doi:10.1002/14651858.CD006273.pub4
47. Buckberry, S., Liu, X., Poppe, D., Tan, J. P., Sun, G., Chen, J., . . . Lister, R. (2023). *Transient naive reprogramming corrects hiPS cells functionally and epigenetically.* *Nature*, 620(7975), 863–872. doi:10.1038/s41586-023-06424-7
48. Buckle, I., Johnson, A., Rojas, I. L., Weinert, V., Sester, D. P., Radford, K., & Guillerey, C. (2023). *High dimensional analysis reveals distinct NK cell subsets but conserved response to stimulation in umbilical cord blood and adult peripheral blood.* *Eur J Immunol*, 53(6), e2250118. doi:10.1002/eji.202250118
49. Burgess, M., Keane, C., Tobin, J. W. D., Law, S. C., Griffin, A., Gill, D., . . . Gandhi, M. K. (2023). *Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.* *Acta Haematologica*, 146(2), 166–171. doi:10.1159/000527631
50. Byrne, A. B., Arts, P., Ha, T. T., Kassahn, K. S., Pais, L. S., O'Donnell-Luria, A., . . . Scott, H. S. (2023). *Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death.* *Nature Medicine*, 29(1), 180–189. doi:10.1038/s41591-022-02142-1
51. Caldwell, J. M., Meredith, P. J., Whittingham, K., Ziviani, J., & Wilson, T. (2023). *Women pregnant after previous perinatal loss: relationships between adult attachment, shame, and prenatal psychological outcomes.* *J Reprod Infant Psychol*, 1–15. doi:10.1080/02646838.2023.2180142

52. Callander, E. J., Tarnow-Mordi, W., Morton, R., Mol, B. W., & Kumar, S. (2023). *Intrapartum use of sildenafil citrate to prevent fetal compromise and emergency operative birth in term pregnancies in the United Kingdom and Australia: A preliminary cost-effectiveness analysis*. *Int J Gynaecol Obstet*. doi:10.1002/ijgo.15135
53. Cao, P., Amiralian, N., Wang, J., Sun, B., Popat, A., Xie, F., . . . Li, L. (2023). *Engineering nano-cellulose bio-composites to improve protein delivery for oral vaccination*. *Biomater Adv*, 149, 213400. doi:10.1016/j.bioadv.2023.213400
54. Cao, P., Wang, Y., Zhang, C., Sullivan, M. A., Chen, W., Jing, X., . . . Luo, L. (2023). *Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy*. *J Nutr Biochem*, 120, 109414. doi:10.1016/j.jnutbio.2023.109414
55. Cao, P., Yue, M., Cheng, Y., Sullivan, M. A., Chen, W., Yu, H., . . . Zhang, Y. (2023). *Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice*. *Food Sci Nutr*, 11(12), 7826-7840. doi:10.1002/fsn3.3700
56. Cao, Y., Janjua, T. I., Qu, Z., Draphoen, B., Bai, Y., Linden, M., . . . Popat, A. (2023). *Virus-like silica nanoparticles enhance macromolecule permeation in vivo*. *Biomater Sci*, 11(13), 4508-4521. doi:10.1039/d3bm00137g
57. Carroll, C., Higgs, J., McCray, S., & Utter, J. (2023). *Implementation and Impact of Health Care Gardens: A Systematic Scoping Review*. *J Integr Complement Med*. doi:10.1089/jicm.2023.0212
58. Carroll, C., McCray, S., & Utter, J. (2023). *Acceptability and Feasibility of a Hospital-based Herb and Vegetable Garden for Health Care Workers*. *J Nutr Educ Behav*. doi:10.1016/j.jneb.2023.10.008
59. Casey, M., Lee, C., Kwok, W. Y., Law, S. C., Corvino, D., Gandhi, M. K., . . . Nakamura, K. (2023). *Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy*. *Haematologica*. doi:10.3324/haematol.2023.283758
60. Catapan, S. C., Haydon, H. M., Hickman, I. J., Webb, L., Isbel, N., Johnson, D., . . . Kelly, J. T. (2023). *Trust and confidence in using telehealth in people with chronic kidney disease: A cross-sectional study*. *J Telemed Telecare*, 29(10_suppl), 16s-23s. doi:10.1177/1357633x231202275
61. Chan, D. N. S., Chow, K. M., Anderson, D. J., Porter-Steele, J., Laing, B., Ling, W. M., . . . McCarthy, A. L. (2023). *Cultural Adaptation of the Younger Women's Wellness After Cancer Program for Younger Chinese Women With Breast Cancer: A Pilot Randomized Controlled Trial*. *Cancer Nurs*. doi:10.1097/ncc.0000000000001210
62. Chan, H. C. N., Fei, X., Leung, E. L. Y., Langston, K., Marshall, S., & van der Meij, B. S. (2023). *Post-discharge consequences of protein-energy malnutrition, sarcopenia, and frailty in older adults admitted to rehabilitation: A systematic review*. *Clin Nutr ESPEN*, 54, 382-397. doi:10.1016/j.clnesp.2023.01.023
63. Chan, L., Owen, K. B., Andrews, C. J., Bauman, A., Brezler, L., Ludski, K., . . . Gordon, A. (2023). *Evaluating the reach and impact of Still Six Lives: A national stillbirth public awareness campaign in Australia*. *Women Birth*, 36(5), 446-453. doi:10.1016/j.wombi.2023.02.006
64. Chapman, J., & Birch, T. (2023). *Augmentation Mastopexy-An Algorithm to Demystify Surgical Planning*. *Aesthetic Plast Surg*, 47(5), 2194-2196. doi:10.1007/s00266-023-03337-8
65. Chappell, K. J., Mordant, F. L., Amarilla, A. A., Modhiran, N., Liang, B., Li, Z., . . . Munro, T. P. (2023). *Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial*. *EBioMedicine*, 97, 104842. doi:10.1016/j.ebiom.2023.104842
66. Cheng, K. C. L., Frost, J. M., Sánchez-Luque, F. J., García-Canãdas, M., Taylor, D., Yang, W. R., . . . Branco, M. R. (2023). *Vitamin C activates young LINE-1 elements in mouse embryonic stem cells via H3K9me3 demethylation*. *Epigenetics Chromatin*, 16(1), 39. doi:10.1186/s13072-023-00514-6
67. Cheon, J. H., Paridaens, K., Awadhi, S. A., Begun, J., Fullarton, J. R., Louis, E., . . . Travis, S. P. (2023). *The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis*. *Intestinal Research*, 21(1), 161-167. doi:10.5217/ir.2022.00006
68. Chetwood, J. D., Gupta, S., Subramaniam, K., De Cruz, P., Moore, G., An, Y. K., . . . Leong, R. W. (2023). *Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature*. *Expert Opin Drug Saf*, 1-8. doi:10.1080/14740338.2023.2278686
69. Chin, P. K. L., Charles, K., Murnion, B., McGuire, T. M., Hilmer, S. N., Martin, J., . . . O'Mara, D. (2023). *Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand*. *Br J Clin Pharmacol*, 89(10), 3105-3115. doi:10.1111/bcp.15814
70. Chong, A., Lewin, J., Goh, I. Y., & Liu, C. (2023). *Brunner's gland adenoma: a robotic approach*. *BMJ Case Rep*, 16(10). doi:10.1136/bcr-2023-254566
71. Chong, J. W., Baer, R. A., & Lee, J. C. (2023). *Differences in bone mineral density of lumbar spine and femur*. *Perit Dial Int*, 43(4), 350. doi:10.1177/08968608231182113
72. Choo, J. M., Martin, A. M., Taylor, S. L., Sun, E., Mobegi, F. M., Kanno, T., . . . Rogers, G. B. (2023). *The Impact of Long-Term Macrolide Exposure on the Gut Microbiome and Its Implications for Metabolic Control*. *Microbiol Spectr*, 11(4), e0083123. doi:10.1128/spectrum.00831-23
73. Chow, K. M., Chan, C. W. H., Anderson, D. J., Porter-Steele, J., Leung, A. W. Y., Law, B. M. H., & McCarthy, A. L. (2023). *Feasibility and acceptability of a culturally-adapted Women's Wellness After Cancer Programme for Chinese women treated for gynaecological cancer: A pilot randomised controlled trial*. *Heliyon*, 9(5), e15591. doi:10.1016/j.heliyon.2023.e15591
74. Christie, V., Riley, L., Green, D., Snook, K., Henningham, M., Rambaldini, B., . . . Gwynne, K. (2023). *Does breast cancer policy meet the needs of Aboriginal and Torres Strait Islander women in Australia? a review*. *Int J Equity Health*, 22(1), 129. doi:10.1186/s12939-023-01941-3
75. Chua, D., Sackey, D., Jones, M., Smith, M., Ball, L., & Johnson, T. (2023). *The M-CHooSe pilot: the acceptability and utilisation of the nurse-led, general practice clinic co-located 'Mater C ALD H healthcare Coordinator Service' for patients from multicultural backgrounds*. *Australian Journal of Primary Health*, 29(2), 175-185. doi:10.1071/PY22147
76. Chundru, V. K., Marioni, R. E., Prendergast, J. G. D., Lin, T., Beveridge, A. J., Martin, N. G., . . . McRae, A. F. (2023). *Rare genetic variants underlie outlying levels of DNA methylation and gene-expression*. *Hum Mol Genet*, 32(11), 1912-1921. doi:10.1093/hmg/ddad028
77. Clark, P. J., Valery, P. C., Strasser, S. I., Weltman, M., Thompson, A., Levy, M. T., . . . Roberts, S. K. (2023). *Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care*. *J Gastroenterol Hepatol*. doi:10.1111/jgh.16440
78. Comeau, A., Mertens, B., Bachwal, L., Utter, J., & van Herwerden, L. (2023). *Effectiveness of nutrition interventions in Australian secondary schools: A systematic review*. *Health Promot J Austr*. doi:10.1002/hpja.787
79. Conway, R., Nikiphorou, E., Demetriou, C. A., Low, C., Leamy, K., Ryan, J. G., . . . McCarthy, G. M. (2023). *Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic*. *Ir J Med Sci*, 192(5), 2495-2500. doi:10.1007/s11845-022-03265-7
80. Crawford, K., Hong, J., & Kumar, S. (2023). *Mediation analysis quantifying the magnitude of stillbirth risk attributable to small for gestational age infants*. *Am J Obstet Gynecol MFM*, 5(12), 101187. doi:10.1016/j.ajogmf.2023.101187

81. Crichton, M., Marshall, S., Isenring, E., Lohning, A., McCarthy, A. L., Molassiotis, A., . . . Marx, W. (2023). *Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial*. *J Acad Nutr Diet*. doi:10.1016/j.jand.2023.09.003
82. Cripps, E. K., Dargaville, P. A., & De Paoli, A. G. (2023). *Impact of probiotic administration on the incidence of necrotising enterocolitis: A single-centre cohort study*. *J Paediatr Child Health*, 59(5), 760-765. doi:10.1111/jpc.16390
83. Crouwel, F., Simsek, M., van Doorn, A. S., Mulder, C. J. J., Buijter, H. J. C., Barclay, M. L., . . . de Boer, N. K. (2023). *Rectally Administered Thioguanine for Distal Ulcerative Colitis: A Multicenter Case Series*. *Inflammatory Bowel Diseases*, 29(6), 1000-1004. doi:10.1093/ibd/izac195
84. Cucinella, G., Schivardi, G., Zhou, X. C., Ailhill, M., Wallace, S., Wohlmuth, C., . . . Glaser, G. (2023). *Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study*. *Int J Gynecol Cancer*. doi:10.1136/ijgc-2023-005032
85. Das, S., Das, J., Mazumder, K., Roy, P., Begum, R., & Das, S. K. (2023). *Trend and risk factors of fatal pregnancy termination: A long-term nationwide population-based cross-section survey in Bangladesh*. *Plos One*, 18(1), e0263467. doi:10.1371/journal.pone.0263467
86. Davidson, S. J., France, M., Callaway, L. K., Lust, K., Chambers, D., Hopkins, P., . . . Barrett, H. L. (2023). *Pregnancy in women with cystic fibrosis and diabetes: An audit of outcomes at two tertiary obstetric hospitals in Australia in the pre-cystic fibrosis transmembrane conductance regulator modulator era*. *Obstet Med*, 16(4), 217-221. doi:10.1177/1753495x221146342
87. de Bruyn, G., Wang, J., Purvis, A., Ruiz, M. S., Adhikarla, H., Alvi, S., . . . Sridhar, S. (2023). *Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study*. *EClinicalMedicine*, 62, 102109. doi:10.1016/j.eclinm.2023.102109
88. de Graaff, E. C., Leisher, S. H., Blencowe, H., Lawford, H., Cassidy, J., Cassidy, P. R., . . . Flenady, V. (2023). *Ending preventable stillbirths and improving bereavement care: a scorecard for high- and upper-middle income countries*. *BMC Pregnancy Childbirth*, 23(1), 480. doi:10.1186/s12884-023-05765-5
89. Dean, J., Cleary, A., Ma, T., McDaid, L., Pollock, D., & Boyle, F. (2023). *Scoping review of nature-based interventions in bereavement care: What are the implications for perinatal loss?* *Social Sciences and Humanities Open*, 8(1). doi:10.1016/j.ssoho.2023.100690
90. Delaforce, A., Farmer, S., Duff, J., Munday, J., Miller, K., Glover, L., . . . Hurst, C. (2023). *Results from a type two hybrid-effectiveness study to implement a preoperative anemia and iron deficiency screening, evaluation, and management pathway*. *Transfusion*, 63(4), 724-736. doi:10.1111/trf.17287
91. Delle Baite, L., Harvey, E. E., Fong, M. W. K., McGonigal, A., & Wilson, S. J. (2023). *Life following epilepsy surgery: Building a holistic framework for enhancing postsurgical recovery and rehabilitation*. *Epilepsia*, 64(7), 1785-1790. doi:10.1111/epi.17646
92. Demichelis, O. P., Grainger, S. A., McKay, K. T., Burr, L., Kim, J., & Henry, J. D. (2023). *Subjective and objective sleep quality does not predict behavioural episodic foresight in younger or older adults*. *Sci Rep*, 13(1), 1056. doi:10.1038/s41598-023-28183-1
93. Dent, E., Hanlon, P., Sim, M., Jylhävä, J., Liu, Z., Vetrano, D. L., . . . Hoogendijk, E. O. (2023a). *Recent developments in frailty identification, management, risk factors and prevention: A narrative review of leading journals in geriatrics and gerontology*. *Ageing Research Reviews*, 91. doi:10.1016/j.arr.2023.102082
94. Dent, E., Hanlon, P., Sim, M., Jylhävä, J., Liu, Z., Vetrano, D. L., . . . Hoogendijk, E. O. (2023b). *Recent developments in frailty identification, management, risk factors and prevention: A narrative review of leading journals in geriatrics and gerontology*. *Ageing Res Rev*, 91, 102082. doi:10.1016/j.arr.2023.102082
95. Desai, A., Liyanaarachchi, K., & Allanson, E. R. (2023). *Ectopic mammary tissue of the vulva*. *Int J Gynecol Cancer*. doi:10.1136/ijgc-2022-004227
96. Di Ciaccio, P. R., Mills, G., Shipton, M. J., Campbell, B., Gregory, G., Langfield, J., . . . Hamad, N. (2023). *The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance*. *Br J Haematol*, 201(5), 887-896. doi:10.1111/bjh.18727
97. Diller, N., Osborn, D. A., & Birch, P. (2023). *Higher versus lower sodium intake for preterm infants*. *Cochrane Database Syst Rev*, 10(10), Cd012642. doi:10.1002/14651858.CD012642.pub2
98. Donnelly, P., Soares, R., Eynon, A., Grundy, P., & Durnford, A. (2023). *Animal products in neurosurgery - navigating informed consent*. *Br J Neurosurg*, 1-4. doi:10.1080/02688697.2023.2256875
99. Dopfer, A., Steele, M., Bogossian, F., & Hough, J. (2023). *High flow nasal cannula for respiratory support in term infants*. *Cochrane Database Syst Rev*, 8(8), Cd011010. doi:10.1002/14651858.CD011010.pub2
100. Dossetor, P. J., Freeman, J. M., Thorburn, K., Oscar, J., Carter, M., Jeffery, H. E., . . . Martinuk, A. L. C. (2023). *Health services for aboriginal and Torres Strait Islander children in remote Australia: A scoping review*. *PLOS Glob Public Health*, 3(2), e0001140. doi:10.1371/journal.pgph.0001140
101. Duke, P. F. R., Bennett, D., Strauss, R., Peters, S. E., & Ross, M. (2023). *Isometric shoulder strength: Normative Australian population data and associated factors*. *Shoulder and Elbow*. doi:10.1177/17585732231190577
102. Dutt, M., Hartel, G., Richards, R. S., Shah, A. K., Mohamed, A., Apostolidou, S., . . . Hill, M. M. (2023). *Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer*. *Proteomics Clin Appl*, 17(4), e2200114. doi:10.1002/prca.202200114
103. Eagleson, K. J., McCombs, D., Gerlich, T. M., Justo, R. N., Kasparian, N. A., & Bora, S. (2023). *Systematic Review of Instruments Assessing Psychosocial Adaptation and Outcomes Among Families of Children With Congenital Heart Disease*. *J Pediatr Psychol*, 48(6), 537-552. doi:10.1093/jpepsy/jsad015
104. Eckold, C., van Doorn, C. L. R., Ruslami, R., Ronacher, K., Riza, A. L., van Veen, S., . . . Cliff, J. M. (2023). *Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity*. *Clin Transl Med*, 13(9), e1375. doi:10.1002/ctm2.1375
105. Edmed, S. L., Huda, M. M., Smith, S. S., Seib, C., Porter-Steele, J., Anderson, D., & McCarthy, A. L. (2023). *Prevalence and predictors of sleep problems in women following a cancer diagnosis: results from the women's wellness after cancer program*. *J Cancer Surviv*. doi:10.1007/s11764-023-01346-9
106. Edwards, N., Franklin, C., King, J., & Watling, H. (2023). *Australian Psychiatrists and Trainee Psychiatrists' Perceptions of Chemical Restraint of Adults with Intellectual Disability*. *Journal of Mental Health Research in Intellectual Disabilities*. doi:10.1080/19315864.2023.2192689
107. Eller, S., Rudolph, J., Barwick, S., Janssens, S., & Bajaj, K. (2023). *Leading change in practice: how "longitudinal prebriefing" nurtures and sustains in situ simulation programs*. *Adv Simul (Lond)*, 8(1), 3. doi:10.1186/s41077-023-00243-6
108. Eweis, T., Begun, J., & Laakso, E. L. (2023). *Protocol for a Single-Arm Feasibility Study of Photobiomodulation for Fatigue, Depression, and Pain in Inflammatory Bowel Disease*. *Biomedicine*, 11(8). doi:10.3390/biomedicine11082179
109. Faber, B. G., Frysz, M., Boer, C. G., Evans, D. S., Ebsim, R., Flynn, K. A., . . . Tobias, J. H. (2023). *The identification of distinct*

protective and susceptibility mechanisms for hip osteoarthritis: findings from a genome-wide association study meta-analysis of minimum joint space width and Mendelian randomisation cluster analyses. *EBioMedicine*, 95, 104759. doi:10.1016/j.ebiom.2023.104759

110. Faulkner, G. J. (2023). Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect. *Neuron*, 111(5), 610–611. doi:10.1016/j.neuron.2023.02.007
111. Fazlollahi, A., Lee, S., Coleman, F., McCann, E., Cloos, M. A., Bourgeat, P., & Nestor, P. J. (2023). Increased Resolution of Structural MRI at 3T Improves Estimation of Regional Cortical Degeneration in Individual Dementia Patients Using Surface Thickness Maps. *J Alzheimers Dis*, 95(3), 1253–1262. doi:10.3233/jad-230030
112. Ferreira, M. E., & Faulkner, G. J. (2023). Endogenous retroviruses can propagate TDP-43 proteinopathy. *Trends Neurosci*, 46(6), 413–414. doi:10.1016/j.tins.2023.03.011
113. Fitzallen, G. C., Griffin, A., Taylor, H. G., Kirby, J. N., Liley, H. G., & Bora, S. (2023). Risk profiles of the preterm behavioral phenotype in children aged 3 to 18 years. *Front Pediatr*, 11, 1084970. doi:10.3389/fped.2023.1084970
114. Fitzallen, G. C., Taylor, H. G., Liley, H. G., & Bora, S. (2023). Within- and between-twin comparisons of risk for childhood behavioral difficulties after preterm birth. *Pediatr Res*. doi:10.1038/s41390-023-02579-1
115. Flanagan, A., Allsopp, S. M., O'Connor, S. A., Tobin, J., Pretorius, C., Brown, I. S., . . . Daveson, A. J. M. (2023). High incidence of inflammatory bowel disease in Northern Australia: a prospective community population-based Australian incidence study in the Mackay-Isaac-Whitsunday region. *Internal Medicine Journal*, 53(9), 1602–1609. doi:10.1111/imj.15941
116. Flavell, J., Franklin, C., & Nestor, P. J. (2023). A Systematic Review of Fragile X-Associated Neuropsychiatric Disorders. *J Neuropsychiatry Clin Neurosci*, 35(2), 110–120. doi:10.1176/appi.neuropsych.21110282
117. Florin, T. H., & Duley, J. A. (2023). Therapeutic Drug Monitoring for IBD Children on Thioguanine. *J Pediatr Gastroenterol Nutr*, 77(3), e64–e65. doi:10.1097/mpg.0000000000003870
118. Foglia, E. E., Davis, P. G., Guinsburg, R., Kapadia, V., Liley, H. G., Rüdiger, M., . . . Weiner, G. M. (2023). Recommended Guideline for Uniform Reporting of Neonatal Resuscitation: The Neonatal Utstein Style. *Pediatrics*, 151(2). doi:10.1542/peds.2022-059631
119. Foo, C. X., Bartlett, S., Chew, K. Y., Ngo, M. D., Bielefeldt-Ohmann, H., Arachchige, B. J., . . . Ronacher, K. (2023). GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. *European Respiratory Journal*, 61(3). doi:10.1183/13993003.01306-2022
120. Fowler, J. A., Warzywoda, S., Nourse, C., Wu, M., Britton, S., Rowling, D., . . . Dean, J. A. (2023). Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation. *Sexual Health*, 20(6), 506–513. doi:10.1071/SH23119
121. Franco, H., Pagliaro, T., Sparti, C., & Walsh, H. J. (2023). Comparing Clinical Examination and Radiological Evaluation in the Preoperative Diagnosis and Location of Symptomatic Interdigital (Morton's) Neuroma. *J Foot Ankle Surg*, 62(5), 883–887. doi:10.1053/j.jfas.2023.06.002
122. Franco, H., & Slee, N. (2023). Pyogenic granuloma of the epiglottis: a common lesion in a rare site. *BMJ Case Rep*, 16(5). doi:10.1136/bcr-2022-253199
123. Frauscher, B., Mansilla, D., Abdallah, C., Astner-Rohracher, A., Beniczky, S., Brazdil, M., . . . McGonigal, A. (2023). Learn how to interpret and use intracranial EEG findings. *Epileptic Disord*. doi:10.1002/epd2.20190
124. Friedman, C. E., Cheatham, S. W., Negi, S., Mills, R. J., Ogawa, M., Redd, M. A., . . . Palpant, N. J. (2023). HOPX-associated molecular programs control cardiomyocyte cell states underpinning cardiac structure and function. *Dev Cell*. doi:10.1016/j.devcel.2023.11.012
125. Fry, J., Wilkinson, S. A., Willcox, J., Henny, M., McGuire, L., Guthrie, T. M., . . . de Jersey, S. (2023). Improving Engagement in Antenatal Health Behavior Programs—Experiences of Women Who Did Not Attend a Healthy Lifestyle Telephone Coaching Program. *Nutrients*, 15(8). doi:10.3390/nu15081860
126. Gallo, L. A., Steane, S. E., Young, S. L., de Jersey, S., Schoenaker, D., Borg, D. J., . . . Wilkinson, S. A. (2023). Dietary supplements, guideline alignment and biochemical nutrient status in pregnancy: Findings from the Queensland Family Cohort pilot study. *Matern Child Nutr*, e13589. doi:10.1111/mcn.13589
127. Gandhi, M. K., & Keane, C. (2023a). CD4 T cells: The complicated key to unlocking the immune environment of classical Hodgkin lymphoma. *Haematologica*, 108(4), 945–946. doi:10.3324/haematol.2022.281440
128. Gandhi, M. K., & Keane, C. (2023b). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. *Haematologica*. doi:10.3324/haematol.2023.283392
129. Ganeshalingam, V., Kaestli, M., Norton, R. E., & Gassie, I. (2023). The effect of climate on melioidosis incidence in Townsville, Australia: a dry tropical region. *Environ Health Prev Med*, 28, 333. doi:10.1265/ehpm.22-00177
130. Gao, Y., Roe, Y., Hickey, S., Chadha, A., Kruske, S., Nelson, C., . . . Kildea, S. (2023). Birthing on country service compared to standard care for First Nations Australians: a cost-effectiveness analysis from a health system perspective. *Lancet Reg Health West Pac*, 34, 100722. doi:10.1016/j.lanwpc.2023.100722
131. Gassie, I., Burnard, D., Permana, B., Bauer, M. J., Cuddihy, T., Forde, B. M., . . . Harris, P. N. A. (2023). Melioidosis Queensland: An analysis of clinical outcomes and genomic factors. *PLoS Negl Trop Dis*, 17(10), e0011697. doi:10.1371/journal.pntd.0011697
132. Gassie, I., Grey, V., Thean, L. J., Farquhar, D., Clark, J. E., Ariotti, L., . . . Harris, P. N. A. (2023). Expanding the Geographic Boundaries of Melioidosis in Queensland, Australia. *Am J Trop Med Hyg*, 108(6), 1215–1219. doi:10.4269/ajtmh.23-0002
133. George, H., Gunawardana, J., Keane, C., Hicks, R. J., & Gandhi, M. K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra-high-risk patient with diffuse large B-cell lymphoma. *Intern Med J*, 53(7), 1105–1109. doi:10.1111/imj.16078
134. Gerdes, P., Chan, D., Lundberg, M., Sanchez-Luque, F. J., Bodea, G. O., Ewing, A. D., . . . Richardson, S. R. (2023). Locus-resolution analysis of L1 regulation and retrotransposition potential in mouse embryonic development. *Genome Res*, 33(9), 1465–1481. doi:10.1101/gr.278003.123
135. Gilbert, S., Irvine, R., D'Or, M., Adam, M. T. P., Collins, C. E., Marriott, R., . . . Rae, K. (2023). *Indigenous Women and Their Nutrition During Pregnancy (the Mums and Bubs Deadly Diets Project): Protocol for a Co-designed mHealth Resource Development Study*. *JMIR Res Protoc*, 12, e45983. doi:10.2196/45983
136. Gilbert, S., Irvine, R., D'Or, M., Rae, K., & Murphy, N. (2023). Working with Indigenous Australian communities designing a nutritional mHealth tool during the Covid-19 pandemic. *AlterNative*, 19(3), 574–583. doi:10.1177/11771801231189346
137. Giles, C., Johnston, R., Kubler, J., Spathis, J., & Beetham, K. (2023). The effects of aerobic and resistance exercise on blood pressure in uncomplicated and at risk pregnancies: A systematic review and meta-analysis. *Women's Health (Lond)*, 19, 17455057231183573. doi:10.1177/17455057231183573
138. Gill, J. R., Brimm, D. J., Dobson, P., Goldberg, M., McMeniman, P. J., McMeniman, T. J., & Myers, P. T. (2023). Long-term results of per-operative knee arthroscopy in confirming suitability for unicompartmental arthroplasty. *Knee*, 44, 142–149. doi:10.1016/j.knee.2023.07.012
139. Gilmore, R., Tan, L., Fernandes, R., An, Y. K., & Begun, J. (2023). Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute

- Severe Ulcerative Colitis. *J Crohns Colitis*. doi:10.1093/ecco-jcc/jjad115
140. Golledge, J., Velu, R., Quigley, F., Jenkins, J., & Singh, T. P. (2023). The predictive value of four serum biomarkers for major adverse events in patients with small abdominal aortic aneurysm. *J Vasc Surg*, 77(4), 1037-1044. doi:10.1016/j.jvs.2022.12.001
 141. Gonzalez Matheus, G., & Muir, J. (2023). A reply to 'Evaluation of dynamic dermoscopic features of melanoma and benign naevi by sequential digital dermoscopic imaging and total body photography in a high-risk Australian cohort'. *Australas J Dermatol*, 64(3), e303-e304. doi:10.1111/ajd.14128
 142. Gough, M., Liu, C., Srinivasan, B., Wilkinson, L., Dunk, L., Yang, Y., . . . Snell, C. E. (2023). Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer. *Histopathology*, 83(4), 647-656. doi:10.1111/his.15000
 143. Gould, J. F., Roberts, R. M., Anderson, P. J., Makrides, M., Sullivan, T. R., Gibson, R. A., . . . Collins, C. T. (2023). High-Dose Docosahexaenoic Acid in Newborns Born at Less Than 29 Weeks' Gestation and Behavior at Age 5 Years: Follow-Up of a Randomized Clinical Trial. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2023.4924
 144. Gracen, L., Muthukumara, W., Aikebuse, M., Russell, A., O'Beirne, J., Irvine, K. M., . . . Powell, E. E. (2023). Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists. *Ann Hepatol*, 28(6), 101142. doi:10.1016/j.aohep.2023.101142
 145. Graham, V., & Arora, B. (2023). Women in surgery: trends in nine surgical specialties. *ANZ J Surg*, 93(10), 2344-2349. doi:10.1111/ans.18600
 146. Graichen, H., Strauch, M., Hirschmann, M. T., Becker, R., Lustig, S., Clatworthy, M., . . . Calliess, T. (2023). Digital TKA Alignment Training with a New Digital Simulation Tool (Knee-CAT) Improves Process Quality, Efficiency, and Confidence. *J Pers Med*, 13(2). doi:10.3390/jpm13020213
 147. Gray, N. L., Stoodley, I., Wood, L. G., Collins, C. E., Brown, L. J., Rae, K. M., . . . The Gomeri Gaaynggal Advisory, C. (2023). Omega-3 Fatty Acids during Pregnancy in Indigenous Australian Women of the Gomeri Gaaynggal Cohort. *Nutrients*, 15(8). doi:10.3390/nu15081943
 148. Gressier, E., Schulte-Schrepping, J., Petrov, L., Brumhard, S., Stubbemann, P., Hiller, A., . . . Bedoui, S. (2023). CD4(+) T cell calibration of antigen-presenting cells optimizes antiviral CD8(+) T cell immunity. *Nat Immunol*, 24(6), 979-990. doi:10.1038/s41590-023-01517-x
 149. Grey, V., Simos, P., Runnegar, N., & Eisemann, J. (2023). Case report: a missed case of chronic Q fever infective endocarditis demonstrating the ongoing diagnostic challenges. *Access Microbiol*, 5(11). doi:10.1099/acmi.0.000628.v3
 150. Griffin, S. B., Palmer, M. A., Strodl, E., Lai, R., Guo, C., Chuah, T. L., . . . Ross, L. J. (2023). Impact of a dietitian-led very low calorie diet clinic on perioperative risk for patients with obesity awaiting elective, non-bariatric surgery: A retrospective cohort study. *Surgery*. doi:10.1016/j.surg.2023.09.047
 151. Grootveld, A. K., Kyaw, W., Panova, V., Lau, A. W. Y., Ashwin, E., Seuzaret, G., . . . Phan, T. G. (2023). Apoptotic cell fragments locally activate tingible body macrophages in the germinal center. *Cell*, 186(6), 1144-1161. doi:10.1016/j.cell.2023.02.004
 152. Guntupalli, S., Park, P., Han, D. H., Zhang, L., Yong, X. L. H., Ringuet, M., . . . Anggono, V. (2023). Ubiquitination of the GluA1 Subunit of AMPA Receptors Is Required for Synaptic Plasticity, Memory, and Cognitive Flexibility. *J Neurosci*, 43(30), 5448-5457. doi:10.1523/jneurosci.1542-22.2023
 153. Gurgenci, T. (2023). Against our post-modern palliation. *Palliat Support Care*, 21(3), 557-558. doi:10.1017/S1478951522000827
 154. Gurgenci, T., Hardy, J., Olson, R., Huggett, G., Foster, K., & Good, P. (2023). Medicinal cannabis in palliative medicine: Lessons learnt from randomised controlled trials. *BMJ Supportive and Palliative Care*, 13(2), 238-240. doi:10.1136/spcare-2022-004035
 155. Gurgenci, T., Kijanka, G., Greer, R., Huggett, G., Good, P., Moniruzzaman, M., & Hardy, J. (2023). Exploring potential anti-inflammatory effects of medicinal cannabis. *Support Care Cancer*, 31(12), 629. doi:10.1007/s00520-023-08069-8
 156. Gurgenci, T., Nicholls, L., Mensingh, S., Broadbent, A., & Grove, G. (2023). Referral patterns and consultation locations for a novel palliative care telehealth service. *Progress in Palliative Care*, 31(2), 95-99. doi:10.1080/09699260.2022.2160084
 157. Gurney, H., Clay, T. D., Oliveira, N., Wong, S., Tran, B., & Harris, C. (2023). Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia. *Asia Pac J Clin Oncol*, 19(6), 585-595. doi:10.1111/ajco.14001
 158. Guthrie, T. M., Dix, C. F., Truby, H., Kumar, S., & de Jersey, S. J. (2023). A Systematic Review Investigating Maternal Nutrition During Pregnancy After Bariatric Surgery. *Obes Surg*, 33(6), 1857-1865. doi:10.1007/s11695-023-06565-8
 159. Hacking, C. P., & Lisle, D. A. (2023). *Imaging for STUDENTS, FIFTH EDITION*.
 160. Halliday, A. J., Vogrin, S., Ignatiadis, S., Gillinder, L., Jones, D., Kiley, M., . . . Whitham, E. (2023). The efficacy and tolerability of adjunctive brivaracetam for the treatment of adult epilepsy: An Australian multi-center retrospective real-world observational cohort study. *Epilepsy Behav*, 145, 109287. doi:10.1016/j.yebeh.2023.109287
 161. Hamdi, H., Boissonneau, S., Valton, L., McGonigal, A., Bartolomei, F., & Regis, J. (2023). Radiosurgical Corpus Callosotomy for Intractable Epilepsy: Retrospective Long-Term Safety and Efficacy Assessment in 19 Patients an Review of the Literature. *Neurosurgery*, 93(1), 156-167. doi:10.1227/neu.0000000000002394
 162. Hamilton-Craig, C., Kostner, K., Colquhoun, D., & Nicholls, S. J. (2023). Omega-3 fatty acids and cardiovascular prevention: is the jury still out? *Intern Med J*, 53(12), 2330-2335. doi:10.1111/imj.16283
 163. Hancock, J. L., Kalimutho, M., Straube, J., Lim, M., Gresshoff, I., Saunus, J. M., . . . Khanna, K. K. (2023). COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. *J Exp Clin Cancer Res*, 42(1), 90. doi:10.1186/s13046-023-02663-8
 164. Hardy, J., Greer, R., Huggett, G., Kearney, A., Gurgenci, T., & Good, P. (2023). Phase IIb Randomised, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). *Journal of Clinical Oncology*, 41(7), 1444-1452. doi:10.1200/JCO.22.01632
 165. Harrington, B. S., Kamdar, R., Ning, F., Korrapati, S., Caminear, M. W., Hernandez, L. F., . . . Annunziata, C. M. (2023). UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer. *J Exp Clin Cancer Res*, 42(1), 270. doi:10.1186/s13046-023-02820-z
 166. Hawley, G., Grogan, A., McGuire, T., van Driel, M., & Hollingworth, S. (2023). Nurse practitioner and midwife antibiotic prescribing in Australia. *Eur J Midwifery*, 7, 11. doi:10.18332/ejm/162439
 167. Hayward, K. L., Weersink, R. A., Bernardes, C. M., Mclvor, C., Rahman, T., Skoien, R., . . . Powell, E. E. (2023). Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data. *Drugs Real World Outcomes*. doi:10.1007/s40801-023-00390-2
 168. Hazratwala, K., Gouk, C., Wilkinson, M. P. R., & O'Callaghan, W. B. (2023). Navigated functional alignment total knee arthroplasty achieves reliable, reproducible and accurate results with high patient satisfaction. *Knee Surg Sports Traumatol Arthrosc*, 31(9), 3861-3870. doi:10.1007/s00167-023-07327-w

169. He, J., & Morton, A. (2023). *Hypokalaemia in pregnancy – Prevalence, underlying causes, and an approach to investigation*. *Obstetric Medicine*. doi:10.1177/1753495X231213537
170. Heynen, J. P., McHugh, R. R., Boora, N. S., Simcock, G., Kildea, S., Austin, M. P., . . . Metz, G. A. S. (2023). *Urinary (1)H NMR Metabolomic Analysis of Prenatal Maternal Stress Due to a Natural Disaster Reveals Metabolic Risk Factors for Non-Communicable Diseases: The QF2011 Queensland Flood Study*. *Metabolites*, 13(4). doi:10.3390/metabo13040579
171. Hocking, L., Wilcox, M., Petrosillo, N., Griffin, P., Steiner, T., Attara, G., . . . Marjanovic, S. (2023). *Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective*. *Frontiers in Medicine*, 9. doi:10.3389/fmed.2022.1033417
172. Hollingworth, S. A., McGuire, T., Van Driel, M., Begum, N., Ford, P. J., Hawley, G., & Walsh, L. J. (2023). *Antimicrobial stewardship: Prescribing across the primary care health professions*. *Pharmacol Res Perspect*, 11(3), e01106. doi:10.1002/prp2.1106
173. Hollis, D., Mendis, M. D., Ng, S. K., Thomas, M., Marks, D., Lewis, J., . . . Bisset, L. (2023). *Are clinical outcomes associated with baseline sensory profiles in people with musculoskeletal shoulder pain? Protocol for a prospective longitudinal observational study*. *Musculoskeletal Care*, 21(3), 895–907. doi:10.1002/msc.1770
174. Hong, J., Crawford, K., Cavanagh, E., da Silva Costa, F., & Kumar, S. (2023). *Placental biomarkers and fetoplacental Dopplers in combination reliably predict preterm birth in pregnancies complicated by fetal growth restriction*. *Ultrasound Obstet Gynecol*. doi:10.1002/uog.27513
175. Hong, J., Crawford, K., Odibo, A. O., & Kumar, S. (2023). *Risks of stillbirth, neonatal mortality, and severe neonatal morbidity by birthweight centiles associated with expectant management at term*. *Am J Obstet Gynecol*, 229(4), 451.e451–451.e415. doi:10.1016/j.ajog.2023.04.044
176. Hong, J., & Kumar, S. (2023). *Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction*. *Clin Sci (Lond)*, 137(8), 579–595. doi:10.1042/cs20220300
177. Horan, E., Romeo, P., & Loch-Wilkinson, A. (2023). *Carpal tunnel syndrome caused by persistent median artery thrombosis with a possible link to COVID-19 vaccination: a case report*. *Australasian Journal of Plastic Surgery*, 6(1). doi:10.34239/ajops.v6n1.70244
178. Hu, Y., Nguyen, H., Smith, C., Chen, T., Byrne, M., Archibald-Heeren, B., . . . Aland, T. (2023). *Clinical assessment of a novel machine-learning automated contouring tool for radiotherapy planning*. *J Appl Clin Med Phys*, 24(7), e13949. doi:10.1002/acm2.13949
179. Hua, T., Robitaille, M., Roberts-Thomson, S. J., & Monteith, G. R. (2023). *The intersection between cysteine proteases, Ca(2+) signalling and cancer cell apoptosis*. *Biochim Biophys Acta Mol Cell Res*, 1870(7), 119532. doi:10.1016/j.bbamcr.2023.119532
180. Huang, G., Wallace, D. F., Powell, E. E., Rahman, T., Clark, P. J., & Subramaniam, V. N. (2023). *Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics*. *Biomedicines*, 11(10). doi:10.3390/biomedicines11102809
181. Huang, S., Carter-Cusack, D., Maxwell, E., Patkar, O. L., Irvine, K. M., & Hume, D. A. (2023). *Genetic and Immunohistochemistry Tools to Visualize Rat Macrophages In Situ*. *Methods Mol Biol*, 2713, 99–115. doi:10.1007/978-1-0716-3437-0_6
182. Hume, D. A. (2023). *Fate-mapping studies in inbred mice: A model for understanding macrophage development and homeostasis?* *Eur J Immunol*, 53(6), e2250242. doi:10.1002/eji.202250242
183. Hume, D. A., Millard, S. M., & Pettit, A. R. (2023). *Macrophage heterogeneity in the single-cell era: facts and artifacts*. *Blood*, 142(16), 1339–1347. doi:10.1182/blood.2023020597
184. Hume, D. A., Teakle, N., Keshvari, S., & Irvine, K. M. (2023). *Macrophage deficiency in CSF1R-knockout rat embryos does not compromise placental or embryo development*. *J Leukoc Biol*, 114(5), 421–433. doi:10.1093/jleuko/qiad052
185. Hurrion, E. M., Badawi, N., Boyd, R. N., Morgan, C., Gibbons, K., Hennig, S., . . . Dawson, P. A. (2023). *SuPreme Study: a protocol to study the neuroprotective potential of sulfate among very/extremely preterm infants*. *BMJ Open*, 13(7), e076130. doi:10.1136/bmjopen-2023-076130
186. Huynh, T. (2023). *Commentary on studies investigating low-dose diazoxide in hyperinsulinism*. *Clin Endocrinol (Oxf)*. doi:10.1111/cen.14996
187. Hyland, C. A., O'Brien, H., McGowan, E. C., Perros, A. J., Flower, R. L., Lopez, G. H., & Gardener, G. J. (2023). *The power of digital PCR in fetal blood group genotyping: a review*. *Annals of Blood*, 8. doi:10.21037/aob-22-4
188. Ilyas Khan, A., Thomas, C., O'Connor, H., Dowker, F., Horgan, L., & Khan, M. A. (2023). *Impact of the COVID-19 Pandemic on the Management of Gallbladder, Biliary Tract, and Pancreatic Diseases*. *Cureus*, 15(8), e43473. doi:10.7759/cureus.43473
189. Janjua, T. I., Cao, Y., Ahmed-Cox, A., Raza, A., Moniruzzaman, M., Akhter, D. T., . . . Popat, A. (2023). *Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma*. *J Control Release*, 357, 161–174. doi:10.1016/j.jconrel.2023.03.040
190. Janssens, S., Clipperton, S., Simon, R., Lowe, B., Griffin, A., Beckmann, M., & Marshall, S. (2023). *Coleadership in Maternity Teams, a Randomized, Counterbalanced, Crossover Trial in Simulation*. *Simulation in Healthcare*, 18(5), 299–304. doi:10.1097/SIH.0000000000000680
191. Jhaveri, D. J., McGonigal, A., Becker, C., Benoliel, J. J., Nandam, L. S., Soncin, L., . . . Bartolomei, F. (2023). *Stress and Epilepsy: Towards Understanding of Neurobiological Mechanisms for Better Management*. *eNeuro*, 10(11). doi:10.1523/eneuro.0200–23.2023
192. Jiao, B., Li, R., Zhou, H., Qing, K., Liu, H., Pan, H., . . . Shen, L. (2023). *Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology*. *Alzheimers Res Ther*, 15(1), 32. doi:10.1186/s13195-023-01181-1
193. Job, J., Nicholson, C., Donald, M., Jackson, C., & Byrnes, J. (2023). *An eConsultant versus a hospital-based outpatient consultation for general (internal) medicine: a costing analysis*. *BMC Health Serv Res*, 23(1), 478. doi:10.1186/s12913-023-09436-1
194. Johnson, D., Feng, L., & Johnson, C. (2023). *Retrospective review of the efficacy for sublingual ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model*. *Disabil Rehabil*. doi:10.1080/09638288.2023.2218652
195. Johnston, E. A., Ekberg, S., Jennings, B., Jagasia, N., & van der Pols, J. C. (2023). *Discussing diet, nutrition, and body weight after treatment for gynecological cancer: a conversation analytic study of outpatient consultations*. *J Cancer Surviv*. doi:10.1007/s11764-023-01345-w
196. Jones, M. N., Palmer, K. R., Pathirana, M. M., Cecatti, J. G., Filho, O. B. M., Marions, L., . . . Li, W. (2023). *Balloon Catheters Versus Vaginal Prostaglandins for Labour Induction (CPI Collaborative): An Individual Participant Data Meta-analysis of Randomised Controlled Trials*. *Obstetrical and Gynecological Survey*, 78(5), 255–257. doi:10.1097/O1.ogx.0000935820.554897e
197. Joshi, K., Harris, M., Cotterill, A., Wentworth, J. M., Couper, J. J., Haynes, A., . . . Huynh, T. (2023). *Continuous glucose monitoring has an increasing role in pre-symptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing*. *Clin Chem Lab Med*. doi:10.1515/cclm-2023-0234
198. Kalhor, A. (2023). *Scapular spine fracture, presentation of two cases and novel surgical treatment*. *JSES International*. doi:10.1016/j.jseint.2023.09.001

199. Kelly, C., Kynoch, K., & Ramis, M. A. (2023). *Implementing Dignity Therapy Service into an Acute Cancer Care Setting – A Feasibility Study*. *J Palliat Care*, 38(4), 456–464. doi:10.1177/08258597231154221
200. Keshvari, S., Masson, J. J. R., Ferraricestari, M., Bodea, L. G., Noor-Mohamed, F., Tse, B. W. C., . . . Irvine, K. M. (2023). *Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolism*. *Am J Physiol Endocrinol Metab*. doi:10.1152/ajpendo.00347.2023
201. Kevat, A., Bernard, A., Harris, M. A., Heussler, H., Black, R., Cheng, A., . . . Chawla, J. (2023). *Impact of adenotonsillectomy on growth trajectories in preschool children with mild–moderate obstructive sleep apnea*. *Journal of Clinical Sleep Medicine*, 19(1), 55–62. doi:10.5664/jcsm.10266
202. Khan, A., Inkster, A. M., Peñaherrera, M. S., King, S., Kildea, S., Oberlander, T. F., . . . Robinson, W. P. (2023). *The application of epigenotyping approaches to DNA methylation array studies of the human placenta*. *Epigenetics Chromatin*, 16(1), 37. doi:10.1186/s13072-023-00507-5
203. Khoo, E., Lee, A., Neeman, T., An, Y. K., & Begun, J. (2023). *Comprehensive systematic review and pooled analysis of real-world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment*. *JGH Open*. doi:10.1002/jgh3.13000
204. Kidman, A. M., Manley, B. J., Boland, R. A., Malhotra, A., Donath, S. M., Beker, F., . . . Bhatia, R. (2023). *Higher versus lower nasal continuous positive airway pressure for extubation of extremely preterm infants in Australia (ÉCLAT): a multicentre, randomised, superiority trial*. *The Lancet Child and Adolescent Health*, 7(12), 844–851. doi:10.1016/S2352-4642(23)00235-3
205. Killeen, S. L., Donnellan, N., O'Reilly, S. L., Hanson, M. A., Rosser, M. L., Medina, V. P., . . . McAuliffe, F. M. (2023). *Using FIGO Nutrition Checklist counselling in pregnancy: A review to support healthcare professionals*. *Int J Gynaecol Obstet*, 160 Suppl 1(Suppl 1), 10–21. doi:10.1002/ijgo.14539
206. Koch, M. K., Ravichandran, A., Murekatete, B., Clegg, J., Joseph, M. T., Hampson, M., . . . Bray, L. J. (2023). *Exploring the Potential of PEG–Heparin Hydrogels to Support Long-Term Ex Vivo Culture of Patient-Derived Breast Explant Tissues*. *Adv Healthc Mater*, 12(14). doi:10.1002/adhm.202202202
207. Koistinen, H., Kovanen, R. M., Hollenberg, M. D., Dufour, A., Radisky, E. S., Stenman, U. H., . . . Mirtti, T. (2023). *The roles of proteases in prostate cancer*. *IUBMB Life*, 75(6), 493–513. doi:10.1002/iub.2700
208. Kostner, K. M., & Kostner, G. M. (2023). *The 10 essential questions regarding lipoprotein(a)*. *Curr Opin Clin Nutr Metab Care*. doi:10.1097/mco.0000000000000994
209. Kou, K., Cameron, J., Youl, P., Pyke, C., Chambers, S., Dunn, J., . . . Baade, P. D. (2023). *Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study*. *Breast Cancer*, 30(3), 466–477. doi:10.1007/s12282-023-01439-4
210. Kumar, S., & Turner, J. M. (2023). *Reply to Letter to Editor: Maternal awareness of decreased fetal movements to prevent stillbirth—no benefit*. *Am J Obstet Gynecol* MFM, 5(8), 100892. doi:10.1016/j.ajogmf.2023.100892
211. Kumarapperuma, H., Wang, R., Little, P. J., & Kamato, D. (2023). *Mechanistic insight: Linking cardiovascular complications of inflammatory bowel disease*. *Trends Cardiovasc Med*. doi:10.1016/j.tcm.2023.01.002
212. Kynoch, K., Liu, X., Tan, J. B., Shi, W., Teus, J. K., & Ramis, M. A. (2023). *Exploring approaches to contemporary clinical incident analysis methods within acute care settings: a scoping review protocol*. *JBI Evid Synth*. doi:10.11124/jbies-23-00343
213. Kynoch, K., Liu, X. L., Cabilan, C. J., & Ramis, M. A. (2023). *Educational programs and interventions for health care staff to prevent and manage aggressive behaviors in acute hospitals: a systematic review*. *JBI Evid Synth*. doi:10.11124/jbies-22-00409
214. Laakso, E. L., & Ewais, T. (2023). *A Holistic Perspective on How Photobiomodulation May Influence Fatigue, Pain, and Depression in Inflammatory Bowel Disease: Beyond Molecular Mechanisms*. *Biomedicine*, 11(5). doi:10.3390/biomedicine11051497
215. Labrom, F. R., Izatt, M. T., Askin, G. N., Labrom, R. D., Claus, A. P., & Little, J. P. (2023). *Quantifying Typical Progression of Adolescent Idiopathic Scoliosis: Longitudinal Three-Dimensional MRI Measures of Disk and Vertebral Deformities*. *Spine (Phila Pa 1976)*, 48(23), 1642–1651. doi:10.1097/brs.00000000000004829
216. Laurie, J. G., Wilkinson, S. A., Griffin, A., & McIntyre, H. D. (2023). *GDM care re-imagined: Maternal and neonatal outcomes following a major model of care change for gestational diabetes mellitus at a large metropolitan hospital*. *Aust N Z J Obstet Gynaecol*, 63(5), 681–688. doi:10.1111/ajo.13691
217. Laurie, J. G., Wilkinson, S. A., McIntyre, H. D., & Snoswell, C. (2023). *Gestational diabetes mellitus care re-imagined – A cost-minimisation analysis: Cost savings from a tertiary hospital, using a novel, digital-based gestational diabetes management model*. *Aust N Z J Obstet Gynaecol*, 63(5), 709–713. doi:10.1111/ajo.13695
218. Lawrence, H., & Morton, A. (2023). *Postpartum complications following neuraxial anaesthesia for obstetric physicians*. *Obstet Med*, 16(3), 142–150. doi:10.1177/1753495x221146329
219. Leditschke, I. A., & Laakso, E. L. (2023). *Acute Delirium and Transcranial Photobiomodulation*. *Photobiomodul Photomed Laser Surg*. doi:10.1089/photob.2023.0143
220. Lee, C. Y., Good, P., Huggett, G., Greer, R., & Hardy, J. (2023). *Drug dependence epidemiology in palliative care medicinal cannabis trials*. *BMJ Support Palliat Care*. doi:10.1136/spcare-2023-004583
221. Lee, G. A., Kong, G. Y. X., & Liu, C. H. (2023). *Visual fields in glaucoma: Where are we now?* *Clin Exp Ophthalmol*, 51(2), 162–169. doi:10.1111/ceo.14210
222. Leech, S. M., Gilbert, M. C., Clifton, V. L., Kumar, S., Rae, K. M., Borg, D., & Dekker Nitert, M. (2023). *Insufficient Evidence of a Breastmilk Microbiota at Six-Weeks Postpartum: A Pilot Study*. *Nutrients*, 15(3). doi:10.3390/nu15030696
223. Lepre, B., Job, J., Martin, Z., Kerrigan, N., & Jackson, C. (2023). *The Queensland Virtual Integrated Practice (VIP) partnership program pilot study: an Australian-first model of care to support rural general practice*. *BMC Health Serv Res*, 23(1), 1183. doi:10.1186/s12913-023-10189-0
224. Lerch, A., & Chau, A. M. T. (2023). *The efficacy of post-operative drains for anterior cervical discectomy and fusion: a systematic review and meta-analysis*. *Br J Neurosurg*, 1–9. doi:10.1080/02688697.2023.2254833
225. Leung, S. S., Lenchik, N., Mathews, C., Pugliese, A., McCarthy, D. A., Le Bagge, S., . . . Forbes, J. M. (2023). *Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes*. *Sci Rep*, 13(1), 12948. doi:10.1038/s41598-023-39243-x
226. Li, Z., Min, S., Alliey-Rodriguez, N., Giase, G., Cheng, L., Craig, D. W., . . . Gershon, E. S. (2023). *Single-neuron whole genome sequencing identifies increased somatic mutation burden in Alzheimer's disease related genes*. *Neurobiol Aging*, 123, 222–232. doi:10.1016/j.neurobiolaging.2022.12.002



227. Lin, S., Zhang, H., Qi, M., Cooper, D. N., Yang, Y., Yang, Y., & Zhao, H. (2023). *Inferring the genetic relationship between brain imaging-derived phenotypes and risk of complex diseases by Mendelian randomization and genome-wide colocalization*. *Neuroimage*, 279, 120325. doi:10.1016/j.neuroimage.2023.120325
228. Lin, X., Yang, Y., Fuh-Ngwa, V., Yin, X., Simpson-Yap, S., van der Mei, I., . . . Zhou, Y. (2023). *Genetically determined serum serine level has a novel causal effect on multiple sclerosis risk and predicts disability progression*. *J Neurol Neurosurg Psychiatry*, 94(7), 526–531. doi:10.1136/jnnp-2022-330259
229. Lin, X., Yang, Y., Gresle, M., Cuellar-Partida, G., Han, X., Stankovich, J., . . . Zhou, Y. (2023). *Novel plasma and brain proteins that are implicated in multiple sclerosis*. *Brain*, 146(6), 2464–2475. doi:10.1093/brain/awac420
230. Lockington, E. P., Sherrell, H. C., Crawford, K., Roe, K., & Kumar, S. (2023). *Intimate partner violence is a significant risk factor for adverse pregnancy outcomes*. *AJOG Glob Rep*, 3(4), 100283. doi:10.1016/j.xagr.2023.100283
231. Loftus, E. V., Jr., Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D'Haens, G., Panaccione, R., . . . Colombel, J. F. (2023). *Upadacitinib Induction and Maintenance Therapy for Crohn's Disease*. *N Engl J Med*, 388(21), 1966–1980. doi:10.1056/NEJMoa2212728
232. Long, D., Anderson, V. A., Crossley, L., Sood, N. T., Charles, K. R., MacDonald, A. D., . . . Gibbons, K. S. (2023). *Longitudinal cohort study investigating neurodevelopmental and socioemotional outcomes in school-entry aged children after open heart surgery in Australia and New Zealand: the NITRIC follow-up study protocol*. *BMJ Open*, 13(8), e075429. doi:10.1136/bmjopen-2023-075429
233. Lumchee, M., Yue, M., Laurie, J., & Morton, A. (2023). *Therapeutic plasma exchange for Graves' disease in pregnancy*. *Obstet Med*, 16(2), 126–129. doi:10.1177/1753495x211031328
234. Luong, D., Griffin, A., Barrett, H. L., Hendrieckx, C., & D'Silva, N. (2023). *Emotional well-being and HbA1c following the implementation of the Diabetes Psychosocial Assessment Tool (DPAT) in young adults with type 1 diabetes (T1DM): An observational study*. *Diabetes Res Clin Pract*, 200, 110696. doi:10.1016/j.diabres.2023.110696
235. Lyons, N. J., Giri, R., Begun, J., Clark, D., Proud, D., He, Y., . . . Kryza, T. (2023). *Reactive Oxygen Species as Mediators of Disease Progression and Therapeutic Response in Colorectal Cancer*. *Antioxid Redox Signal*, 39(1–3), 186–205. doi:10.1089/ars.2022.0127
236. Macente, J., Nauwelaerts, N., Russo, F. M., Deprest, J., Allegaert, K., Lammens, B., . . . Annaert, P. (2023). *PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia*. *Front Pharmacol*, 14, 1068153. doi:10.3389/fphar.2023.1068153
237. Madrid, L. I., Hafey, K., Bandhavkar, S., Bodea, G. O., Jimenez-Martin, J., Milne, M., . . . Jhaveri, D. J. (2023). *Stimulation of the muscarinic receptor M4 regulates neural precursor cell proliferation and promotes adult hippocampal neurogenesis*. *Development*. doi:10.1242/dev.201835
238. Mahoney, A., Shiner, C. T., Grierson, A. B., Sharrock, M. J., Loughnan, S. A., Harrison, V., & Millard, M. (2023). *Online cognitive behaviour therapy for maternal antenatal and postnatal anxiety and depression in routine care*. *J Affect Disord*, 338, 121–128. doi:10.1016/j.jad.2023.06.008
239. Mamun, A., Biswas, T., Scott, J., Sly, P. D., McIntyre, H. D., Thorpe, K., . . . Callaway, L. K. (2023). *Adverse childhood experiences, the risk of pregnancy complications and adverse pregnancy outcomes: a systematic review and meta-analysis*. *BMJ Open*, 13(8), e063826. doi:10.1136/bmjopen-2022-063826
240. Manley, B. J., Kamlin, C. O. F., Donath, S., Huang, L., Birch, P., Cheong, J. L. Y., . . . McKinlay, C. J. D. (2023). *Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial*. *Trials*, 24(1), 320. doi:10.1186/s13063-023-07257-5
241. Mann, Z., Lim, F., Verma, S., Nanavati, B. N., Davies, J. M., Begun, J., . . . Duszczyk, K. (2023). *Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia*. *Mol Biol Cell*, mbcE23080337. doi:10.1091/mbc.E23-08-0337
242. Marella, P., Laupland, K. B., Shekar, K., Tabah, A., Edwards, F., & Ramanan, M. (2023). *Institution-free days after critical illness: A multicenter retrospective study*. *J Crit Care*, 74, 154253. doi:10.1016/j.jcrr.2023.154253
243. Marella, P., Ramanan, M., Shekar, K., Tabah, A., & Laupland, K. B. (2023). *Determinants of 90-day case fatality among older patients admitted to intensive care units: A retrospective cohort study*. *Aust Crit Care*. doi:10.1016/j.aucc.2023.07.039
244. Marsden, T., Khong, T. Y., Dahlstrom, J. E., Ellwood, D., Moghimi, A., Prystupa, S., . . . Flenady, V. (2023). *Validation of a tool for determining the clinical utility of stillbirth investigations*. *Aust N Z J Obstet Gynaecol*, 63(4), 535–540. doi:10.1111/ajo.13681
245. Marsh, N., Larsen, E., O'Brien, C., Peach, H., Keogh, S., Davies, K., . . . Rickard, C. M. (2023). *Controlling peripheral intravenous catheter failure by needleless connector design: A pilot randomised controlled trial*. *J Clin Nurs*, 32(21–22), 7909–7919. doi:10.1111/jocn.16852
246. Martin, A. K., Green, T. L., McCarthy, A. L., Sowa, P. M., & Laakso, E. L. (2023). *Allied health transdisciplinary models of care in hospital settings: A scoping review*. *Journal of Interprofessional Care*, 37(1), 118–130. doi:10.1080/13561820.2022.2038552
247. Martin, E., Ayoub, B., & Miller, Y. D. (2023). *A systematic review of the cost-effectiveness of maternity models of care*. *BMC Pregnancy Childbirth*, 23(1), 859. doi:10.1186/s12884-023-06180-6
248. Massi, L., Weatherall, L., Nielsen, C., Toombs, M., Fredericks, B., & Rae, K. M. (2023). *"It's research, our input can grow": identifying health research priorities with Aboriginal and Torres Strait Islander communities-study protocol*. *Res Involv Engagem*, 9(1), 59. doi:10.1186/s40900-023-00467-w
249. Maxwell, C. V., Shirley, R., O'Higgins, A. C., Rosser, M. L., O'Brien, P., Hod, M., . . . McAuliffe, F. M. (2023). *Management of obesity across women's life course: FIGO Best Practice Advice*. *Int J Gynaecol Obstet*, 160 Suppl 1(Suppl 1), 35–49. doi:10.1002/ijgo.14549
250. Mazzoni, D., Daly, T., & Muir, J. (2023a). *Comment on 'Method of Assessing Skin Cancerization and Keratoses™ (MASCk™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization'*. *Clin Exp Dermatol*, 48(3), 239. doi:10.1093/ced/llac067
251. Mazzoni, D., Daly, T., & Muir, J. (2023b). *Role of volumetric modulated arc therapy in skin field cancerisation*. *Aust J Gen Pract*, 52(8), 543–546. doi:10.31128/ajgp-11-22-6600
252. McCann, E., Lee, S., Coleman, F., O'Sullivan, J. D., & Nestor, P. J. (2023). *Pareidolias are a function of visuoperceptual impairment*. *Plos One*, 18(11), e0293942. doi:10.1371/journal.pone.0293942
253. McGonigal, A. (2023). *Investigating the Inverse Problem of Epileptogenic Zone Localization: Insights From Simultaneous EEG and SEEG*. *Neurology*, 100(20), 937–938. doi:10.1212/wnl.000000000000207228
254. McGonigal, A., Becker, C., Fath, J., Hammam, K., Baumstarck, K., Fernandes, S., . . . Bartolomei, F. (2023). *BDNF as potential biomarker of epilepsy severity and psychiatric comorbidity: pitfalls in the clinical population*. *Epilepsy Res*, 195, 107200. doi:10.1016/j.eplepsyres.2023.107200
255. McGowan, E. C., O'Brien, H., Sarri, M. E., Lopez, G. H., Daly, J. J., Flower, R. L., . . . Hyland, C. A. (2023). *Feasibility for non-invasive prenatal fetal blood group and platelet genotyping by massively parallel sequencing: A single test system for multiple atypical red cell, platelet and quality control markers*. *Br J Haematol*. doi:10.1111/bjh.19197

256. McGuckin, M. A., Davies, J. M., Felgner, P., Wong, K. Y., Giri, R., He, Y., . . . Sheng, Y. H. (2023). *MUC13 Cell Surface Mucin Limits Salmonella Typhimurium Infection by Protecting the Mucosal Epithelial Barrier*. *Cell Mol Gastroenterol Hepatol*, 16(6), 985-1009. doi:10.1016/j.jcmgh.2023.08.011
257. McKeague, S. J., O'Rourke, K., Fanning, S., Joy, C., Throp, D., Adams, R., . . . Keng, T. B. (2023). *Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review*. *Am J Clin Pathol*. doi:10.1093/ajcp/aqad135
258. McKenna, E., Futrega, K., Klein, T. J., Altalhi, T. A., Popat, A., Kumeria, T., & Doran, M. R. (2023). *Spray nebulization enables polycaprolactone nanofiber production in a manner suitable for generation of scaffolds or direct deposition of nanofibers onto cells*. *Biofabrication*, 15(2). doi:10.1088/1758-5090/aca5b7
259. McKinlay, C. J. D., Anderson, C., Cheong, J. L. Y., Gordon, A., Harris, S. L., Hurion, E. M., . . . Groom, K. M. (2023). *Childhood outcomes after maternal antenatal sildenafil treatment for severe early-onset fetal growth restriction: a randomized trial (STRIDER NZAus)*. *J Perinatol*. doi:10.1038/s41372-023-01838-7
260. McLindon, L. A., James, G., Beckmann, M. M., Bertolone, J., Mahomed, K., Vane, M., . . . Li, W. (2023). *Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial*. *Hum Reprod*, 38(4), 560-568. doi:10.1093/humrep/dead029
261. Meakin, A. S., Nathanielsz, P. W., Li, C., Clifton, V. L., Wiese, M. D., & Morrison, J. L. (2023). *Maternal obesity impacts fetal liver androgen signalling in a sex-specific manner*. *Life Sci*, 337, 122344. doi:10.1016/j.lfs.2023.122344
262. Medeiros, P. B., Bailey, C., Pollock, D., Liley, H., Gordon, A., Andrews, C., & Flenady, V. (2023). *Neonatal near-miss audits: a systematic review and a call to action*. *BMC Pediatr*, 23(1), 573. doi:10.1186/s12887-023-04383-6
263. Medeiros, P. B., Flenady, V., Andrews, C., Forbes, M., Boyle, F., Loughnan, S. A., . . . Gordon, A. (2023). *Evaluation of an online education program for healthcare professionals on best practice management of perinatal deaths: IMPROVE eLearning*. *Aust N Z J Obstet Gynaecol*. doi:10.1111/ajo.13743
264. Meloncelli, N., O'Connor, H., Wilkinson, S. A., Nitert, M. D., Kearney, L., & de Jersey, S. (2023). *Preventing Gestational Diabetes with a Healthy Gut Diet: Protocol for a Pilot, Feasibility Randomized Controlled Trial*. *Nutrients*, 15(21). doi:10.3390/nu15214653
265. Meloncelli, N. J., Barnett, A. G., Cameron, C. M., McIntyre, D., Callaway, L. K., d'Emden, M. C., & de Jersey, S. J. (2023). *Gestational diabetes mellitus screening and diagnosis criteria before and during the COVID-19 pandemic: a retrospective pre-post study*. *Med J Aust*, 219(10), 467-474. doi:10.5694/mja2.52129
266. Mena, G. P., & McLindon, L. A. (2023). *Fertility awareness education improves fertility cycle knowledge and may reduce time-to-pregnancy in subfertile women*. *Hum Fertil (Camb)*, 26(2), 405-412. doi:10.1080/14647273.2023.2214952
267. Meyer, B. J., Cortie, C., Dekker-Nitert, M., Barrett, H. L., & Freeman, D. J. (2023). *Women with gestational diabetes mellitus, controlled for plasma glucose level, exhibit maternal and fetal dyslipidaemia that may warrant treatment*. *Diabetes Res Clin Pract*, 204, 110929. doi:10.1016/j.diabres.2023.110929
268. Micoulaud-Franchi, J. A., Gauld, C., & McGonigal, A. (2023). *Networked vision of epilepsy and mental symptoms: Proposal for a "city map of traffic lights"*. *Epilepsy Behav*, 141, 109118. doi:10.1016/j.yebeh.2023.109118
269. Ming, Z., Lim, S. Y., Stewart, A., Pedersen, B., Shklovskaya, E., Menzies, A. M., . . . Rizos, H. (2023). *IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics*. *J Invest Dermatol*, 143(7), 1246-1256.e1248. doi:10.1016/j.jid.2023.01.017
270. Minogue, J., Schlapbach, L. J., Keogh, S., Gibbons, K., & Long, D. (2023). *Long-term outcomes after paediatric sepsis (LOTUS)-A protocol for an Australian cohort study*. *Nurs Crit Care*. doi:10.1111/nicc.12938
271. Mnataganian, G., Taylor, M., He, F., Yuen, N., McIntyre, H. D., Woodward, M., . . . Huxley, R. R. (2023). *Differences in neonatal adverse outcomes among women with gestational diabetes mellitus managed by diet or medication: a propensity score matched analysis of a population-based sample*. *Gynecol Endocrinol*, 39(1), 2250005. doi:10.1080/09513590.2023.2250005
272. Mokari-Mahallati, M., Ebrahimpour, R., Bagheri, N., & Karimi-Rouzbahani, H. (2023). *Deeper neural network models better reflect how humans cope with contrast variation in object recognition*. *Neurosci Res*, 192, 48-55. doi:10.1016/j.neures.2023.01.007
273. Momtazmanesh, S., & Moghaddam, S. S. (2023). *Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019*. *EClinicalMedicine*, 59, 101936. doi:10.1016/j.eclinm.2023.101936
274. Moniruzzaman, M., Janjua, T. I., Martin, J. H., Begun, J., & Popat, A. (2023). *Cannabidiol - Help and hype in targeting mucosal diseases*. *J Control Release*. doi:10.1016/j.jconrel.2023.11.010
275. Moniruzzaman, M., Rahman, M. A., Wang, R., Wong, K. Y., Chen, A. C., Mueller, A., . . . Hasnain, S. Z. (2023). *Interleukin-22 suppresses major histocompatibility complex II in mucosal epithelial cells*. *J Exp Med*, 220(11). doi:10.1084/jem.20230106
276. Moniruzzaman, M., Wong, K. Y., Wang, R., Symon, H., Mueller, A., Rahman, M. A., & Hasnain, S. Z. (2023). *IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis*. *Int J Mol Sci*, 24(1). doi:10.3390/ijms24010174
277. Monnelly, V., Josephsen, J. B., Isayama, T., de Almeida, M. F. B., Guinsburg, R., Schmölzer, G. M., . . . Solevåg, A. L. (2023). *Exhaled CO(2) monitoring to guide non-invasive ventilation at birth: a systematic review*. *Arch Dis Child Fetal Neonatal Ed*. doi:10.1136/archdischild-2023-325698
278. Morais, R., Le, V., Morgan, C., Spittle, A., Badawi, N., Valentine, J., . . . Venkatesh, S. (2023). *Robust and Interpretable General Movement Assessment Using Fidgety Movement Detection*. *IEEE Journal of Biomedical and Health Informatics*, 27(10), 5042-5053. doi:10.1109/JBHI.2023.3299236
279. Morgan, T. J. (2023). *Flaws in the Van Slyke buffer algorithm?* *J Appl Physiol* (1985), 135(1), 200. doi:10.1152/japplphysiol.00273.2023
280. Morgan, T. J., Scott, P. H., Langley, A. N., Barrett, R. D. C., & Anstey, C. M. (2023). *Single-FIO(2) lung modelling with machine learning: a computer simulation incorporating volumetric capnography*. *J Clin Monit Comput*, 37(5), 1303-1311. doi:10.1007/s10877-023-00996-5
281. Morley, G., Dierckx de Casterlé, B., Kynoch, K., Ramis, M. A., Suhonen, R., Ventura, C., & Arries-Kleyenstuber, E. (2023). *Ethical challenges faced by nurses during the COVID-19 pandemic: a scoping review protocol*. *JBI Evid Synth*, 21(5), 970-976. doi:10.11124/jbies-22-00247
282. Morris, D. R., Singh, T. P., Zaman, T., Velu, R., Quigley, F., Jenkins, J., & Golledge, J. (2023). *Rates of Stroke in Patients With Different Presentations of Carotid Artery Stenosis*. *Eur J Vasc Endovasc Surg*, 66(4), 484-491. doi:10.1016/j.ejvs.2023.05.041
283. Morton, A. (2023a). *Diabetic ketoacidosis with severe hypokalaemia and valproate-associated Fanconi syndrome*. *Intern Med J*, 53(1), 155-156. doi:10.1111/imj.15986
284. Morton, A. (2023b). *Gordon's syndrome in pregnancy*. *Obstet Med*, 16(3), 151-155. doi:10.1177/1753495x221146331
285. Morton, A. (2023c). *Hyperventilation imitating preeclampsia*. *Obstet Med*, 16(1), 72-73. doi:10.1177/1753495x211064142

286. Morton, A. (2023d). *Hypoglycaemia in non-diabetic pregnancy*. *Obstet Med*, 16(2), 123–125. doi:10.1177/1753495x211032787
287. Morton, A. (2023e). *Investigating gastrointestinal disorders in pregnancy*. *Obstetric Medicine*. doi:10.1177/1753495x231206211
288. Morton, A. (2023f). *Possible additional criteria for the diagnosis of preeclampsia with severe features*. *Obstet Med*, 16(1), 9–11. doi:10.1177/1753495x221103981
289. Morton, A. (2023g). *Response to: rare causes of abdominal pain: a primer for the admitting general surgeon*. *ANZ J Surg*. doi:10.1111/ans.18692
290. Morton, A. (2023h). *Severe hyponatraemia peripartum associated with omeprazole therapy*. *Obstet Med*, 16(4), 245–246. doi:10.1177/1753495x221113489
291. Morton, A., Li, L., & Wilson, C. (2023). *Pregnancy outcome with maternal HNF1B gene mutations and 17q12 deletions*. *Obstet Med*, 16(2), 78–82. doi:10.1177/1753495x221109734
292. Morton, S. K., Ozluer, S., & Muir, J. (2023). *Field cancerisation and radiotherapy: a case of treatment complications*. *Med J Aust*, 219(1), 12–14. doi:10.5694/mja2.51980
293. Mou, J. Y., Wang, Z. Y., Ma, Z. W., Liu, Q. H., Sullivan, M. A., Liu, Z., & Wang, L. (2023). *Is glycofen an important constituent of human milk?* *Journal of Food Composition and Analysis*, 124. doi:10.1016/j.jfca.2023.105719
294. Moya, L., Walpole, C., Rae, F., Srinivasan, S., Seim, I., Lai, J., . . . Batra, J. (2023). *Characterisation of cell lines derived from prostate cancer patients with localised disease*. *Prostate Cancer Prostatic Dis*, 26(3), 614–624. doi:10.1038/s41391-023-00679-x
295. Muir, J., Morton, S. K., & Ozluer, S. (2023). *Field cancerisation and radiotherapy: a case of treatment complications*. *Med J Aust*, 219(7), 335. doi:10.5694/mja2.52085
296. Muirhead, R., Ballard, E., Kynoch, K., Peacock, A., Birch, P., & Lewis, P. A. (2023). *A survey of pain practices in the surgical neonate. An Australasian perspective*. *Journal of Neonatal Nursing*, 29(6), 857–861. doi:10.1016/j.jnn.2023.07.010
297. Muirhead, R., & Bates, A. (2023). *Does the Implementation of Multidisciplinary Developmental Care Rounds Increase the Utilization of Developmental Caregiving Interventions in the Neonatal Unit?* *J Perinat Neonatal Nurs*, 37(2), 153–163. doi:10.1097/jpn.0000000000000725
298. Muirhead, R., Kynoch, K., Peacock, A., Birch, P., & Lewis, P. A. (2023). *Developing a model of neonatal nurse-controlled analgesia: A Delphi study*. *J Adv Nurs*. doi:10.1111/jan.15972
299. Mullan, L., Armstrong, K., & Job, J. (2023). *Barriers and enablers to structured care delivery in Australian rural primary care*. *Aust J Rural Health*, 31(3), 361–384. doi:10.1111/ajr.12963
300. Munday, J., Delaforce, A., Heidke, P., Rademakers, S., Sturgess, D., Williams, J., & Douglas, C. (2023). *Perioperative temperature monitoring for patient safety: A period prevalence study of five hospitals*. *Int J Nurs Stud*, 143, 104508. doi:10.1016/j.ijnurstu.2023.104508
301. Munday, J., Duff, J., Wood, F. M., Sturgess, D., Ralph, N., & Ramis, M. A. (2023). *Perioperative hypothermia prevention: development of simple principles and practice recommendations using a multidisciplinary consensus-based approach*. *BMJ Open*, 13(11), e077472. doi:10.1136/bmjopen-2023-077472
302. Munday, J., Ramis, M. A., Kynoch, K., Maffey, S., Steelman, V., & Osborne, S. (2023). *Hypothermia With Paradoxical Symptoms: A Case Series of Cesarean Deliveries With Intrathecal Morphine*. *AORN Journal*, 117(6), e1–e9. doi:10.1002/aorn.13932
303. Nair, S., Ormazabal, V., Carrion, F., Handberg, A., McIntyre, H. D., & Salomon, C. (2023). *Extracellular vesicle-mediated targeting strategies for long-term health benefits in gestational diabetes*. *Clin Sci (Lond)*, 137(16), 1311–1332. doi:10.1042/cs20220150
304. Ngo, E. D., Lee, G. A., Girgis, S., & Shah, P. (2023). *Only Eye Study 5 (ONES 5): A quantitative study of patient experiences undergoing surgery in their only seeing eye*. *Clin Exp Ophthalmol*. doi:10.1111/ceo.14322
305. Nguyen, T. N., Qureshi, M. M., Klein, P., Yamagami, H., Mikulik, R., Czlonkowska, A., . . . Nogueira, R. G. (2023). *Global Effect of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events A 1-Year Follow-up*. *Neurology*, 100(4), E408–E421. doi:10.1212/WNL.000000000000201426
306. O'Brien, L. J., Walpole, C. M., Leal-Rojas, I. M., Shatunova, S., Moore, A., Winkler, I. G., . . . Radford, K. J. (2023). *Characterization of Human Engraftment and Hemophagocytic Lymphohistiocytosis in NSG-SGM3 Neonate Mice Engrafted with Purified CD34(+) Hematopoietic Stem Cells*. *Exp Hematol*, 104134. doi:10.1016/j.exphem.2023.11.008
307. O'Connor, H., Li, S., Hodge, A., Callaway, L., David McIntyre, H., Barrett, H., . . . Nitert, M. D. (2023). *Gut microbiome composition is similar between pregnant women with excess body fat with healthy and less healthy dietary intake patterns*. *Journal of Human Nutrition and Dietetics*, 36(4), 1425–1437. doi:10.1111/jhn.13123
308. O'Connor, H., Willcox, J. C., de Jersey, S., Wright, C., & Wilkinson, S. A. (2023). *Digital preconception interventions targeting weight, diet and physical activity: A systematic review*. *Nutr Diet*. doi:10.1111/1747-0080.12842
309. O'Leary, C., Murphy, G., Yeung, Y., Tang, M., Jain, V., & O'Leary, C. G. (2023). *Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers*. *Cancers (Basel)*, 15(23). doi:10.3390/cancers15235582
310. O'Leary, C., Wong, D., & Wilson, G. (2023). *Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge*. *BMJ Case Rep*, 16(9). doi:10.1136/bcr-2023-254715
311. O'Moore-Sullivan, T., Paxton, J., Cross, M., Teppala, S., Chikani, V., Hopkins, G., . . . Scuffham, P. A. (2023). *Health outcomes of patients with type 2 diabetes following bariatric surgery: Results from a publicly funded initiative*. *Plos One*, 18(2), e0279923. doi:10.1371/journal.pone.0279923
312. Ofri, A., Elstner, K., Mann, G. B., Kumar, S., & Warriar, S. (2023). *Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective*. *Surgeon*, 21(6), 356–360. doi:10.1016/j.surge.2023.04.001
313. Ong, C. T. W., Palamuthusingam, P., & Avramovic, J. (2023). *Emergency Gastrectomy for Oesophageal and Gastric Polyps With Massive Bleeding Induced by Anticoagulation*. *American Surgeon*, 89(4), 1297–1299. doi:10.1177/0003134821998669
314. Pagnozzi, A. M., van Eijk, L., Pannek, K., Boyd, R. N., Saha, S., George, J., . . . Fripp, J. (2023). *Early brain morphometrics from neonatal MRI predict motor and cognitive outcomes at 2-years corrected age in very preterm infants*. *Neuroimage*, 267. doi:10.1016/j.neuroimage.2022.119815
315. Parkinson, J., Bandera, A., Crichton, M., Shannon, C., Woodward, N., Hodgkinson, A., . . . van der Meij, B. S. (2023). *Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up*. *Curr Oncol*, 30(1), 688–703. doi:10.3390/curoncol30010054
316. Pegg, C. L., Modhiran, N., Parry, R. H., Liang, B., Amarilla, A. A., Khromykh, A. A., . . . Watterson, D. (2023). *The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant*. *Glycobiology*. doi:10.1093/glycob/cwad097
317. Pervin, S., Emmett, P., Northstone, K., Townsend, N., Fatima, Y., Huda, M. M., . . . Al Mamun, A. (2023). *Trajectories of dietary patterns from pregnancy to 12 years post-pregnancy and associated maternal characteristics: evidence from the Avon Longitudinal Study of Parents and Children*. *Eur J Nutr*, 62(7), 2763–2777. doi:10.1007/s00394-023-03185-x
318. Pervin, S., Emmett, P., Townsend, N., Biswas, T., Huda, M. M., Northstone, K., . . . Al Mamun, A. (2023). *The myth and reality of familial resemblance*

- in dietary intake: a systematic review and meta-analysis on the resemblance of dietary intake among parent and offspring. *EClinicalMedicine*, 60, 102024. doi:10.1016/j.eclinm.2023.102024
319. Pham, A., Volmer, J. G., Chambers, D. C., Smith, D. J., Reid, D. W., Burr, L., & Wells, T. J. (2023). *Genomic analyses of Burkholderia respiratory isolates indicates two evolutionarily distinct B. anthina clades*. *Front Microbiol*, 14, 1274280. doi:10.3389/fmicb.2023.1274280
320. Plinsinga, M. L., Singh, B., Rose, G. L., Clifford, B., Bailey, T. G., Spence, R. R., . . . Hayes, S. C. (2023). *The Effect of Exercise on Pain in People with Cancer: A Systematic Review with Meta-analysis*. *Sports Med*, 53(9), 1737-1752. doi:10.1007/s40279-023-01862-9
321. Poon, L. C., Nguyen-Hoang, L., Smith, G. N., Bergman, L., O'Brien, P., Hod, M., . . . McAuliffe, F. M. (2023). *Hypertensive disorders of pregnancy and long-term cardiovascular health: FIGO Best Practice Advice*. *Int J Gynaecol Obstet*, 160 Suppl 1, 22-34. doi:10.1002/ijgo.14540
322. Ramaswamy, V. V., Dawson, J. A., de Almeida, M. F., Trevisanuto, D., Nakwa, F. L., Kamlin, C. O. F., . . . Liley, H. G. (2023). *Maintaining normothermia immediately after birth in preterm infants <34 weeks' gestation: A systematic review and meta-analysis*. *Resuscitation*, 191, 109934. doi:10.1016/j.resuscitation.2023.109934
323. Ramis, M. A., Jackman, K., & Gray, S. (2023). *Changes to teaching and learning about medication administration within a diploma of nursing course due to the Covid-19 pandemic: A staff and student multi-method evaluation*. *Nurse Educ Pract*, 67, 103547. doi:10.1016/j.nepr.2023.103547
324. Ramis, M. A., & Perrenoud, B. (2023). *Educating future generations of health professionals: looking back and moving forward*. *JBI Evid Synth*, 21(7), 1348-1350. doi:10.11124/jbies-23-00256
325. Raininga, P. V., He, Y., Datta, K. K., Lu, X., Maheshwari, U. R., Venkat, P., . . . Khanna, K. K. (2023). *Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma*. *Molecular Therapy*, 31(3), 729-743. doi:10.1016/j.jymth.2022.12.011
326. Rayward, L., Pearcy, M., Izatt, M., Green, D., Lobrom, R., Askin, G., & Little, J. P. (2023). *Predicting spinal column profile from surface topography via 3D non-contact surface scanning*. *Plos One*, 18(3), e0282634. doi:10.1371/journal.pone.0282634
327. Reid, C., Jones, L., Janda, M., Langbecker, D., Stone, L., Laing, B., & McCarthy, A. (2023). *Development and testing of a patient-reported experience measure for cancer: A cross-sectional survey*. *J Adv Nurs*. doi:10.1111/jan.15767
328. Reis, A. L. M., Rapadas, M., Hammond, J. M., Gamaarachchi, H., Stevanovski, I., Ayuputeri Kumaheri, M., . . . Deveson, I. W. (2023). *The landscape of genomic structural variation in Indigenous Australians*. *Nature*, 624(7992), 602-610. doi:10.1038/s41586-023-06842-7
329. Retell, J. D., Cameron, J. K., Aitken, J. F., Youl, P., Pyke, C., Dunn, J., . . . Baade, P. D. (2023). *Individual and area level factors associated with the breast cancer diagnostic-treatment interval in Queensland, Australia*. *Breast Cancer Res Treat*. doi:10.1007/s10549-023-07134-4
330. Rizzo, M., Colletti, A., Penson, P. E., Katsiki, N., Mikhaelidis, D. P., Toth, P. P., . . . Banach, M. (2023). *Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)*. *Pharmacol Res*, 189, 106679. doi:10.1016/j.phrs.2023.106679
331. Robinson, J. L., Gatford, K. L., Clifton, V. L., Morrison, J. L., & Stark, M. J. (2023). *Preclinical models of maternal asthma and progeny outcomes: a scoping review protocol*. *JBI Evid Synth*, 21(10), 2115-2126. doi:10.11124/jbies-23-00006
332. Robinson, J. L., Gatford, K. L., Hurst, C. P., Clifton, V. L., Morrison, J. L., & Stark, M. J. (2023). *Do improvements in clinical practice guidelines alter pregnancy outcomes in asthmatic women? A single-center retrospective cohort study*. *J Asthma*, 60(10), 1907-1917. doi:10.1080/02770903.2023.2200824
333. Rose, G. L., Stewart, E. M., Clifford, B. K., Bailey, T. G., Rush, A. J., Abbott, C. R., . . . McCarthy, A. L. (2023). *Efficacy of exercise interventions for women during and after gynaecological cancer treatment - a systematic scoping review*. *Support Care Cancer*, 31(6), 342. doi:10.1007/s00520-023-07790-8
334. Salga, M., Samuel, S. G., Tseng, H. W., Gatin, L., Girard, D., Rival, B., . . . Alexander, K. A. (2023). *Bacterial Lipopolysaccharides Exacerbate Neurogenic Heterotopic Ossification Development*. *J Bone Miner Res*. doi:10.1002/jbmr.4905
335. Samaratunga, H., Egevad, L., Yaxley, J., Perry-Keene, J., Le Fevre, I., Kench, J., . . . Delahunt, B. (2023). *Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients*. *Pathology*. doi:10.1016/j.pathol.2023.10.005
336. Samoylovich, A., Jennings, B., Shannon, C., Coward, J. I., Lurie, R., Riordan, J., . . . Barry, S. C. (2023). *Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context*. *Aust N Z J Obstet Gynaecol*, 63(5), 702-708. doi:10.1111/ajo.13694
337. Sandford, A., Haywood, A., Rickett, K., Good, P., Khan, S., Foster, K., & Hardy, J. R. (2023). *Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer*. *Cochrane Database Syst Rev*, 1(1), Cd013782. doi:10.1002/14651858.CD013782.pub2
338. Santoro, J. D., Spinazzi, N. A., Filipink, R. A., Hayati-Rezvan, P., Kammeyer, R., Patel, L., . . . Rafii, M. S. (2023). *Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder*. *Transl Psychiatry*, 13(1), 276. doi:10.1038/s41398-023-02579-z
339. Santoro, S. L., Baumer, N. T., Cornacchia, M., Franklin, C., Hart, S. J., Haugen, K., . . . Skotko, B. G. (2023). *Response to Letter to the Editor by Palffy and Ghaziuddin*. *Am J Med Genet A*, 191(5), 1470-1473. doi:10.1002/ajmg.a.63116
340. Scheuer, C. M., Jensen, D. M., McIntyre, H. D., Ringholm, L., Mathiesen, E. R., Nielsen, C. P. K., . . . Clausen, T. D. (2023). *Applying WHO2013 diagnostic criteria for gestational diabetes mellitus reveals currently untreated women at increased risk*. *Acta Diabetol*, 60(12), 1663-1673. doi:10.1007/s00592-023-02148-2
341. Scheuer, C. M., Tvarnø, C. D., Gils, C., Ravn, J. D., David McIntyre, H., Jensen, D. M., . . . Overgaard, M. (2023). *The impact of inter-laboratory glucose bias on the diagnosis of gestational diabetes mellitus: Comparison of common automated central laboratory methods*. *Clin Chim Acta*, 546, 117414. doi:10.1016/j.cca.2023.117414
342. Schreiber, V., Hurst, C., da Silva Costa, F., Stoke, R., Turner, J., & Kumar, S. (2023). *Definitions matter: detection rates and perinatal outcome for infants classified prenatally as having late fetal growth restriction using SMFM biometric vs ISUOG/Delphi consensus criteria*. *Ultrasound in Obstetrics and Gynecology*, 61(3), 377-385. doi:10.1002/uog.26035
343. Schultz, K., Kannis-Dymland, L., Jamieson, D., McLoughlin, L. T., Loughnan, S., Allen, A., & Hermens, D. F. (2023). *Examining the Longitudinal Relationship Between Metacognitive Beliefs and Psychological Distress in an Adolescent Population: A Preliminary Analysis*. *Child Psychiatry Hum Dev*. doi:10.1007/s10578-023-01611-z
344. Schweitzer, D. R., Baumeister, R., Laakso, E. L., & Ting, J. (2023). *Self-control, limited willpower and decision fatigue in healthcare settings*. *Intern Med J*, 53(6), 1076-1080. doi:10.1111/imj.16121
345. Sehgal, A., Carter-Cusack, D., Keshvari, S., Patkar, O., Huang,

- S., Summers, K. M., . . . Irvine, K. M. (2023). *Intraperitoneal transfer of wild-type bone marrow repopulates tissue macrophages in the Csf1r knockout rat without contributing to monocytopoiesis*. *Eur J Immunol*, 53(8), e2250312. doi:10.1002/eji.202250312
346. Sengal, A. T., Bonazzi, V., Smith, D., Moiola, C. P., Lourie, R., Rogers, R., . . . Pollock, P. M. (2023). *Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition*. *NPJ Precis Oncol*, 7(1), 127. doi:10.1038/s41698-023-00478-6
347. Shajib, M. S., Futrega, K., Franco, R. A. G., McKenna, E., Guillester, B., Klein, T. J., . . . Doran, M. R. (2023). *Method for manufacture and cryopreservation of cartilage microtissues*. *J Tissue Eng*, 14, 20417314231176901. doi:10.1177/20417314231176901
348. Sharma, O., Jones, L., Sii, F., Whittaker, J., Dulk, S., Lee, G., . . . Shah, P. (2023). *Mapping vision loss of patients in a glaucoma backlog following the COVID-19 pandemic: a real-world analysis using the Glauc-Strat-Fast risk stratification tool*. *Eye (Lond)*. doi:10.1038/s41433-023-02821-4
349. Sharma, V., Doig, F., Maxwell, R., Grout, D., Saeed, U., & Wall, D. (2023). *Anomalous Right Coronary Artery Originating From the Pulmonary Artery (ARCAPA): A Rare Presentation in the Fifth Decade*. *World Journal for Pediatric and Congenital Heart Surgery*, 14(2), 241-243. doi:10.1177/21501351221141437
350. Shen, E., Dhanani, J., Milford, E. M., Raileanu, V., & Laupland, K. B. (2023). *Publication outcomes among intensive care trainees*. *Anaesth Intensive Care*, 310057x231194079. doi:10.1177/0310057x231194079
351. Sheng, Y. H., & Zhang, L. (2023). *Editorial: The mucosal barrier to infection*. *Front Cell Infect Microbiol*, 13, 1141131. doi:10.3389/fcimb.2023.1141131
352. Shipton, E. V., Foxcroft, K., Dekker Nitert, M., McIntyre, H. D., Barrett, H., Tang, M., & Callaway, L. (2023). *OFFSPRING: A SPRING Follow-Up Study Assessing the Efficacy of Maternal Probiotics and Allergic Disease in the Child*. *Int Arch Allergy Immunol*, 1-6. doi:10.1159/000535179
353. Sidhu, T. S., Jhamb, S., Welch, C., & Whiting, S. (2023). *Minimally invasive management of sleeve gastrectomy collection with a nasobiliary drainage tube*. *J Surg Case Rep*, 2023(11), rjad626. doi:10.1093/jscr/rjad626
354. Sikder, M. A. A., Rashid, R. B., Ahmed, T., Sebina, I., Howard, D. R., Ullah, M. A., . . . Phipps, S. (2023). *Maternal diet modulates the infant microbiome and intestinal Ftl3L necessary for dendritic cell development and immunity to respiratory infection*. *Immunity*, 56(5), 1098-1114.e1010. doi:10.1016/j.immuni.2023.03.002
355. Skalecki, S., Lawford, H., Gardener, G., Coory, M., Bradford, B., Warrilow, K., . . . Flenady, V. (2023). *My Baby's Movements: An assessment of the effectiveness of the My Baby's Movements phone program in reducing late-gestation stillbirth rates*. *Aust N Z J Obstet Gynaecol*, 63(3), 378-383. doi:10.1111/ajo.13647
356. Smith, A., Olson, R. E., da Costa, N. C., Cuerton, M., Hardy, J., & Good, P. (2023). *Quality of life beyond measure: Advanced cancer patients, wellbeing and medicinal cannabis*. *Social Health Illn*, 45(8), 1709-1729. doi:10.1111/1467-9566.13684
357. Smith, S., Houghton, A., Mockeridge, B., & van Zundert, A. (2023). *The Internet, Apps, and the Anesthesiologist*. *Healthcare (Basel)*, 11(22). doi:10.3390/healthcare11223000
358. Snelling, P. J., Aruljoe Thanasingam, A., Jones, P., & Connors, J. (2023). *Response to Re: Comparison of abusive head trauma versus non-inflicted subdural haematoma in infants: A retrospective cohort study*. *Emerg Med Australas*, 35(3), 531-532. doi:10.1111/1742-6723.14204
359. Soncin, L. D., Arthuis, M., Scholly, J., Carron, R., McGonigal, A., Pizzo, F., . . . Bartolomei, F. (2023). *"Plok-plok" syndrome: Posttraumatic stress disorder following an SEEG thermocoagulation and direct electrical stimulation procedure*. *Epileptic Disord*, 25(3), 390-396. doi:10.1002/epd2.20023
360. Soncin, L. D., Belquaid, S., McGonigal, A., Giusiano, B., Bartolomei, F., & Faure, S. (2023). *Post-traumatic stress disorder (PTSD), cognitive control, and perceived seizure control in patients with epilepsy: An exploratory study*. *Epilepsy Behav*, 147, 109396. doi:10.1016/j.yebeh.2023.109396
361. Song, M., Le, T. T. A., Denny, S., Lennox, N. G., McPherson, L., Ware, R. S., & Harley, D. (2023). *Reasons for Encounters and Comorbidities in Adolescents with Intellectual Disability in General Practice: A Retrospective Analysis of Data from the Ask Study*. *Children (Basel)*, 10(9). doi:10.3390/children10091450
362. Song, M., Rubin, B. S., Ha, J. W., Ware, R. S., Doan, T. N., & Harley, D. (2023). *Use of psychotropic medications in adults with intellectual disability: A systematic review and meta-analysis*. *Aust N Z J Psychiatry*, 57(5), 661-674. doi:10.1177/00048674221149864
363. Sonkusare, S., Wegner, K., Chang, C., Dionisio, S., Breakspear, M., & Cocchi, L. (2023). *Dynamic interactions between anterior insula and anterior cingulate cortex link perceptual features and heart rate variability during movie viewing*. *Netw Neurosci*, 7(2), 557-577. doi:10.1162/netn_a_00295
364. Soranno, D. E., Simon, T. D., Bora, S., Lohr, J. L., Bagga, B., Carroll, K., . . . Spector, N. D. (2023). *Justice, Equity, Diversity, and Inclusion in the Pediatric Faculty Research Workforce: Call to Action*. *Pediatrics*, 152(3). doi:10.1542/peds.2022-060841
365. Sourris, K. C., Ding, Y., Maxwell, S. S., Al-Sharea, A., Kantharidis, P., Mohan, M., . . . Coughlan, M. T. (2023). *Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation*. *Kidney Int*. doi:10.1016/j.kint.2023.09.029
366. Sowula, P. T., Izatt, M. T., Labrom, R. D., Askin, G. N., & Little, J. P. (2023). *Assessing progressive changes in axial plane vertebral deformity in adolescent idiopathic scoliosis using sequential magnetic resonance imaging*. *Eur Spine J*. doi:10.1007/s00586-023-08004-9
367. Spannenburg, L., & Reed, H. (2023). *Adverse cognitive effects of glucocorticoids: A systematic review of the literature*. *Steroids*, 200, 109314. doi:10.1016/j.steroids.2023.109314
368. Spark, A., Schweitzer, D., & Ting, J. (2023). *Leveraging personality science to enhance junior doctor well-being, leadership and performance: It's not just about who we are, but also how we act*. *Intern Med J*, 53(7), 1100-1104. doi:10.1111/imj.16158
369. Srinivasan, S., Kryza, T., Bock, N., Tse, B. W., Sokolowski, K. A., Panchadsaram, J., . . . Batra, J. (2023). *Biochemical activity induced by a germline variation in KLK3 (PSA) associates with cellular function and clinical outcome in prostate cancer*. *Res Sq*. doi:10.21203/rs.3.rs-2650312/v1
370. Sriselvakumar, S. (2023). *Spontaneous small bowel volvulus in young adult male*. *Radiol Case Rep*, 18(9), 3080-3083. doi:10.1016/j.radcr.2023.06.006
371. Stoke, R., Schreiber, V., Hocking, K., Jardine, L., & Kumar, S. (2023). *Perinatal antecedents of moderate and severe neonatal hypoxic ischaemic encephalopathy: An Australian birth cohort study*. *Aust N Z J Obstet Gynaecol*, 63(3), 409-417. doi:10.1111/ajo.13665
372. Suárez-Idueta, L., Blencowe, H., Okwaraji, Y. B., Yargawa, J., Bradley, E., Gordon, A., . . . Lawn, J. E. (2023). *Neonatal mortality risk for vulnerable newborn types in 15 countries using 125.5 million nationwide birth outcome records, 2000-2020*. *BJOG*. doi:10.1111/1471-0528.17506
373. Suárez-Idueta, L., Ohuma, E. O., Chang, C. J., Hazel, E. A., Yargawa, J., Okwaraji, Y. B., . . . Blencowe, H. (2023). *Neonatal mortality risk of large-for-gestational-age and macrosomic live births in 15 countries, including 115.6 million nationwide linked records, 2000-2020*. *BJOG*. doi:10.1111/1471-0528.17706

374. Suárez-Idueta, L., Yargawa, J., Blencowe, H., Bradley, E., Okwaraji, Y. A., Pingray, V., . . . Lawn, J. E. (2023). *Vulnerable newborn types: Analysis of population-based registries for 165 million births in 23 countries, 2000–2021*. *BJOG*. doi:10.1111/1471-0528.17505
375. Subramanian, S., Thoms, J. A. I., Huang, Y., Cornejo-Páramo, P., Koch, F. C., Jacquelin, S., . . . Pimanda, J. E. (2023). *Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs*. *Blood*, 142(17), 1448–1462. doi:10.1182/blood.2023021120
376. Summers, K. M. (2023). *Genetic models of fibrillinopathies*. *Genetics*. doi:10.1093/genetics/iyad189
377. Summers, K. M., Bush, S. J., Davis, M. R., Hume, D. A., Keshvari, S., & West, J. A. (2023). *Fibrillin-1 and asprosin, novel players in metabolic syndrome*. *Mol Genet Metab*, 138(1), 106979. doi:10.1016/j.ymgme.2022.106979
378. Swarnamali, H., Ranasinghe, P., Hills, A. P., & Jayawardena, R. (2023). *Coconut oil consumption and bodyweight reduction: a systematic review and meta-analysis*. *Minerva Endocrinology*, 48(1), 76–87. doi:10.23736/S2724-6507.21.03654-X
379. Tan, H. H., Goh, I. Y., & Mudiua, G. (2023). *A rare case of inflammatory breast cancer with delayed auto-amputation in modern times*. *J Surg Case Rep*, 2023(3), rjad159. doi:10.1093/jscr/rjad159
380. Tan, L. N., Gardener, G. J., JR, R. J., Naidu, A., Hassan, G., Ahmad Zainuddin, R., & Kilby, M. D. (2023). *Fetoscopic laser ablation for twin-to-twin transfusion syndrome in Malaysia: A 15-month retrospective cohort review from an emerging centre in South East Asia*. *Med J Malaysia*, 78(1), 68–73.
381. Tanner, H. L., Ng, H. T., Murphy, G., Barrett, H. L., Callaway, L. K., McIntyre, H. D., & Nitert, M. D. (2023). *Habitual carbohydrate intake is not correlated with circulating β -hydroxybutyrate levels in pregnant women with overweight and obesity at 28 weeks' gestation*. *Diabetologia*. doi:10.1007/s00125-023-06044-w
382. Tarnow-Mordi, W. O., Robledo, K., Marschner, I., Seidler, L., & Simes, J. (2023). *To guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomes*. *Semin Perinatol*, 47(5), 151789. doi:10.1016/j.semperi.2023.151789
383. Tay, J., Bisht, K., Winkler, I. G., & Levesque, J. P. (2023). *Imaging Flow Cytometric Analysis of Primary Bone Marrow Erythroblastic Islands*. *Methods Mol Biol*, 2635, 43–61. doi:10.1007/978-1-0716-3020-4_3
384. Terblanche, N. C., Sharman, J. E., Jones, M. A., Gregory, K., & Sturgess, D. J. (2023). *Uterine atony prophylaxis with carbetocin versus oxytocin and the risk of major haemorrhage during caesarean section: A retrospective cohort study*. *Anaesth Intensive Care*, 51(4), 288–295. doi:10.1177/0310057x221140128
385. Thai, L. M., O'Reilly, L., Reibe-Pal, S., Sue, N., Holliday, H., Small, L., . . . Biden, T. J. (2023). *β -cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving *Axl*, *Mertk*, and *TGF β* receptor signaling*. *iScience*, 26(4), 106477. doi:10.1016/j.isci.2023.106477
386. Thamm, C., McCarthy, A. L., & Yates, P. (2023). *A Discourse of Deviance: Blame, Shame, Stigma and the Social Construction of Head and Neck Cancer*. *Qual Health Res*, 10497323231213819. doi:10.1177/10497323231213819
387. Thanigaimani, S., Iyer, V., Bingley, J., Browne, D., Phie, J., Doolan, D., & Golledge, J. (2023). *Association Between Serum MicroRNAs and Abdominal Aortic Aneurysm Diagnosis and Growth*. *Eur J Vasc Endovasc Surg*, 65(4), 573–581. doi:10.1016/j.ejvs.2022.12.028
388. Thomas, D., McDonald, V. M., Stevens, S., Harvey, E. S., Baraket, M., Bardin, P., . . . Gibson, P. G. (2023). *Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients*. *Allergy*. doi:10.1111/all.15867
389. Thompson, S., Hertzog, A., Selvanathan, A., Batten, K., Lewis, K., Nisbet, J., . . . Bhattacharya, K. (2023). *Treatment of HMG-CoA Lyase Deficiency-Longitudinal Data on Clinical and Nutritional Management of 10 Australian Cases*. *Nutrients*, 15(3). doi:10.3390/nu15030531
390. Titmuss, A., Barzi, F., Barr, E. L. M., Webster, V., Wood, A., Kelaart, J., . . . Maple-Brown, L. J. (2023). *Association between maternal hyperglycemia in pregnancy and offspring anthropometry in early childhood: the pandora wave 1 study*. *Int J Obes (Lond)*, 47(11), 1120–1131. doi:10.1038/s41366-023-01366-6
391. Tong, M. Z., Sng, J. D., Carney, M., Cooper, L., Brown, S., Lineburg, K. E., . . . Short, K. R. (2023). *Elevated BMI reduces the humoral response to SARS-CoV-2 infection*. *Clin Transl Immunology*, 12(12), e1476. doi:10.1002/cti2.1476
392. Trotman, J., Presgrave, P., Carradice, D. P., Lenton, D. S., Gandhi, M. K., Cochrane, T., . . . Johnston, A. M. (2023). *Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study*. *Hemasphere*, 7(3), e836. doi:10.1097/hs9.0000000000000836
393. Turner, J. V., McLindon, L. A., Turner, D. V., Alefsen, Y., & Ecochard, R. (2023). *Relationship Between Steroid Hormone Profile and Premenstrual Syndrome in Women Consulting for Infertility or Recurrent Miscarriage*. *Reprod Sci*. doi:10.1007/s43032-023-01375-w
394. Utter, J., McCray, S., & Denny, S. (2023). *Eating Behaviours Among Healthcare Workers and Their Relationships With Work-Related Burnout*. *American Journal of Lifestyle Medicine*. doi:10.1177/15598276231159064
395. Valley, L. M., Calvert, B., De Silva, M., Panisi, L., Babona, D., Bolnga, J., . . . Homer, C. S. E. (2023). *Improving maternal and newborn health and reducing stillbirths in the Western Pacific Region – current situation and the way forward*. *Lancet Reg Health West Pac*, 32, 100653. doi:10.1016/j.lanwpc.2022.100653
396. Vear, N. K., Goodman, W., Rose, G. L., & McCarthy, A. L. (2023). *Impact of exercise and/or dietary interventions, and their behaviour change techniques, on quality of life in middle-aged and older women following treatment for cancer: A systematic review*. *Maturitas*, 175, 107783. doi:10.1016/j.maturitas.2023.05.007
397. Vear, N. K., Moon, Y., Mielke, G. I., Skinner, T. L., Coombes, J. S., McCarthy, A. L., . . . Bailey, T. G. (2023). *Efficacy of exercise training for improving vascular dysfunction in people with cancer: a systematic review with meta-analyses*. *J Cancer Surviv*. doi:10.1007/s11764-023-01372-7
398. Veen, E. J. D., Smits, E. J., Ker, A., Whitehouse, S. L., Ziegenfuss, B. L., Pivonka, P., . . . Cutbush, K. (2023). *Anterior deltoid muscle reflection using a deltopectoral approach is safe and does not influence outcome of reverse shoulder arthroplasty*. *Journal of Shoulder and Elbow Surgery*, 32(6), 1135–1145. doi:10.1016/j.jse.2023.01.029
399. Vinayagam, R., Tanner, C., Harley, D., Karatella, S., & Brooker, K. (2023). *"My Autism is Linked with Everything": at the Crossroads of Autism and Diabetes*. *J Autism Dev Disord*. doi:10.1007/s10803-023-06033-3
400. Vivash, L., Johns, H., Churilov, L., MacPhail, S., Casillas-Espinosa, P., Malpas, C., . . . O'Brien, T. J. (2023). *Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol*. *BMJ Open*, 13(10), e075888. doi:10.1136/bmjopen-2023-075888
401. Waddell, L. A., Wu, Z., Sauter, K. A., Hope, J. C., & Hume, D. A. (2023). *A novel monoclonal antibody against porcine macrophage colony-stimulating factor (CSF1) detects expression on the cell surface of macrophages*. *Vet Immunol Immunopathol*, 266, 110681. doi:10.1016/j.vetimm.2023.110681
402. Wan, Y., Chua, S. M. H., Yao, Y., Adler, L., Navarro, M., Roura, E., . . . Sullivan, M. A. (2023). *Comparing different techniques for obtaining molecular size distributions of glycogen*. *European Polymer Journal*, 201. doi:10.1016/j.eurpolymj.2023.112518

403. Wang, Y., McCarthy, A. L., Hayes, S. C., Gordon, L. G., Chiu, V., Bailey, T. G., . . . Tuffaha, H. (2023). *Economic evaluation of exercise interventions for individuals with cancer: A systematic review*. *Prev Med*, 172, 107491. doi:10.1016/j.jpmed.2023.107491
404. Wang, Y., McCarthy, A. L., & Tuffaha, H. (2023). *Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer*. *Supportive Care in Cancer*, 31(7), 391. doi:10.1007/s00520-023-07819-y
405. Ward, N. C., Watts, G. F., Bishop, W., Colquhoun, D., Hamilton-Craig, C., Hare, D. L., . . . Sullivan, D. R. (2023). *Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations*. *Heart Lung Circ*, 32(3), 287-296. doi:10.1016/j.hlc.2022.11.015
406. Warzywoda, S., Fowler, J. A., Nourse, C., Wu, M., Britton, S., Rowling, D., . . . Dean, J. A. (2023). *Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland*. *Sex Health*, 20(4), 330-338. doi:10.1071/sh22193
407. Webbe, J., Baba, A., Butcher, N. J., Rodrigues, C., Stallwood, E., Goren, K., . . . Offringa, M. (2023). *Strengthening Reporting of Neonatal Trials*. *Pediatrics*, 152(3). doi:10.1542/peds.2022-060765
408. Whitty, J. A., Wagner, A. P., Kang, E., Ellwood, D., Chaboyer, W., Kumar, S., . . . Gillespie, B. M. (2023). *Cost-effectiveness of closed incision negative pressure wound therapy in preventing surgical site infection among obese women giving birth by caesarean section: An economic evaluation (DRESSING trial)*. *Aust N Z J Obstet Gynaecol*, 63(5), 673-680. doi:10.1111/ajo.13677
409. Wilks, K., Mason, D., Rice, M., Seaton, R., Redpath, L., Gibbons, K., . . . Venkatesh, B. (2023). *Impact of 1-hour and 3-hour sepsis time bundles on antibiotic use in emergency departments in Queensland, Australia: a before-and-after cohort study*. *BMJ Open*, 13(9), e072167. doi:10.1136/bmjopen-2023-072167
410. Wilson, C., Lai, J., & Morton, A. (2023). *Idiopathic orbital myositis in a pregnant woman*. *Obstet Med*, 16(1), 62-65. doi:10.1177/1753495x211042728
411. Wojcieszek, A. M., Bonet, M., Portela, A., Althabe, F., Bahl, R., Chowdhary, N., . . . Oladapo, O. T. (2023). *WHO recommendations on maternal and newborn care for a positive postnatal experience: strengthening the maternal and newborn care continuum*. *BMJ Glob Health*, 8(Suppl 2). doi:10.1136/bmjgh-2022-010992
412. Wong, C., Schreiber, V., Crawford, K., & Kumar, S. (2023). *Male infants are at higher risk of neonatal mortality and severe morbidity*. *Aust N Z J Obstet Gynaecol*, 63(4), 550-555. doi:10.1111/ajo.13689
413. Woods, A., Ballard, E., Kumar, S., Mackle, T., Callaway, L., Kothari, A., . . . Lehner, C. (2023). *The impact of the COVID-19 pandemic on antenatal care provision and associated mental health, obstetric and neonatal outcomes*. *J Perinat Med*. doi:10.1515/jpm-2023-0196
414. Xiong, X., Huang, L., Herd, D. W., Borland, M. L., Davidson, A., Hearn, S., . . . Babl, F. E. (2023). *Cost-effectiveness of Prednisolone to Treat Bell Palsy in Children: An Economic Evaluation Alongside a Randomized Controlled Trial*. *Neurology*, 100(24), e2432-e2441. doi:10.1212/wnl.000000000000207284
415. Yang, Y., Zhou, Y., Nyholt, D. R., Yap, C. X., Tannenberg, R. K., Wang, Y., . . . Gratten, J. (2023). *The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders*. *Cell Genom*, 3(2), 100249. doi:10.1016/j.xgen.2022.100249
416. Yap, C. X., Henders, A. K., Alvares, G. A., Giles, C., Huynh, K., Nguyen, A., . . . Gratten, J. (2023). *Interactions between the lipidome and genetic and environmental factors in autism*. *Nat Med*, 29(4), 936-949. doi:10.1038/s41591-023-02271-1
417. Yen, H. Y., Lin, G. H., & Huang, H. Y. (2023). *Leisure Participation for Mental Health Promotion in Later Life: A Six-Year Longitudinal Study*. *J Appl Gerontol*, 7334648231223299. doi:10.1177/07334648231223299
418. Yenson, V. M., Amgarth-Duff, I., Brown, L., Caperchione, C. M., Clark, K., Cross, A., . . . Agar, M. R. (2023). *Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study*. *Support Care Cancer*, 31(7), 436. doi:10.1007/s00520-023-07889-y
419. Zadran, B., Sudhindar, P. D., Wainwright, D., Bury, Y., Luli, S., Howarth, R., . . . Shukla, R. (2023). *Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation*. *Br J Cancer*, 128(7), 1236-1248. doi:10.1038/s41416-023-02154-9
420. Zammit, A. P., Brown, I., Hooper, J. D., Clark, D. A., & Riddell, A. D. (2023). *Malignant polyps in the COVID-19 era: a population-based analysis*. *ANZ J Surg*, 93(4), 932-938. doi:10.1111/ans.18253
421. Zeng, Z., Ngo, H. L., Proctor, M., Rizos, H., Dolcetti, R., Cruz, J. G., . . . Gabrielli, B. (2023). *Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas*. *Pigment Cell Melanoma Res*. doi:10.1111/pcmr.13120
422. Zhang, J., Ghasemi, N., Zare, F., Duley, J. A., Cowley, D. M., Shaw, P. N., . . . Bansal, N. (2023). *Nanosecond pulsed electric field treatment of human milk: Effects on microbiological inactivation, whey proteome and bioactive protein*. *Food Chemistry*, 406. doi:10.1016/j.foodchem.2022.135073
423. Zhang, X., Wan, Y., Karunathilaka, N., Chan, W., Kostner, K., Hartel, G., . . . Punyadeera, C. (2023). *Prognostic utility of serum NT-proBNP (fragments 1-76aa and 13-71aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure*. *Heart Vessels*. doi:10.1007/s00380-023-02296-z
424. Zhao, B., McGonigal, A., Hu, W., Zhang, C., Wang, X., Mo, J., . . . Zhang, J. (2023). *Interictal HFO and FDG-PET correlation predicts surgical outcome following SEEG*. *Epilepsia*, 64(3), 667-677. doi:10.1111/epi.17485

